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“Men ought to know that from nothing else but the brain come joys, delights laughter 
and sports, and sorrows, grief, despondency, and lamentations. And by this in an 
especial manner we acquire wisdom and knowledge, and see and hear and know 
what are foul and what are fair, what are bad and what are good, what are sweet 
and what are unsavoury… And by the same organ we became mad and delirious, and 
fear and terrors assail us… All these things we endure from the brain when it is not 
healthy…”  
                       Hippocrates, On the Sacred Disease (Fourth century B.C.) 
 
 
Part of this chapter has been accepted for publication in Behavioural Brain Research. The 
Basal Forebrain Cholinergic System in Ageing and Dementia. Rescuing Cholinergic Neurons 
from Neurotoxic Amyloid-42 with Memantine. Csaba Nyakas, Ivica Granic, Laszlo G. 
Halmy Pradeep Banerjee Paul G.M. Luiten.  
1.1 INTRODUCTION 
1.1.1 Neurodegenerative Disorders 
Neurodegenerative disorders represent conditions in which cells in the central 
nervous system are damaged or lost, they have long been viewed among the most 
enigmatic and intractable problems in medicine. Unlike in other parts of the body, 
cells in the CNS have only limited regenerative capacity and are therefore extremely 
vulnerable to damage. Once a cell is lost it can hardly be replaced. Depending on 
the cell type and area which is affected the loss of cells within the CNS ultimately 
leads to physiological and behavioral dysfunctions. The cause of neurodegeneration 
can be of various origins and is often poorly understood. 
 
1.1.2 Protein misfolding in neurodegenerative disease 
During the last decade, there is growing evidence that misfolding and aggregation of 
particular proteins are a possible cause for the development of a subset of 
neurodegenerative disorders among which Alzheimer’s, Parkinson’s and 
Huntington’s disease. These insoluble fibrous protein aggregates are generally 
referred as amyloids and share specific structural traits.  
Therefore, Carrell and Lomas proposed a new group of disorders: the 
conformational diseases or protein conformational disorders (Carrell and Lomas, 
1997). Despite the differences in disease progression and clinical symptoms, these 
disorders share some common features.  First of all, they consolidate usually in the 
fourth or fifth decade of life with characteristic loss of neurons or dysfunction of 
inter neuronal signaling. The second feature of conformational disorders is the 
deposition of fibrillar protein, as a result of the misfolding and aggregation of a 
native protein. It is quite striking that those protein deposits from different diseases 
have some similar morphological, structural and staining characteristics. 
Furthermore, these deposits have a high resistance to proteolytic degradation and a 
fibrillar appearance under electron microscopy (Soto, 2003). The common 
structural motif of virtually all amyloid fibres are cross-β-sheets in which the peptide 
strands are arranged perpendicular to the long axis of the 7-10nm fibre (Selkoe, 
2003).  
1.1.3 Alzheimer’s Disease 
Alzheimer’s disease (AD) and its underlying pathogenic mechanisms will be the 
main topic of this thesis. Alzheimer’s disease is the most common progressive and 
age related neurodegenerative disorder and was first described in 1906 by the 





Oskar Fischer published detailed histopathological findings associated with AD 
(Fischer, 1910). Alzheimer and Fisher described two major neuropathological 
features, which are still considered to confirm the definitive diagnosis of the disease, 
namely extracellular plaques composed of the fibrillar β-amyloid protein (Aβ), and 
neurofibrillary tangles (NFT) that consist of paired helical filaments of 
hyperphosphorylated tau protein. These histopathological lesions are mainly 
present in the hippocampus and the cerebral cortex, two large forebrain domains 
that are crucial for memory and other higher cognitive functions. The characteristic 
pathology eventually leads to the typical clinical symptoms e.g. general cognitive 
decline, memory impairment and personality changes associated with AD.  
The causes of AD are still rather poorly understood, with various etiologies (e.g. 
genetics, Aβ overproduction, Aβ impaired clearance) leading to amyloid plaques, 
tangle formation and extensive neuronal death. However, several lines of evidence 
point to Aβ as the major driving force in the pathogenesis of AD. The amyloid 
cascade hypothesis proposes that the Aβ peptides form toxic assemblies which 
initiate several processes leading to neuronal dysfunction and eventually large scale 
cell death (Haass and Selkoe, 2007).  
 
1.1.4 Epidemiology and genetics of Alzheimer’s Disease 
The most important risk factor for developing AD is age. After the age of 65 the 
prevalence of AD in Western societies has been forecasted to double every 5 years 
(http://www.alz.org). By the age of 80 the number of patients suffering from AD 
has increased up to 40%. Interestingly, most of the AD cases are sporadic and only 
1% are of familial nature. The pathology of sporadic and familial AD are the same, 
which suggests a common pathogenesis. In order to identify genetic risk factors 
leading to AD, families with autosomal dominant forms of Alzheimer's dementia 
have been screened for genes involved in the incidence of AD. Such screening 
revealed three genes which are involved in the early-onset of AD, namely the genes 
for presenilin-1 (PS1) on chromosome 14, presenilin-2 (PS2) on chromosome 1, and 
the gene for the amyloid precursor protein (APP) located on chromosome 21. 
Carrying a mutation in one of those genes increases the risk of early-onset AD 
before the age of 60. Most of the mutations in the APP gene accumulate near the 
cleavage site of the secretases. Mutations in the PS1 and PS2 genes also enhance the 
amyloidogenic Aβ processing. Individuals with Down syndrome carry 3 copies of 
the APP gene, which in all cases leads to increased Aβ production and early 
development of typical AD pathology in their second decade of life (Selkoe, 2005).    
Another risk factor that promotes the incidence for the sporadic late-onset AD is 
the epsilon 4 variant of apolipoprotein E (ApoE ε4). The gene for apolipoprotein E 
(ApoE) is located on chromosome 19. ApoE is a polymorphic, multifunctional 
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protein which is expressed by several cell types including liver, kidney, adipose 
tissue, macrophages and brain cells. ApoE mediates the uptake of cholesterol, 
triglycerides and other lipids. The exact mechanism how ApoE ε4 is involved the 
pathogenic process is not fully understood yet. However, accumulating evidence 
suggest that ApoE ε4 enhances the Aβ aggregation and reduces the Aβ clearance 
(Mattson, 2004). It has been shown that ApoE is able to bind Aβ in vitro and 
promotes a β-sheet structure in Aβ peptides (Golabek et al., 1996; Wilhelmus et al., 
2005).    
 
1.2 MOLECULAR MECHANISMS UNDERLYING                      
ALZHEIMER’S DISEASE 
1.2.1 The cholinergic hypothesis of Alzheimer’s Disease 
The dysfunction and loss of basal forebrain cholinergic neurons and their cortical 
projections are among the earliest pathological events in the pathogenesis of AD. In 
addition to the widespread neuronal loss in these brain regions, the evidence 
pointing to cholinergic impairments come from studies that report a decline in the 
activity of choline acetyltransferase (ChAT) and acetylcholine esterase (AChE), 
reduced acetylcholine (ACh) release and a decrease in the levels of nicotinic and 
muscarinic receptors in the AD brain (Auld et al., 1998). This observation led in 
the 70’s to the postulation of the cholinergic hypothesis for Alzheimer's disease, 
which is the oldest AD hypothesis (Bartus et al., 1982; Bowen et al., 1976; Davies 
and Maloney, 1976).  
Cholinergic neurotransmission may be a specific target for Aβ, as it has been shown 
to reduce both choline uptake and ACh release in vitro (Auld et al., 1998; Kar et 
al., 1998). It has been stated that ACh release and synthesis are depressed and ACh 
degradation is affected in the presence of Aβ peptides (Auld et al., 2002).  
When AChE becomes associated with amyloid fibrils, some of its characteristics, 
like sensitivity to low pH, change. Therefore, AChE might play an important role in 
neurotoxicity induced by Aβ. This notion is supported by the observation that Aβ-
AChE complexes are more toxic than amyloid fibrils alone (Alvarez et al., 1998).   
Although AChE levels are reduced in AD brain, its activity is increased around 
plaques and in NFT bearing neurons (Talesa, 2001). The increase in activity of this 
enzyme is likely due to an indirect effect of Aβ, mediated via oxidative stress (Melo 
et al., 2003), via voltage dependent calcium channels or via nicotinic acetylcholine 
receptors (nAChRs) of the α7 subtype (Fodero et al., 2004). Aβ42 proved to be far 
more potent then Aβ40 in increasing enzymatic activity of AChE. nAChRs are 





shown to bind to α7-nAChRs, affecting its nicotinic currents (Pettit et al., 2001) 
and Erk/MAPK signaling. By binding to α7-nAChRs, Aβ42 triggers membrane 
depolarization due to the Ca2+ influx which activates Erk/MAPK (Dineley et al., 
2001). However, the relationship between Aβ and the cholinergic system is not 
unidirectional. There is a considerable amount of evidence that cholinergic 
dysfunction influences APP metabolism and consequent Aβ production. For 
example, it has been shown that stimulation of the M1 and M3 muscarinic receptor 
subtypes increased the release of APP through activation of PLC/protein kinase C 
(PKC) cascade (Nitsch et al., 1992). BACE expression was also increased by 
activation of these receptor subtypes (Zuchner et al., 2004). Furthermore, it has also 
been found that AChE promotes Aβ aggregation, possibly through Aβ-AChE 
interaction by a hydrophobic environment close to the peripheral anionic binding 
site of the enzyme, thus promoting fibril formation (Inestrosa et al., 1996).  
 
1.2.2 The tau hypothesis of Alzheimer’s Disease 
Another hypothesis focuses on a causative role for the microtubule binding tau 
protein, the main component of the NFTs in AD. NFTs are formed of 
hyperphosphorylated tau monomers. Several mechanisms have been elucidated 
which all lead to NFT formation. In vivo studies have demonstrated that kinases 
such as glycogen synthase kinase 3 (GSK3) and cyclin dependent kinase 5 (Cdk5) 
can phosphorylate tau (Noble et al., 2003; Spittaels et al., 2000) and both are 
probably involved in AD. Cdk5 is only active when it is bound to its activator p35. 
p35 can be cleaved into p25 via calcium dependent proteases (calpains), as a 
consequence of sustained elevated calcium levels due to oxidative stress, 
inflammation and excitotoxicity. The Cdk5/p25 complex is more stable then 
Cdk5/p35 and is thought to be main responsible kinase for tau 
hyperphosphorylation. Furthermore, the Cdk5 can decrease the activity of 
phosphatase-1 (PP1) by activating PP1 inhibitors (Shelton and Johnson, 2004). PP1 
is mainly involved in the de-phosphorylation of tau. These mechanisms seem to be 
independent of Aβ, it is however, not impossible that Aβ also could influence these 
mechanisms indirectly.  
These and other studies suggest calpain as a potential target for therapeutic 
intervention both at early and late stages of AD. Moreover, initial studies using 
calpain inhibitors in a mouse model of AD showed an encouraging recovery of 
cognitive function in transgenic mice that were treated with a calpain inhibitor at 
an early age (Battaglia et al., 2003). However, it remains unclear whether the 
inhibition of calpains provides protection against neurodegenerative insults, such as 
excitotoxicity or oligomeric Aβ, as observed in AD. 
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1.2.3 The amyloid-β cascade hypothesis 
The amyloid hypothesis states that the accumulation of Aβ fibrils resulting from an 
imbalance between production and clearance is the initiating molecular event that 
triggers the downstream neuropathological conditions in AD (Hardy and Selkoe, 
2002). Several observations suggest that tau hyperphosphorylation is a downstream 
process induced by Aβ (Gotz et al., 2001; Hutton et al., 1998; Lewis et al., 2001; 
Rapoport et al., 2002). More recent data led to a modified version, the Aβ cascade 
hypothesis. According to this hypothesis other, less well characterized, soluble, non-
fibrillar species of Aβ may be responsible for the damage to brain tissue and 
subsequent cognitive impairments in AD. This hypothesis has gained increased 
interest over the past few years and is now more and more supported by 
experimental findings (Walsh and Selkoe, 2007). 
There are several lines of evidence supporting the notion of a causal role for Aβ. 
AD like neuropathology is invariably seen in Down’s syndrome patients, which 
results from increased APP expression and consequent higher Aβ levels as can be 
expected by the localization of the APP gene on chromosome 21 (Prasher et al., 
1998). Mutations in or near the Aβ region in the APP gene alter the amount or 
aggregation properties of Aβ and are sufficient to cause early-onset AD (Levy et al., 
1990). Furthermore, Aβ peptides are toxic to cortical and hippocampal neurons 
(Deshpande et al., 2006). Mutations in presenilins, which constitute the catalytic 
site of β- and γ-secretase increase the Aβ42/Aβ40 ratio and cause very early forms of 
AD (Kumar-Singh et al., 2006). More evidence is provided by experiments from 
mice transgenic for human APP which reveal an increase in extracellular Aβ, 
neuropathological and behavioral changes similar to those seen in AD (Ashe, 2005). 
Finally, injection of Aβ or co-expression of human APP in tau transgenic mice 
increases tangle formation (Gotz et al., 2001; Lewis et al., 2001). 
 
1.2.4 Amyloid-β precursor protein 
The Aβ peptide is part of  the larger amyloid precursor protein (APP), which is a 
type –I transmembrane protein, that belongs to a protein family, that includes APL-
1 in C. elegans, APPL in Drosophila and Amyloid Precursor Protein like Protein 1 
and 2 (APLP1 and APLP2) in mammals (Zhang and Xu, 2007). These proteins 
share several conserved domains such as E1 and E2 in the extracellular part and the 
APP intracellular domain (AICD), however the Aβ domain is only found in APP 
(Zheng and Koo, 2006). APP consists of a large extracellular N-terminal (aa 28-128) 
and a short intracellular (cytoplasmic) C-terminal (Reinhard et al., 2005). 
The gene encoding for APP is located on the long arm of chromosome 21 in 





ranging from 365 to 770 amino acid residues. The major Aβ peptide encoding 
isoforms are APP695, APP751, APP770, consisting of 695, 751 and 770 amino 
acids respectively. Whereas APP 751 and APP 770 are mostly found in the brain 
but also in the rest of the body, APP 695 is predominantly found in neurons. 
However, it is not known yet why APP 695 shows tissue specificity (Zheng and Koo, 
2006).  
 
Figure 1.1. Schematic representation of APP processing and down-stream signals leading to neuronal 
cell death or survival. Non amyloidogenic APP processing by α- and g-secretase leads to cell survival, 
whereas amyloidogenic cleavage by β- and -secretase results in Aβ production and eventually to 
neurodegeneration. 
1.2.4.1 APP processing and generation of Aβ 
Full length APP is synthesized in the endoplasmatic reticulum (ER) and transported 
through the Golgi to the trans-Golgi- network (TGN), which is the major site of 
APP residence in neurons at steady state. It is transported to the cell surface in 
TGN derived vesicles (Zhang and Xu, 2007). APP can be proteolytically processed in 
two distinct pathways; the amyloidogenic pathway in which Aβ is generated and the 
non-amyloidogenic pathway (see Figure 1.1) (Zhang and Xu, 2007).  
In the non-amyloidogenic pathway, APP is cleaved at the cell surface by α-secretase, 
a zinc-metalloproteinase, probably consisting of members of the ADAM (a 
disintegrin and metalloproteinase) family. By cleavage the soluble ectodomain of 
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APP is released (sAPPα) and a C-terminal stub (CTFα, C-terminal APP fragment α, 
or C83) is formed. Subsequently, γ-secretase cleaves CTFα which leads to the release 
of AICD (APP intracellular domain) and the P3 fragment. The γ-secretase is a 
complex protein consisting of at least four subunits; presenilin (PS), nicastrin, APH-
1 and presenilin enhancer-2 (PEN-2). Interestingly, α-secretase cleaves within the Aβ 
-domain so that no Aβ is formed in this pathway (see Figure 1.1)  (Zhang and Xu, 
2007).  
 
Figure 1.2. Aβ can be processed by numerous proteases, indicated in the lower part of the panel. The 
Aβ42 amino acid sequence with cleavage sites for α-, β- and γ-secretase is shown along with: N, 
Neprilysin (NEP) and I, Insulin degrading enzyme (IDE). 
If APP is not cleaved by α-secretase it can be re-internalized to an 
endosomal/lysosomal pathway and enter the amyloidogenic pathway where it is 
cleaved by β-secretase, a transmembrane protease also referred to as BACE1 (β-site 
of APP cleaving enzyme) (Small and Gandy, 2006). A soluble ectodomain is secreted 
(sAPPβ) and a C-terminal stub (CTFβ or C99) is generated. Subsequently γ-secretase 
cleaves CTFβ which leads to the release of AICD and Aβ. The γ-secretase cleaving 
site is variable, in this way Aβ peptides of different length are generated, ranging 
from 39 – 43 amino acids (Figure 1.1). The longer Aβ peptides (e.g. Aβ42) have the 
tendency to aggregate more rapidly than shorter Aβ species (e.g. Aβ40) and thus 
form the seed for larger oligomers, fibrils and finally for the macroscopic amyloid 
plaques (DeMattos et al., 2001; Walsh et al., 2002b; Walsh and Selkoe, 2004). In 
Alzheimer’s diseased brains there is more Aβ42 present compared to healthy control 
brains, whereas Aβ40 is far more abundant in healthy brains (Small and Gandy, 
2006). Aβ can be degraded by various enzymes such as neprilysin (NEP), insulin 
degrading enzyme (IDE), endothelin-converting enzyme and plasmin (Figure 1.2) 





1.2.5 Physiological and pathophysiological effects of A 
Like Dr. Jekyll and Mr. Hyde, some apparently innocent peptides have evil alter 
egos and vice versa. For a long time Aβ was supposed to have only toxic 
characteristics and to be a waste product of APP cleavage. However, this view is 
slowly changing as more and more studies find evidence for possible physiological 
functions of Aβ in synaptic function, memory formation and neuronal survival. In 
addition, the large amounts of Aβ found in healthy subjects, both in the brain and 
the rest of the body hints to possible physiological roles (Bishop and Robinson, 
2004; Giuffrida et al., 2009; Morley et al., 2009).  
 
1.2.5.1 The role of A in synaptic plasticity and negative feedback in 
neuronal activity 
About 25 years ago Aβ was identified as a major component of the senile plaques in 
AD (Glenner and Wong, 1984). In human brain it has long been recognized that 
senile plaque numbers have a weak correlation with severity of cognitive decline 
(Terry et al., 1991). However, soluble Aβ levels associate well with synaptic loss and 
severity of dementia (McLean et al., 1999; Wang et al., 1999). Indeed memory 
impairment and changes in neuron function in APP transgenic mice appear to 
occur before amyloid deposition (Chapman et al., 1999; Moechars et al., 1999). 
Animal models of AD show disruption of excitatory synaptic transmission and long-
term potentiation (LTP) (Rowan et al., 2003). Walsh and colleagues could show 
that a low-n oligomeric (dimer, trimer, tetramer) assemblies of naturally secreted 
human Aβ alters hippocampal synaptic plasticity (Walsh et al., 2002a; Walsh et al., 
2005). Also the number of dendritic spines (specialized synaptic sites) was 
dramatically decreased when neurons were incubated with Aβ oligomers but not 
with monomers. This decrease in spine density could be reversed when neurons 
were treated with an anti- Aβ antibody (Shankar et al., 2007). Oligomeric Aβ 
inhibited neuronal viability 10 fold more than fibrillar Aβ and 40 fold more than 
monomeric Aβ (Dahlgren et al., 2002).  
Glutamate is the most abundant excitatory neurotransmitter in the brain. The 
glutamatergic receptors α-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) and N-
methyl D-aspartate (NMDA) receptors (amongst others) are typically found in 
postsynaptic spines. They have an excitatory effect and can undergo changes in their 
synaptic strength and efficacy in response to neuronal activity, which is a 
prerequisite for synaptic plasticity. Long term potentiation (LTP) and long-term 
depression (LTD) are the most extensively studied forms of synaptic plasticity of the 
glutamatergic synapse. It is generally considered that synaptic plasticity is the 
cellular correlate of memory formation (Parameshwaran et al., 2008). LTP is an 
increase in the communication between two neurons via enhanced synaptic 
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transmission between excitatory glutamate synapses. LTP is induced by coincident 
presynaptic glutamate release and postsynaptic depolarization, resulting in 
postsynaptic calcium influx through NMDA receptors.  
The hippocampus is crucial for the acquisition of episodic memory. Impaired 
acquisition of episodic memory is one of the first symptoms which can be observed 
in AD patients. It can be correlated with the loss of synapses in the course of the 
disease (DeKosky and Scheff, 1990; Terry et al., 1991). This and other observations 
draw the attention to the synaptotoxic effects of Aβ and in particular to deficits in 
hippocampal synaptic plasticity. 
Kamenetz and colleagues could show that Aβ may be a negative feedback regulator 
of synaptic activity as higher neuronal activity increases the production of Aβ which 
again leads to a reduced synaptic function and decreases neuronal activity. In this 
way Aβ might prevent cells from excitotoxicity (Kamenetz et al., 2003). On the 
other hand, excitatory synaptic transmission is strongly increased in neurons lacking 
APP mainly due to an increase in synapse numbers (Priller et al., 2006). A possible 
mechanism could be that Aβ induces the endocytosis of AMPA receptors which 
leads to decreased surface AMPA receptors and impaired synaptic transmission 
(Hsieh et al., 2006). Gu and co-workers reported that Aβ reduces CaMKII in 
synapses which in turn prevents surface delivery of AMPA receptors. This finding 
links Aβ causally to the loss of synaptic AMPA receptors (Gu et al., 2009).  
The degree of aggregation and quantity of Aβ assemblies seem to be critical for the 
biological processes which are activated by Aβ. Application of micromolar 
concentrations of Aβ42 (a mixture of mature fibrils and protofibrils) attenuated 
AMPA-evoked neuronal firing whereas application of Aβ40 had no effect 
(Parameshwaran et al., 2007). Other studies using physiological amounts of Aβ42 (in 
the picomolar range) showed an enhancement in hippocampal LTP, whereas 
nanomolar amounts attenuated LTP (Puzzo et al., 2008). Oligomer secondary 
structure and degree of assembly correlated directly with fibril nucleation activity. 
Very recently Ono and colleagues studied specific Aβ oligomers assemblies, which 
have been stabilized structurally and isolated in pure form (Ono et al., 2009). Those 
isolated oligomers were tested for neurotoxic activity. Neurotoxic activity which 
increased disproportionately (order dependence >1) with oligomer order (Figure 







Figure 1.3. Toxicity and assembly state. A can exist in multiple assembly states — 
monomers, oligomers, protofibrils and fibrils. In its monomeric state, A does not appear to be 
neurotoxic. By contrast, oligomeric and protofibrillar species are considered to be most toxic. 
Since Aβ is very hydrophobic and can bind to many cell surface proteins and 
receptors (Verdier and Penke, 2004) it has been suggested that Aβ directly binds to 
and modulates AMPA receptors. Indeed, Aβ42 iontophoretically applied to neurons 
from the hippocampal CA1 region attenuated AMPA-evoked neuronal firing 
whereas NMDA-evoked firing was potentiated (Szegedi et al., 2005). Even a mild 
abnormal NMDA receptor activation, either via Aβ or by glutamate, could cause 
neuronal death by initiating cyclic neurotoxic effects in which a shift from α-
secretase to β-secretase results in excessive Aβ production and further glutamate 
accumulation (Harkany et al., 2000; Lesne et al., 2005; Parameshwaran et al., 2008). 
Aβ oligomers appear to bind to NMDA receptors at the synapse and trigger NMDA 
receptor internalization and deregulation of NMDA signaling pathways (Lacor et 
al., 2007; Shankar et al., 2007). 
 
1.2.5.2 A and lipid metabolism 
Next to its actions in synaptic plasticity Aβ might also have a crucial role in lipid 
homeostasis via the regulation of cholesterol and sphingolipid metabolism. The 
brain contains about 25% of the total body cholesterol and is thus the most 
cholesterol-rich organ. As cholesterol is essential for development and maintenance 
of neural plasticity and function, cholesterol homeostasis, including synthesis, 
removal, storage and transport, must be strictly regulated (Hartmann, 2006). 
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Cholesterol is very abundant in neurons and glia cells and is essential for Aβ 
binding to cell membranes and cytotoxicity (Subasinghe et al., 2003). Furthermore, 
cholesterol can be oxidized by Aβ, leading to 7β-hydroxycholesterol which might be 
neurotoxic as a pro apoptotic oxycholesterol (Nelson and Alkon, 2005).  
 
1.2.5.3 Oxidative stress  
It is currently believed that oxidative stress has a significant role in the pathogenesis 
associated with Aβ peptides. In AD brain, increased levels of protein carbonyl and 
nitration of tyrosine residues are found, which is indicative of elevated oxidative 
modification of proteins (Smith et al., 1996). Protein oxidation is only observed in 
brain region where Aβ42 is present, and not in e.g. the cerebellum, which is largely 
spared in AD (Hensley et al., 1995). Furthermore, there is also indirect evidence 
from studies showing that treatment with antioxidants, e.g. vitamin E (tocopherol, 
TCP) delays the progression of AD (Sano et al., 1997). Aβ peptides have been 
proposed as a source and a consequence of oxidative stress in an animal model of 
AD. It has been shown that, an increased load of reactive oxygen species (ROS) is 
associated with amyloid plaques (McLellan et al., 2003). During Aβ aggregation, 
H2O2 is generated through electron transfer interactions involving bound redox-
active metal ions (Curtain et al., 2001; Huang et al., 1999a; Huang et al., 1999b; 
Opazo et al., 2003). Furthermore, Aβ induces lipid peroxidation and subsequent 4-
hydroxynonenal (4-HNE) production, a cytotoxic aldehyde, which can lead to 
increased vulnerability to apoptosis via JNKs and P38MAPK (Tamagno et al., 2003). 
Oxidative stress also seems to play a role in Aβ induced neurotrophin mediated 
neuronal toxicity, which is, however, beyond the scope of this thesis.  
 
1.2.5.4 Insulin signaling 
There is evidence that AD is linked to a state of relative brain insulin resistance, 
also called type III diabetes (de la Monte et al., 2006). In the healthy brain, insulin 
and insulin-like growth factor 1 (IGF-1) promote glucose utilization and neuronal 
survival mainly through PI3K/Akt/GSK-3β signaling, which is essential for 
neuronal metabolism and survival (Bondy and Cheng, 2004). In the AD brain, 
however, levels of insulin and IGF-1 are deregulated (Moloney et al., 2008). 
Intracellular expression of Aβ leads to a decrease in phosphorylated Akt levels, an 
increase in activated GSK-3β, and induction of apoptosis (Magrane et al., 2005). 
There is recent evidence that intracellular Aβ interrupts insulin signaling by 
inhibiting 3-phosphoinositide dependent protein kinase (PDK) activity, via 
interference of binding to its target, Akt (Lee et al., 2009). It was discovered that 





al., 2003). Application of soluble Aβ prevents insulin from binding to its receptor 
(Xie et al., 2002) and causes loss of surface expression of insulin receptors 
(Townsend et al., 2007) adding to the above described insulin resistance. 
 
1.2.5.5 Calcium homeostasis 
Calcium signaling is of paramount importance for neuronal functioning. Calcium 
controls membrane excitability, triggers neurotransmitter release, mediates activity-
dependent changes in gene expression and modulates neuronal differentiation and 
transition to apoptosis to mention only a few of its functions (Berridge et al., 1998). 
Tangle-bearing neurons have increased amounts of calcium and increased levels of 
calcium-dependent proteases and calcium activated kinases, pointing to a possible 
role of calcium imbalance in AD pathogenesis (Grynspan et al., 1997). In areas 
close to amyloid plaques, increased basal intracellular calcium levels are observed in 
a large proportion of spines and show a strong correlation with the adjacent 
dendrites. This suggests that local calcium homeostasis has been lost and calcium 
leaks out of the spine into the dendrite, preventing independent calcium signaling 
of spines and dendrites (Green and LaFerla, 2008). Aβ42 may disrupt intraneuronal 
calcium levels and regulation by inducing oxidative stress (increased levels of 4-
HNE) which impairs membrane calcium pumps and enhances calcium influx 
through voltage-dependent channels and ionotropic glutamate receptors (Mattson 
and Chan, 2003). It has also been shown that addition of Aβ leads to abnormal 
functioning of Na+/K+-ATPase (Colom et al., 1998), which in turn could lead to 
increased levels of intracellular Ca2+ via elevated concentrations of intracellular Na+ 
which triggers membrane depolarization (Good and Murphy, 1996). In addition, 
muscarinic acetylcholine receptors (mAChRs) are also targeted by Aβ, leading to 
Ca2+ release from intracellular calcium stores via activation of G-proteins and 
phospholipase C (PLC) (Kelly et al., 1996).  
These excessive and sustained free calcium induces free-radical production by 
altering mitochondrial oxidative phosphorylation and via the activation of 
oxygenases, which makes it likely that perturbed calcium homeostasis and free-
radicals are components of a self-amplifying cascade (Bezprozvanny and Mattson, 
2008). Furthermore, it has been described that in the presence of Aβ peptides there 
are ion conducting channels formed in the membrane, which could possibly be 
ascribed to the fact that Aβ oligomers share structural and functional homology 
with pore-forming bacterial toxins and perforin (Yoshiike et al., 2007). Neurons 
exposed to phosphatidylserine, which is indicative of apoptotic or energy deprived 
cells, show enhanced Aβ binding (Lee et al., 2002). Therefore, it is possible that age-
related mitochondrial impairments facilitate Aβ-mediated pore formation and 
calcium influx. In addition, cell-surface receptors coupled to calcium influx are 
activated and calcium release from the ER is enhanced (Mattson and Chan, 2003). 
The activation of calpains and caspases and the dysregulation of calcium 
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homeostasis were shown to be involved in impaired neuronal survival, cell 
proliferation and differentiation induced by Aβ (Haughey et al., 2002). The main 
site of calcium dysregulation seems to be the synapse, where Aβ impairs plasma 
membrane Ca2+ ATPase in exposed synaptosomes (Mark et al., 1995). 
Amyloidogenic processing of APP impairs neuronal calcium homeostasis by 
decreasing the production sAPPα, a secreted form that activates K+-channels 
(Furukawa et al., 1996). 
 
1.2.5.6 Small-conductance calcium-activated potassium channels 
Several groups have investigated Aβ effects on membrane ion channels (Davidson et 
al., 1994; Etcheberrigaray et al., 1994; Etcheberrigaray et al., 1993; Good and 
Murphy, 1996; Ueda et al., 1997). However, the role of ion channels in Aβ-induced 
cell death remains controversial and poorly understood. In neurons potassium 
channels set the resting potential, keep fast action potentials short, terminate 
periods of intense activity and lower the effectiveness of excitatory inputs. The 
modulation of neuronal excitability is mediated via calcium dependent potassium 
channels. These channels allow an efflux of K+ ions through the plasma membrane, 
inhibiting subsequent electrical activity (Colom et al., 1998). Small conductance 
Ca2+ activated K+ channels (KCa2 or SK channels) are strictly voltage-independent, 
and are activated by changes in intracellular Ca2+ levels. KCa2 channels consist of 
six transmembrane segments (S1-S6), with the pore located between S5 and S6. To 
activate the KCa2 channel, Ca2+ has to bind to calmodulin (CaM), which is 
associated with the pore-forming channel subunits and serves as the Ca2+ sensor. 
KCa2 channels at spines are activated by Ca2+ entry through NMDARs. Low 
concentrations of Ca2+ (300-700nM) are sufficient to open the KCa2 channels, 
which results in the afterhyperpolarization (AHP) (Alger and Nicoll, 1980; Stocker, 
2004). In this way the activation of the channel also counteracts further increases in 
intracellular calcium (Stocker, 2004). After induction of NMDAR dependent long-
term potentiation (LTP), cAMP-dependent protein-kinase (PKA) phosphorylates 
KCa2.2, resulting in endocytosis and therefore removal of KCa channels (Lin et al., 
2008).  
There are different subtypes of KCa2 channels (KCa2.1 KCa2.2 KCa2.3) which are 
predominantly expressed in the nervous system (Kohler et al., 1996; Stocker, 2004; 
Stocker and Pedarzani, 2000) and show partially overlapping but distinct expression 
patterns. KCa2.1 and KCa2.2 are the predominant subtypes in cortical regions 







1.2.5.8 Excitotoxicity and apoptosis in Alzheimer’s Disease 
Programmed cell death (apoptosis) is an important biological process during 
development and under pathological conditions. The most widely studied type of 
programmed cell death in the nervous system is apoptosis, a process that is 
regulated by specific cystein proteases called caspases (Yuan and Yankner, 2000). 
Several different triggers of neuronal apoptosis have been documented in AD, many 
of them are related to Aβ-mediated processes including oxidative stress, 
overactivation of glutamate receptors, trophic factor insufficiency, DNA damage 
and accumulation of damaged proteins (Mattson, 2000; Yuan and Yankner, 2000).   
Nevertheless, the over activation (excitotoxicity) is caused by an overstimulation of 
N-methyl-D-aspartate (NMDA) receptors is widely seen as a common principle in 
several neurodegenerative disorders including AD (Harkany et al., 2000; Lipton and 
Rosenberg, 1994; Mattson, 2004). Aβ oligomers have been reported to mediate 
their pathological effects in vitro via the NMDA receptor (DeFelice and Goswami, 
2007; Kelly and Ferreira, 2006; Shankar et al., 2007). Overstimulation of the 
NMDA receptor leads to excessive entry of calcium into the cell, which activates 
proteases that are involved in cell death signaling (Chan et al., 1999; Chan and 
Mattson, 1999; Gingrich et al., 2000). Calpain is such a protease, which can 
modulate the conformation, localization, and activity of various proteins. The 
activation of calpain has been linked to a wide range of pathological conditions 
including Stroke, type 2 diabetes mellitus (T2DM) and AD (Blomgren et al., 2001; 
Horikawa et al., 2000; Tsuji et al., 1998).  As described earlier Aβ exposure can lead 
to the activation (via elevated Ca2+ levels) of calpain, which is due to elevated levels 
in intracellular calcium homeostasis, which in turn leads to DNA fragmentation by 
cleavage of poly-ADP-ribose polymerase, a DNA repair enzyme (Boland and 
Campbell, 2003).  For this reason, calpains have been discussed extensively as target 
for therapeutic interventions in a number of neurodegenerative diseases that are 
associated with neuronal loss (Goll et al., 2003; Huang and Wang, 2001; Zatz and 
Starling, 2005). 
1.2.5.9 Neuroinflammation 
All neurodegenerative diseases are accompanied by activated inflammatory and 
neuroinflammatory systems. The notion that inflammatory processes are involved 
in the pathogenesis of AD is also strongly supported by epidemiological studies, 
indicating that chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) 
reduces the risk of developing AD (Stewart et al., 1997). The neuroinflammatory 
process involves astrocytes, microglia, the complement system and to a lesser extent 
neurons (Akiyama et al., 2000a). Senile plaques are known to be associated with 
activated microglia and reactive astrocytes. Microglia interaction with these amyloid 
deposits triggers the phenotypic activation and as a consequence a number of pro-
inflammatory immune receptors and cell surface proteins are overexpressed, such as 
the leukocyte antigen CD45, complement receptors such as CR3, CR4 and LFA-1, 
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MHC II surface antigens and the immunoglobulin receptors Fcγ RI, RII and RIII. 
Moreover, the acute phase proteins amyloid P and C-reactive protein and the 
protease inhibitors α1-antichymotrypsin and α1-antitrypsin are elevated (Tuppo and 
Arias, 2005). There is also a large body of evidence reporting that fibrillar Aβ 
peptides induce the synthesis and release from microglia of pro-inflammatory 
cytokines interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α) and the 
chemokines macrophage inflammatory protein-1 and IL-8 (Yates et al., 2000).  
TNF- is one of the most prominent pro-inflammatory cytokines that is significantly 
increased in AD. It plays a central role in initiating and regulating the cytokine 
cascade during inflammatory responses (Akiyama et al., 2000b; Fillit et al., 1991). 
For example, TNF- increases the expression of adhesion molecules on the vascular 
endothelium, which allows leukocytes and immune cells to infiltrate areas of tissue 
damage and infection (Perry et al., 2001). TNF- exerts its biological functions via 
two distinct receptors: TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). The 
55 kDa TNFR1 (p55/60) is a membrane-receptor and is expressed in most tissues 
where it can be stimulated by both the membrane-bound and the soluble form of 
TNF-. The functions of TNFR1 range from inducing apoptosis and differentiation 
to NF-B-mediated cell survival (Hu, 2003). Similar to TNFR1, also the 75 kDa 
TNFR2 (p75/80) is a membrane-receptor, but because of its low affinity to soluble 
TNF- it can be fully activated only by membrane-bound TNF-. The functions of 
TNFR2 are as complex as those of TNFR1 and are still not fully clear in all its 
detail. It is known that the action of the TNF receptors is strongly dependent on the 
cell type. For instance, TNFR2 is able to amplify apoptotic signals from TNFR1 in 
cancer cell lines (Wajant, 2003) but has also been reported to mediate protection of 
nerve cells, as shown in a model for glutamate-induced excitotoxicity (Marchetti et 
al., 2004b). TNFR2 exerts its protective properties when pre-stimulated with TNF-, 
which suggests a neuroprotective role in the CNS (Dolga et al., 2008; Marchetti et 
al., 2004b). In AD patients, TNFR1 levels are increased (Fillit et al., 1991), whereas 
TNFR2 (Taoufik et al., 2007) levels are decreased. Recently, it was demonstrated 
that overexpression of TNFR1 promotes Aβ-induced neuronal death in an APP 
overexpressing mouse model for AD (Li et al., 2004). In contrast, such APP 
overexpressing mice lacking TNFR1 have a decreased amyloid plaque burden, lower 
expression of β-secretase (BACE), and improved learning abilities compared to 
controls (He et al., 2007). Interestingly, the stimulation of both TNF receptors can 
lead to the activation of NF-B, which has binding sites in the promoter regions of 
both the APP and the BACE gene (Grilli et al., 1996). Mutations in the NF-B 
promotor region of BACE lead to a significant decrease in promotor activity of 
TNF- activated glia cells or A exposed neurons, which indicates an activating role 
of NF-B in BACE expression (Bourne et al., 2007). In this way, NF-B activation 
can lead to increased APP expression and enhanced amyloidogenic APP processing. 
Elevated APP and BACE expression will ultimately lead to increase in Aβ 






1.3 THERAPEUTIC STRATEGIES FOR ALZHEIMER’S DISEASE 
TREATMENT   
Alzheimer's disease has a tremendous negative economic impact since the treatment 
of AD costs more per patient than management of any other major age-associate 
brain disease (Golde, 2003) which is one of the factors that explains the great effort 
which has been made to find ways for a successful treatment strategies. However, 
the causes of AD are still rather poorly understood, with various etiologies leading 
to the hallmarks of plaque and tangle pathology, associated neuroinflammation and 
extensive neuronal death. Therefore it is not surprising that the most advanced 
strategies for treating this devastating disease have been focused on upstream 
pathogenic events and preventing Aβ or tau aggregation and thereby protect 
neurons from death. Currently available therapies however are aimed at rather late 
processes of the neuropathogenic cascades and for probably that reason only exert 
limited beneficial outcomes. 
 
1.3.1 Acetyl cholinesterase inhibitors 
The reduction and degeneration of cholinergic fibres during aging is a well known 
phenomenon. The loss of cholinergic transmission is directly associated to memory 
deficits and cognitive decline (Winkler et al., 1998). The enzyme choline 
acetyltransferase (ChAT) is the key enzyme for the synthesis of the neurotransmitter 
acetylcholine. In patients with AD, the ChAT-positive nerve cells are decreased by a 
factor 4 compared to age-matched, non-demented patients (Pietrzik and Behl, 
2005). Based on these findings, in the 70's the cholinergic hypothesis of AD was 
postulated. This cholinergic hypothesis for Alzheimer's disease, which is the oldest 
AD hypothesis, stood at the basis for the use of acetyl cholinesterase (AChE) 
inhibitors, which were the first used pharmacological drugs for the treatment of 
AD.  
At present only five drugs are approved by the U.S. food and drug administration 
for treating the cognitive symptoms of AD. Four of those drugs (galantamine, 
rivastagmine, donepezil and tacrine) belong to the class of cholinesterase inhibitors. 
AChE inhibitors block the disassembly of the neurotransmitter acetylcholine (ACh) 
by acetyl cholinesterase (AChE). The resulting effect of using AChE inhibitors is an 
elevated level of ACh in the synapse and thereby enhancing the activity of 
cholinergic neurotransmission in the AD affected brain regions. Clinical studies 
showed that the use of AChE inhibitors in patients with mild to moderate AD leads 
to a modest improvement in learning and memory performance. It should be 
realized that the usage of AChE inhibitors is only weakening the symptoms and it 
does not stop any processes leading to AD and its neuropathology. Therefore, the 
usage of AChE inhibitors is reasonable in combination with other drugs, which 
intervene in the pathological process of AD.  
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1.3.2 RAGE inhibitors 
Binding of Aβ to the receptor for advanced glycation endproducts (RAGE) is 
known to contribute to pro-inflammatory processes and neurotoxicity (Deane et al., 
2007). Small molecules, which inhibit binding of Aβ to RAGE, like PF-0494700 
(formerly TTP488) are able to reduce Aβ toxicity and amyloid aggregation. 
Currently these compounds are being investigated in a phase II clinical study (Chen 
et al., 2007). 
 
1.3.3 Modulation of APP processing 
The APP processing is a crucial step in the generation of Aβ. β- and γ-Secretase  are 
the enzymes, which are involved in the amyloidogenic pathway. Therefore, they are 
attractive targets for AD therapy. By inhibiting these enzymes, the generation of Aβ 
should be reduced, which might in turn slow down the amyloid deposition in the 
brain.   
In case of β-secretase, great efforts have been made by pharmaceutical industries in 
order to develop potent small molecule inhibitors that can fit the large active site of 
this aspartyl protease and still penetrate the blood brain barrier (BBB) (Selkoe and 
Schenk, 2003). For γ-secretase effective inhibitors are already available, but there are 
concerns about their testing in humans (Hardy and Selkoe, 2002). Both enzymes, β- 
and γ- secretase may have other substrates which could be essential for the normal 
functioning of the cell. For example, it has been shown that γ-secretase is involved 
in the processing of Notch, which has several important and diverse functions in 
vivo (Esler and Wolfe, 2001; Mattson, 2004). Therefore, inhibition of the secretases 
may have profound toxicological effects and in some cases further developments 
were abandoned. 
1.3.4 Non-steroidal anti-inflammatory drugs 
In the 1980s, it was observed that drug treated patients with rheumatoid arthritis 
had a lower incidence of dementia. Since then scientists have hypothesized that 
non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin may 
delay the onset and risk of Alzheimer's disease (AD) by decreasing the inflammatory 
changes that occur in the brain (Van Dam et al., 2008). However, the beneficial 
effects of NSAIDs against AD are not attributed to reduced inflammation but are 
rather caused by modulating the cleavage of the amyloid precursor protein. In a 
study to investigate the effect of NSAIDs on the interaction between γ-secretase and 
APP in cell culture, Hyman and colleagues (Lleo et al., 2004) were able to show that 
NSAID treatment results in a reduced production of Aβ1-42, whereas the total 





secretase and changes the balance of APP cleavage, which results in a reduced 
production of the toxic Aβ1-42 species by shifting the cleavage towards the shorter 
non-toxic peptides such as Aβ1-38 (Lleo et al., 2004). A clinical trial with NSAIDs 
however was aborted in 2005 because of suspicion for causing cardiovascular 
problems (Gandy, 2005). Another NSAID, tarenflurbil showed in a preclinical 
study that it modulates gamma secretase cleavage and lowered Aβ42 levels in vivo 
(Eriksen et al., 2003). The drug entered a clinical phase II study where it proved to 
be safe and well tolerated, however it did not show any benefits on cognition or 
function in mild to moderate AD patients (Wilcock et al., 2008). A large 18 month 
phase III clinical trial with tarenflurbil failed to show benefits of the treatment and 
was discontinued.   
 
1.3.5 Statins 
The majority of the epidemiological evidence points to beneficial effect of 
cholesterol lowering drugs (statins) on AD, although more recent investigations 
have not always been able to replicate this observation. It is therefore suggested that 
statins do not prevent AD entirely, but can slow its progression (Hoglund and 
Blennow, 2007; Wolozin et al., 2006).  
HMGR (3-hydroxy-3-methylglutaryl-CoA reductase) is the rate-limiting enzyme in 
the biosynthesis of cholesterol and catalyzes the conversion of HMG-CoA to 
mevalonic acid. Drugs like statins completely block this enzyme resulting in lower 
cholesterol levels (Buhaescu and Izzedine, 2007; van der Most et al., 2009). The 
mechanism of how statins influence the development of AD is not yet fully 
understood. However, there are several possibilities how statins might alter AD 
pathogenesis and exert neuroprotection (van der Most et al., 2009). Statins can 
reduce cholesterol, which is an important regulator of membrane fluidity. Reduced 
cholesterol levels could render APP processing by altering the secretase activity, 
since the cleavage of APP takes place within the membrane. After statin application 
to primary hippocampal neurons and mixed cortical neurons in culture, Aβ levels 
were reduced indicating that, when cholesterol levels are lowered, there is a reduced 
production of Aβ, which is a reversible process (Fassbender et al., 2001). 
Conversely, a cholesterol-enriched diet increases cerebral Aβ levels in APP-
transgenic mice. There is also evidence that cholesterol enhances γ-secretase 
mediated Aβ production, thus causing a shift from the non-amyloidogenic to the 
amyloidogenic pathway (Grimm et al., 2007). Furthermore, cholesterol could 
directly influence the deposition of Aβ or indirectly by altering ApoE levels (Golde, 
2003; Mattson, 2004).  
Another mechanism of statins was shown by Dolga and colleagues, where pre-
treatment of cultured cortical neurons led to protection against excitotoxic damage 
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(Dolga et al., 2008). Lovastatin was found to increase selectively the expression of 
TNFReceptor 2. TNF receptor levels, rather than TNF itself, were found to be 
increased in ischemic tissue and TNFReceptor 2 was found to activate a 
neuroprotective signaling cascade including PKB/Akt and NF-kB (Fontaine et al., 
2002; Marchetti et al., 2004a). 
Taken together, the overall benefits observed with statins can not be fully attributed 
to changes in lipid levels alone, suggesting pleiotropic effects beyond cholesterol 
lowering, such as improving endothelial function, decreasing oxidative stress and 
inflammation (James K. Liao, and Ulrich Laufs 2005). Furthermore, it remains 
elusive whether statin treatment provides protection against neurodegenerative 
conditions. 
 
1.3.6 Vaccination and immune therapy 
Another promising strategy to reduce the plaque load in Alzheimer's disease is 
immunotherapy. The idea behind this strategy is to inject pre-aggregated synthetic 
Aβ-peptides into AD patients to elicit an immune response against the toxic 
amyloid-fibrils and to promote the clearance of amyloid plaques. This approach was 
validated successfully in an animal model for AD, were the number of amyloid 
plaques was reduced. The Aβ-vaccination has reached clinical phase II were AD-
affected patients received immunotherapy. Sixty-six % of the patients who 
participated in this randomized trial responded to the Aβ immunization by 
generating antibodies that recognized the pathological Aβ species but not soluble 
Aβ or APP (Hock et al., 2002). Unfortunately, the clinical trial had to be aborted 
because 6 % of the treated patients developed severe inflammatory side effects, e.g. 
meningo-encephalitis.    
 
1.3.7 N-methyl-D-aspartate receptor antagonists 
Accumulating evidence suggests that Aβ-induced neuronal death is caused by N-
methyl-D-aspartate (NMDA) receptor-mediated glutamate excitotoxicity (Harkany et 
al., 2000; Hynd et al., 2004). The central role of the glutamate-induced 
excitotoxicity in many diseases (e.g. stroke, cerebral-ischemia) was the impulse for 
the pharmaceutical industry to develop NMDA-receptor antagonists which are 
capable to block glutamate-induced cell death. Many clinical trials with NMDA 
receptor antagonists (e.g. MK-801) have failed, because of undesired side effects 
such as hallucinations, agitation, increased blood pressure and anaesthesia. These 
side effects occurred because the high binding affinity towards the NMDA receptors 





More recently the low affinity, uncompetitive NMDA receptor antagonist 
memantine (1-amino-3,5-dimethyladamantane) has gained increasing interest. 
Clinical trials have shown that memantine treatment leads to functional 
improvement in AD patients with severe dementia and it is well-tolerated (Hynd et 
al., 2004). Based on the successful clinical trials the use of memantine in the 
modulation of glutamatergic function may therefore represent a novel approach for 
the treatment of AD.   
 
1.3.8 Aggregation inhibitor peptides 
Compounds that block Aβ aggregation and fibril formation provide a further 
potential therapeutic approach against AD. This can be achieved by short synthetic 
peptides (also referred as β-sheet breaker peptides or Anti Amyloid Peptides) which, 
are designed to bind to specific Aβ -regions thereby neutralizing or interfering with 
the negative properties of oligomeric Aβ species. Pioneering work for this approach 
was done by Hilbich, Esler and Tjernberg. They identified the amino acid sequence 
in the amyloid-β peptide which is thought to be responsible for aggregation by 
replacing amino acids in the hydrophobic core of Aβ (Esler et al., 1996; Hilbich et 
al., 1992; Tjernberg et al., 1996). Based on this KLVFF (which represents the 
hydrophobic trans-membrane region of the Aβ peptide) and other sequences, which 
are known to be involved in aggregation, several aggregation inhibiting peptides 
were designed. The initially synthesized compounds were peptides of 11 to 5 amino 
acids targeting the center region of the Aβ peptide and evolved to compounds like 
LPFFD (iAβ5) and/or LPYFDa. These pentapeptides are partially homologous to 
this hydrophobic center region and bind with a relatively high affinity to Aβ 
(Hetenyi et al., 2002a; Permanne et al., 2002; van Groen et al., 2009) by similar 
intermolecular interactions, leading to a competitive replacement of Aβ molecules. 
A major drawback with peptide drugs for neurological disorders is their rapid 
degradation in vivo by proteolytic enzymes and their poor blood-brain permeability 
(Adessi and Soto, 2002). These issues were overcome by chemical modifications, 
like C-terminal amidation and N-terminal carboxylation, which resulted in 





1.4 OUTLINE OF THE THESIS 
This thesis elaborates therapeutic strategies based on our best current 
understanding of the pathogenesis of AD. Thereby we try to either slow or halt 
processes associated with AD pathology. The approaches used in this thesis engage 
different molecular mechanisms of the disease, such as inflammation, excitotoxicity, 
Aβ aggregation and toxicity.  
Epidemiological studies on cholesterol lowering agents suggest that these drugs 
might be useful in the prevention of AD. Next to its cholesterol lowering properties, 
lovastatin induces the up-regulation of TNFR2 in vitro and provides 
neuroprotection against glutamate induced excitotoxicity. Recent studies have 
demonstrated that the activation of NF-B via TNFR2 and PKB/Akt signaling 
provides neuroprotection and might offer a potential drug target for many 
neurodegenerative disorders.  
In Chapter 2 the neuroprotective actions of lovastatin were studied in an in vivo 
model for neurodegeneration in which the nucleus basalis is lesioned via NMDA 
injections. The dysfunction and loss of basal forebrain cholinergic neurons and 
their cortical projections are among the earliest pathological events in the 
pathogenesis of AD. We evaluated whether pretreatment with lovastatin prevents 
degeneration of cholinergic fibers and associated cognitive decline. Furthermore, we 
investigated whether PKB/Akt signaling is involved in the lovastatin mediated 
neuroprotection. 
Chapter 3 is focused on downstream targets of TNF- induced NF-B activation 
and the underlying neuroprotective mechanism. Recently it has been found that 
NF-B binds in the promoter region of KCNN2 and regulates transcription KCa2. 
KCa2 channels are important regulators of neuronal excitability. Therefore, we 
investigated if TNF- signaling is able to induce expression of KCa2 channels and 
whether this contributes to TNF- induced neuronal survival against excitotoxic 
stimuli. 
Excitotoxicity is thought to be a major mechanism contributing to 
neurodegeneration during central nervous system ischemia, trauma, AD and other 
neurological disorders. Such excitotoxic conditions lead to a disturbance of the 
intracellular ionic homeostasis and excess intracellular Ca2+ ions which can activate 
Ca2+-dependent proteases (calpains) that eventually lead to neuronal cell death. 
Therefore the inhibition of calpain provides a promising target to stop 
neurodegenerative processes. In Chapter 4 and 5 I evaluated calpain inhibition as 
therapeutic intervention against NMDA or oligomeric Aβ induced lesion of the 
NBM in vivo. Injection of NMDA or oligomeric Aβ to the nucleus basalis caused a 
strong deterioration of cortical cholinergic projections leading to deficits in learning 





decline were prevented by the application of the calpain inhibitor A-705253. 
Moreover, the extent of microglia activation around the injection site was evaluated.  
Inflammatory processes are a hallmark of many chronic diseases including AD and 
DM. Statistical evidence published in the Rotterdam study and other studies linked 
DM with an increased risk to develop AD, researchers worldwide have searched for 
the causal mechanisms underlying this relationship. Chapter 6 provides an overview 
on the current literature linking AD and DM via inflammatory processes and NF-
B. Because the NF-B pathway plays a major role in the aetiology in both diseases, 
it seems reasonable to assume that mechanisms causing disturbances in this 
pathway are at the core of the relationship.   
The deposition of Aβ peptide into plaques is a defining pathological feature of AD 
and mutations that alter Aβ generation cause AD. Therefore it seems obvious that 
blocking the aggregation into oligomers and fibrils is a potential strategy to 
overcome the toxic effects of this peptide. Compounds which are designed to delay 
and block Aβ aggregation are Aβ derived short synthetic peptides. In Chapter 7 and 
8 the potential therapeutic effects of such aggregation inhibiting peptides was 
examined. These short synthetic peptides are designed to neutralize the devastating 
actions of oligomeric Aβ peptide. In Chapter 7 the aggregation inhibitor LPYFDa is 
tested for its properties to neutralize Aβ oligomer induced toxicity and memory 
deficits.  
Chapter 8 elaborates the design of new improved aggregation inhibiting peptides 
using a computer model of an oligomer Aβ to study three dimensional structure of 
the Aβ peptide/aggregation inhibiting peptide complex to gain more insight into 
the molecular dynamics of the Aβ aggregation process. The resulting peptide from 
this design was synthesized and evaluated in vitro and in vivo for Aβ neutralizing 
























Pretreatment with Lovastatin prevents        
N-Methyl-D-Aspartate-induced 
neurodegeneration in the Magnocellular 
Nucleus Basalis and behavioral dysfunction 
 
Amalia M. Dolga1,3, Ivica Granic1, Ingrid M. Nijholt1, Csaba 
Nyakas1,4, Eddy A. van der Zee1, Paul G. M. Luiten1, 2, and Ulrich L. 
M. Eisel1 
 
1Department of Molecular Neurobiology and 2Biological Psychiatry, Graduate School of Behavioral and 
Cognitive Neurosciences, University of Groningen, Kerklaan 30, 9751 NN, Haren, The Netherlands 
3Current address: Institute of Pharmacology and Toxicology, Clinical Pharmacy, 
Philipps-University, Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg, Germany 
4Neuropsychopharmacological Research Group of Semmelweis University and Hungarian Academy of 















Besides a beneficial cardiovascular effect, it was recently suggested that statins can 
also exert neuroprotective actions. In a previous study we provided in vitro evidence 
that lovastatin treatment abates excitotoxic cell death in primary cortical neurons. 
Here, we investigated the neuroprotective effect of lovastatin in an in vivo mouse 
model. We found that administration of lovastatin (20 mg/kg) significantly protects 
cholinergic neurons and their cortical projections against N-methyl-D-aspartate 
(NMDA, 60 nmol) induced cell death in the magnocellular nucleus basalis (MNB), 
a neuronal cell group that is characteristically affected in Alzheimer’s disease (AD). 
Furthermore, lovastatin-mediated neuroprotection was shown to be dependent on 
protein kinase B (PKB)/Akt signaling since treatment with the PKB/Akt inhibitor 
LY294002 blocked the lovastatin-induced neuroprotective effect. The loss of 
cholinergic neurons after the MNB lesion resulted in memory impairment as tested 
in a passive avoidance paradigm. This was reverted by pre- lesion lovastatin 
treatment. From these studies we conclude that treatment with lovastatin may 
provide protection against neuronal injury in excitotoxic conditions associated with 
neurodegenerative diseases including AD. 
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Statins or 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors 
are commonly used as pharmaceutical compounds to lower cholesterol levels. 
Besides the beneficial cardiovascular effects statins exert pleiotropic actions in the 
central nervous system and were suggested to have neuroprotective properties. For 
example, in a model for brain injury statins (simvastatin and atorvastatin) were 
shown to increase neurogenesis in the hippocampal dentate gyrus and to reduce 
neuronal loss in the cornu ammonis 3 (Lu et al., 2007). Simvastatin enhanced 
neuronal survival in axotomized retinal ganglion cells after optic nerve injury via the 
overexpression of heat shock protein 27 (Kretz et al., 2006). 
In a previous study we showed that lovastatin mediates neuroprotective effects 
against glutamate-induced excitotoxicity in cultured primary cortical neurons (Dolga 
et al., 2008). The neuroprotective effect of lovastatin against glutamate-induced 
excitotoxicity was, at least partly, mediated by the activation of tumor necrosis 
factor-receptor 2 (TNFR2) signaling pathways, which include protein kinase B 
(PKB)/Akt phosphorylation and NF-κB activation (Dolga et al., 2008; Marchetti et 
al., 2004). 
A well-established model to study excitotoxic brain damage in vivo was originally 
developed in rats (Dunnett et al., 1987; Luiten et al., 1995; Luiten et al., 1987; 
Stuiver et al., 1996) and consists of the injection of a neurotoxic dose of the 
glutamate analog NMDA into the magnocellular nucleus basalis (MNB). 
Subsequently the neuronal damage is quantified. The basal forebrain cholinergic 
neurons and their projections to the cerebral cortex are susceptible to experimental 
conditions generally associated with cerebral ischemia and Alzheimer’s disease 
(AD), including exposure to glutamate, NMDA or amyloid beta peptides (Harkany 
et al., 1999b; Luiten et al., 1995). Therefore, NMDA-induced lesion of the MNB is 
an effective in vivo method to study neurodegenerative mechanisms associated with 
NMDA receptor overstimulation (Luiten et al., 1995) and to assess the efficacy of 
potential therapeutic treatments that may interfere with neurodegenerative 
processes. 
Interestingly, damage to cholinergic MNB neurons and to their cortical target areas 
is associated with a decline in memory function during aging and in AD and is in 
fact the basis of the acetylcholinesterase inhibition therapy in AD (Bartus et al., 
1982). In the rat model NMDA-induced excitotoxicity in the MNB also led to 
cognitive deficits (Van der Zee et al., 1994). Hitherto the effects of statins on 
behavior remain rather unexplored. A few studies, however, showed that statins 
improve the spatial learning and memory deficits after hypoxic-ischemic or 
traumatic brain injuries (simvastatin and atorvastatin) in rats (Balduini et al., 2003; 
Lu et al., 2007) and increase learning and attention (lovastatin) in a mouse model of 
neurofibromatosis type I (Li et al., 2005). Simvastatin treatment reversed learning 
and memory deficits in a mouse model for AD (Tg2576 mice). However, 
simvastatin enhanced also learning and memory performance in the non-transgenic 
mice, independent of the levels of amyloid-beta protein in the brain (Li et al., 2006). 
In the current study, we aimed to substantiate our in vitro findings by testing the 
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protective potential of lovastatin against excitotoxic brain damage in vivo. Since our 
previous in vitro studies provided evidence for a role of PKB/Akt in the 
neuroprotective effect of lovastatin, we also investigated whether PKB/Akt 
activation is essential in the protective mechanism of lovastatin against NMDA-
induced excitotoxicity in vivo. To extend the effects of lovastatin in our mouse 
model we tested memory performance of untreated and lovastatin-treated mice with 




2.2 MATERIAL AND METHODS 
 
2.2.1 Animals and treatments 
 
Experiments were carried out on male C57BL/6J mice (12 weeks, 25-30 g, Harlan, 
Horst, The Netherlands). The animals were individually housed and kept on a 
standard laboratory diet and tap water ad libitum with a 12/12 h dark-light cycle. All 
procedures were approved by the Ethical Committee for the use of experimental 
animals of the University of Groningen, The Netherlands (DEC 4681B). 
 
 
2.2.2 Nucleus basalis lesion 
 
Animals were anesthetized with avertin (tri-bromo-ethanol) and their heads 
positioned in a Kopf stereotactic frame adapted to mouse brain coordinates (Kopf 
Instruments model 900, Tujunga, CA, USA). Unilateral lesions were achieved by a 
slow (0.1 μl/min) injection of 0.4 μl and a total of 60 nmol NMDA (Sigma, St. 
Louis, MO, USA solved in phosphate buffered saline, PBS pH=7.4) into the MNB 
(0.6 mm posterior to bregma, 1.8 mm lateral to the sagital suture, 4.6 mm and 4.4 
mm ventral to the dura mater (Franklin and Paxinos, 1997) in two steps of 0.2 μl 
each with an interval of 5 min. Injections were performed with a Hamilton 
microsyringe (Hamilton, Bonaduz, Switzerland) in an infusion pump (TSE, Bad 
Homburg, Germany). Control lesions (0.4 μl PBS) were made in the contralateral 
MNB of each animal in a manner identical to the NMDA infusion procedure. 
Thereafter, mice were returned to their home cages and allowed to recover. 
 
2.2.3 Neuroprotective action of lovastatin (experiment I) 
 
In the first experiment we investigated the neuroprotective action of lovastatin 
against neurotoxic damage induced by a unilateral injection of 60 nmol NMDA in 
the MBN. In pilot experiments 60 nmol NMDA was shown to induce 
approximately 50% reduction in cholinergic neurons and projection fibers which 
was similar to the results found in rat studies in our laboratory (Luiten et al., 1987). 
Experiment I comprised the following five groups (n = 7 per group). (1) In the first 
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 group mice received 20 mg/kg monosodium salt lovastatin (in DMSO and PBS) 
(Calbiochem, San Diego, CA, USA) i.p. for 5 consecutive days. Afterwards 60 nmol 
NMDA dissolved in PBS was injected in one hemisphere and PBS in the 
contralateral hemisphere. The PBS injected site served as an internal control. (2) In 
the second group, mice were injected with saline i.p. for 5 consecutive days followed 
by an unilateral 60 nmol NMDA lesion and PBS infusion contralateral. (3) In the 
third group, mice received lovastatin and NMDA injections as in group 1) but the 
PKB/Akt inhibitor LY294002 (100 μM, Calbiochem, San Diego, CA, USA) was 
infused into the MNB together with NMDA (4). In the fourth group, mice were 
treated as in group 2) but received LY294002 together with NMDA into the MNB. 
(5) To check whether LY294002 treatment by itself already affects cholinergic 
neurons, we infused LY294002 without NMDA into the MNB of saline-pretreated 







Figure 2.1. Schematic outline of the experimental setup. Mice were injected for 5 consecutive days with 
saline or lovastatin (20 mg/kg of body weight) for 5 consecutive days prior to unilateral NMDA lesions 
(60 nmol) into the magnocellular nucleus basalis. A. Eight days after the last i.p injection mice were 
transcardially perfused (for histochemical analysis) and their brains fixated with paraformaldehyde. B. 
Memory performance was assessed using spontaneous alternation and one-way step-through passive 
avoidance paradigms.  These tests were performed eight days after the drug delivery. 
 
 
The lovastatin dose given in the above described experiments is based on the results 
of earlier pharmacokinetic studies (Endres et al., 1998). In this mouse model of 
focal cerebral ischemia pre-administration of either lovastatin or simvastatin for 3 
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consecutive days resulted in a slightly reduced cerebral infarct volume when 2 
mg/kg statins were administered. However, significantly reduced cerebral infarct 
volumes were observed after administration of 20 mg/kg statin (Endres et al., 
1998). 
 
2.2.4 Behavioral assessment (experiment II) 
 
To study the behavioral consequences of lovastatin treatment and MNB lesions, 
four groups of animals were formed: (1) mice injected with saline i.p. for 5 
consecutive days; (2) mice injected with 20 mg/kg lovastatin i.p. for 5 consecutive 
days; (3) mice receiving saline for 5 days i.p. followed by bilateral 60 nmol NMDA 
lesions on the next day; (4) mice receiving lovastatin for 5 days i.p. prior to bilateral 
60 nmol NMDA lesions. 8-10 days after the last i.p injection, mice were tested in 





2.2.4.1 Behavioral testing 
 
2.2.4.1.1 Spontaneous alternation task 
 
Short-term spatial memory performance (working memory) was assessed by 
recording spontaneous alternation behavior in a Y-maze paradigm. The Y maze 
consisted of three tubular and transparent Plexiglas arms forming the Y. All three 
arms were 5 cm in diameter, 27.5 cm long, and at a 120° angle to each other. The 
experimental room contained visual cues, which served as distal spatial cues. 
A naive mouse was placed into the centre of the Y maze and allowed to explore the 
maze freely during an 8-min session. The series of arm entries was recorded visually. 
Arm entry was considered to be completed when all four paws of the animal had 
entered the arm. Alternation was defined as successive entries into the three arms 
on overlapping triplet sets. The alternation percentage was calculated as the ratio of 
actual to possible alternations (defined as the total number of arm entries minus 
two). Since this behavior is not reinforced it is considered “spontaneous”. The 
exploratory activity was assessed by counting the total number of arm entries. 
 
2.2.4.1.2 Passive avoidance paradigm 
 
For this test we used a two-compartment (one-way) step-through device. During the 
training trial mice were placed in an illuminated compartment, which was separated 
from the dark compartment by a door. Mice were allowed to explore the light 
compartment for one minute before the door to the dark compartment was opened. 
The latency to step into the dark compartment was recorded (pre-shock latency). 
Upon entry into the dark compartment the door was closed and a mild foot shock 
(0.3 mA for 2 sec) was delivered through the grid floor. 30 sec after shock 
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 application the mice were returned to their home cages. Memory retention was 
checked 24 h later. The mice were placed in the illuminated compartment for 20 
sec and after opening of the door the latency to step into the dark compartment was 
recorded (post-shock latency) up to a maximum of 8 min. 
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 2  2.2.5 Tissue processing and ChAT histochemistry  
Fixation of the brains was carried out under deep sodium pentobarbital anesthesia 
by transcardial perfusion with 200 ml fixative composed of 4% paraformaldehyde in 
0.1 M phosphate buffer (PB, pH 7.4), which was preceded by a short prerinse (50 
ml) with ice-cold physiological salt solution. Brains were post-fixed for 24 h in the 
same fixative, cryoprotected by 3 days immersion in 30% sucrose in 0.1 M PB at 
4°C. Thereafter, 20 μm coronal sections were cut on a Leica cryostat microtome 
and collected in 0.01 M PBS containing 0.1% sodium azide (Sigma, St. Louis, MO, 
USA). Free floating sections were pre-incubated overnight at room temperature in 5% 
normal rabbit serum (NRS, Zymed, San Francisco, CA, USA) with 0.2% Triton-X. The 
following day, sections were incubated with goat anti choline-acetyltransferase (ChAT) 
primary antibody (Millipore, Billerica, MA, USA) diluted 1:500 in PBS for 2 - 4 days at 
4 °C. Then, sections were exposed to biotinylated rabbit anti-goat IgG (Vector, 
Brunschwig Chemie, Amsterdam, The Netherlands) diluted 1:500 in PBS followed 
by an incubation step for 2 h with Vectastain Elite ABC kit, according to the 
manufacturer’s protocol (Vector, Brunschwig Chemie, Amsterdam, The 
Netherlands). For visualization, Sigma Fast 3,3`-diaminobenzidine tablets (Sigma, St. 
Louis, MO, USA) were used as chromogen with ammonium nickel sulphate (BDH 
Chemicals Ltd., UK) enhancement.  The specificity of immunostaining was confirmed 
in stainings where incubation with the primary antibody was omitted (data not shown). 
 
 
2.2.6 Quantitative image analysis 
 
ChAT fiber density was measured in layer V of the posterior somatosensory cortex 
according to a standardized protocol using an Image Analysis System (Leica 
Quantimet, Cambridge, UK) with a Leica DFC 350FK camera. The images were 
analyzed with Leica Qwin Image Analyse software. Surface area density of cortical 
ChAT positive fibers was measured in parietal cortical sections (0.6 mm posterior to 
bregma) (Franklin and Paxinos, 1997), the cortical area that receives a strong 
cholinergic projection from the lesioned MNB region (Gaykema et al., 1990). After 
background subtraction and grey-scale threshold determination, the surface area of 
the skeletonized ChAT immunoreactive (ir) fibers ([the area covered by ChAT-ir 
fibers]/[total sampling area]) was computed in each parietal region using a 470 nm 
band pass filter. The relative value of ChAT fibers was calculated as the percentage 
difference between the surface area density of the lesioned hemisphere and the 






The statistical test used in this study is ANOVA with LSD or Bonferroni correction 
using SPSS 14 for windows. A p-value smaller then 0.05 was considered to be 






2.3.1 Lovastatin treatment protects against NMDA-induced lesions in 
mouse magnocellular nucleus basalis 
 
The sensitivity of cholinergic neurons to excitotoxicity can be quantified by the loss 
of the cholinergic cortical innervation that originates from the MNB (Gaykema et 
al., 1989) visualized with the cholinergic marker choline-acetyltransferase (ChAT, 
EC3.2.1.6) (Harkany et al., 2000). Histochemical detection of ChAT-ir projection 
fibers revealed a dense fiber network in the layer V of the somatosensory cortex with 
a smooth appearance and a layer specific homogenous staining pattern. The 
cholinergic fiber density decreased after NMDA infusion proportional to the loss of 
the number of neurons in MNB (Harkany et al., 2000). Characteristic 
morphological patterns of neuronal degeneration such as the appearance of 
shrunken or rounded somatic profiles without emanating dendrites, and 
fragmented cholinergic fibers ascertained the excitotoxic effect of NMDA-induced 
lesions (Figure 2.2A and B). Quantification of ChAT positive projection fibers 
revealed a significant loss of cholinergic innervation in the NMDA-lesion 
hemisphere compared to the sham-injected hemisphere of 35.33 ± 5.77%. Pre-
lesion administration of lovastatin significantly attenuated the NMDA-induced fiber 
reduction in the parietal cortex (cholinergic fiber loss 11.25 ± 4.2%, p<0.05 










Figure 2.2. Lovastatin protects cholinergic fibers against NMDA-induced lesions. A. ChAT-ir neuronal 
perikarya and proximal fiber branches in the MBN following NMDA or PBS infusion. Depicted 
representative region of intact cholinergic neurons (1, 2) after sham lesions in MNB whereas in (3, 4) it 
shows the loss of proximal fiber branches emanating from ChAT-ir perikarya. Noteworthy is the loss of 
cholinergic neurons as a consequence of NMDA toxicity. Arrows show ChAT-ir stained cholinergic 
processes. B. Distribution of ChAT-positive projection fibers in the posterior somatosensory cortex 
following NMDA or PBS infusion in the mouse MNB.  Depicted representative region of contralateral 
sham-operated control (1, 3, 5, 7). Noteworthy is the loss of cholinergic projections as a consequence of 
(2) NMDA infusion.  Pre-lesion lovastatin administration (20 mg/kg) significantly attenuated the 
NMDA-induced damage (4) whereas LY294002  (6, 8) failed to rescue cholinergic projections in 
lovastatin-treated mice (8). Horizontal bars in (1) represent layer V of the somatosensory cortex where 




Figure 2.3. Quantitative measurements of cholinergic fiber densities in layer V of the somatosensory 
cortex. Whereas NMDA infusion into MNB induced a massive loss of ChAT fiber loss, lovastatin 
treatment significantly antagonized this NMDA detrimental effect. However, inhibition of PKB/Akt 
pathway with LY294002 did not rescue cholinergic fiber projections in saline- or lovastatin-treated 
mice. **P<0.01, *P<0.05 NMDA vs. all other groups examined (Univariate ANOVA), n = 5-7 per 
group. Data represent means ± S.E.M. 
 
2.3.2 Lovastatin-mediated neuroprotection is dependent on PKB/Akt 
activation 
 
Our previous in vitro data already revealed an essential role of PKB/Akt pathways in 
lovastatin-induced protection in primary cortical neurons exposed to glutamate 
excitotoxicity (Dolga et al., 2008). To further elucidate the lovastatin-mediated 
neuroprotective pathways in vivo we included in our experiments LY294002 as a 
specific inhibitor of PKB/Akt signalling. The concentration used (100 μM) was 
based on previous in vivo studies, where LY294002 delivered in rat brain by a single 
injection abolished PKB/Akt phosphorylation (Cheng et al., 2002). This study 
showed a concentration-dependent effect of LY294002 (100 μM to 800 μM) on 
PKB/Akt phosphorylation. PKB/Akt phosphorylation was already significantly 
reduced when 100 μM LY294002 was administrated (Cheng et al., 2002). 
Lovastatin or saline was administered for 5 consecutive days prior to a combined 
NMDA and LY294002 infusion into MNB. 
Quantitative analysis of the cholinergic fiber loss indicated no effect of the 
LY294002 treatment alone in the NMDA lesion model (38.67 ± 3.33% for NMDA 
plus LY294002 vs. 35.33 ± 5.77% for NMDA alone). In the lovastatin treated 
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 animals the ChAT-positive fiber loss in the NMDA plus LY294002 group (31.6 ± 
5.41%) showed significantly more fiber loss than the NMDA lesioned cases, which 
were not treated with LY294002 (11.25 ± 4.2%; p<0.05). The lovastatin treated 
NMDA+LY294002 fiber loss values were not statistically different from the saline-
pretreated NMDA nor the saline pretreated NMDA+LY294002 animals. It can thus 
be concluded that the neuroprotective lovastatin effect is almost completely blocked 
by LY294002 treatment. Moreover, LY294002 treatment alone did not affect 




2.3.3 NMDA-induced lesions do not alter spatial short-term memory in a 
spontaneous alternation task 
 
Four experimental groups of mice (saline i.p.; lovastatin i.p.; saline i.p. and MNB 
lesion; lovastatin i.p. and MNB lesion) were tested for spontaneous alternation 
behavior and locomotor activity. The spontaneous alternation test in a Y maze is a 
task based on the natural tendency of rodents to alternate in their choices of arm 
visits (Dudchenko, 2004). Spontaneous alternation behavior is generally regarded as 
a measure of spatial working memory (Dudchenko, 2004; Senechal et al., 2008). 
Alternation rates of the mice with MNB lesion showed no significant difference 
when compared with the non-lesioned animals. Moreover, lovastatin treatment in 
NMDA-induced lesioned mice did not significantly increase spontaneous 
alternation rates compared to the saline-treated animals (see Figure 2.4A). 
Furthermore, we did not find a difference in the number of arm entries between 
any of the groups, which suggested that the exploratory activity was neither affected 





Figure 2.4. NMDA-induced lesions do not cause changes in working memory A. In the spontaneous 
alternation task there is no difference in alternation rate between the four groups. Note, however that 
the pool of lovastatin-treated groups had a significantly higher alternation rate when compared to the 
pooled two saline-treated groups (p=0.045, two-way ANOVA). B. There was no significant difference in 





2.3.4 Lovastatin decreased lesion-induced memory deficits 
 
Neuronal projections from MNB directly modulate neocortical information 
processing. The passive avoidance task is a learning task which depends, in part, on 
proper neocortical information processing. In rats NMDA-induced lesions in MNB 
were indeed reported to result in memory impairments in a passive avoidance 
paradigm (Harkany et al., 1999a; Van der Zee et al., 1994). Therefore, we used this 
behavioral paradigm to investigate whether preserved cortical cholinergic function 
in lovastatin-treated mice is able to reverse the cognitive deficits induced by NMDA 
lesions into MNB. 
Altered retention mechanisms and acquisition were investigated at 8 days post-
surgery or 8 days after the last intra-peritoneal injection in the passive avoidance 
paradigm. Pre-shock latencies did not exhibit significant differences among the 
experimental groups (Figure 2.5A). NMDA infusion into the MNB resulted in a 
significant impairment of passive avoidance learning. This was indicated by shorter 
post-shock latencies in the retention trial 24 h after delivery of the foot-shock in the 
saline-treated NMDA lesion group (4.5 ± 0.75 min) in comparison to the saline-
treated group (8 min) (Figure 2.5B). However, lovastatin pretreatment in NMDA 
lesioned mice significantly increased the post-shock latency time compared to 
NMDA lesioned animals (6.5 ± 0.8 min vs. 4.5 ± 0.75 min; p<0.05 ANOVA with 
LSD correction) indicative of an improved memory performance in this test 





Figure 2.5. Lovastatin pretreatment decreased the NMDA lesion-induced memory deficits. A. 
Lovastatin treatment or NMDA infusion in the mouse MNB did not change pre-shock latencies in the 
passive avoidance test. B. Lovastatin administration by itself did not elicit any significant changes in the 
post-shock latencies, as compared with the latencies of saline-injected mice. In contrast, NMDA infusion 
(60 nmol) into the MNB significantly impaired memory retention as shown by the reduced post-shock 
latencies. However, lovastatin pretreatment (20 mg/kg) attenuated this NMDA-induced memory 
deficit. *P<0.05 NMDA vs. all other groups examined (ANOVA with LSD correction), n=5-6 per 









In the present study we show, that administration of lovastatin protects cholinergic 
neurons and their cortical projections against excitotoxic damage in vivo. Decline of 
ChAT positive neurons in the basal forebrain nucleus and their projection fibers in 
the parietal cortex as a result of excitotoxic stimuli is a well-established technique to 
test bioactive substances in vivo (Dunnett et al., 1987; Luiten et al., 1987). Here, this 
method was applied for the first time in mice. We could demonstrate a similar 
outcome of the NMDA lesion as compared with the well-established rat model 
(Gaykema et al., 1989; Luiten et al., 1995; Stuiver et al., 1996). The advantage of 
this in vivo model is the precisely quantifiable neuronal lesion effect on cholinergic 
fiber loss. Moreover, because of the strictly unilateral projections of the MNB, the 
contra lateral sham hemisphere can serve as a control within each individual case. 
In the current study, five days of lovastatin treatment induced highly significant 
neuroprotection against NMDA excitotoxicity in vivo. 
In a recent in vitro study, we provided evidence that lovastatin mediates the specific 
up-regulation of TNFR2 in cultured neurons but not of TNFR1 (Dolga et al., 
2008). Interestingly, this TNFR2 up-regulation in combination with TNF signaling 
led to a strong neuroprotection against glutamate exposure. In several studies we 
could demonstrate that neuroprotection initiated by activation of TNFR2 is 
mediated by PKB/Akt (Marchetti et al., 2004; Senechal et al., 2008). In vitro this 
PKB/Akt pathway was also shown to underlie the lovastatin-mediated protection 
against glutamate-induced excitotoxicity (Dolga et al., 2008). To investigate if this is 
also the case in the in vivo situation, we used the inhibitor of PI3 kinase, LY294002, 
to block the activation of PKB/Akt. In the presently used experimental setup this 
LY294002 treatment resulted in a strong reduction of lovastatin-mediated 
neuroprotection in vivo. 
The neuroprotective effect of PKB/Akt activation was previously reported in in vivo 
models for brain injury. In a mid-cerebral artery occlusion model (Fontaine et al., 
2002; Prinz et al., 2008) PKB/Akt activation was found to be essential for 
neuroprotective signaling since neuroprotection after post-conditioning was 
inhibited in the presence of the PKB/Akt inhibitor LY294002. Besides suppressing 
the PI3 kinase activity, LY294002 also has the capacity to block casein kinase 2. 
However casein kinase 2 in turn uses phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) as major substrate which will also lead in the end to 
inhibition of the PKB/Akt signaling pathway (Duncan and Litchfield, 2008). 
Our findings corroborate recently reported microarray and RT-PCR studies that 
identified several genes of which the expression was altered in statin-treated mice. 
Lovastatin treatment increased the expression levels of 26 genes particularly genes 
related to apoptosis (c-myc, Bcl2) (Johnson-Anuna et al., 2005) and PKB/Akt 
phosphorylation (Li et al., 2006). Bcl2 proteins exhibit neuroprotective functions 
against various excitotoxic insults, such as glutamate or amyloid beta peptides. Bcl2 
gene expression is of particular interest in this respect since this major anti-
apoptotic gene is under direct PKB/Akt regulation (Pugazhenthi et al., 2000). 
41 
In order to assess whether the cholinergic neurons rescued by lovastatin treatment 
are able to counteract the behavioral deficits observed in NMDA-induced lesion 
mice we subjected the animals to a spontaneous alternation task and a passive 
avoidance memory test. To test the selectivity of the MNB lesion to cortical 
functions we used the spontaneous alternation paradigm for working memory, since 
this test is commonly associated with hippocampus and pre-frontal-related memory. 
We found no significant difference in alternation rates between NMDA-lesioned 
animals compared with non-lesioned control mice. This suggests that brain regions 
as the hippocampus are not affected by NMDA-induced lesions of MNB, which is 
in line with the known projection patterns of the MNB and medial septum complex 
(Gaykema et al., 1989; Luiten et al., 1987). On the other hand, pre-lesion 
administration of lovastatin significantly attenuated the memory retention deficit 
induced by the NMDA lesion of the MNB. The passive avoidance paradigm is one 
of the test conditions of choice for the behavioral assessment of the integrity of the 
neocortical system. Thus, the neuroprotective effect of lovastatin on NMDA-
induced damage to the MNB and its neocortical innervation are in line with the 
improved memory retention in lovastatin treated mice.  In summary, our behavioral 
data indicate impaired behavioral performance associated with damage to the MNB 
that specifically affects neocortical denervation and its memory functions while 
leaving particular hippocampal innervation and its learning functions unaffected. 
Whereas lovastatin treatment reverted the memory deficits produced by NMDA 
lesions as observed in the passive avoidance paradigm, lovastatin treatment itself 
had a modest albeit significant effect on improving hippocampal memory and 
prefrontal cortex function irrespective of damage to cholinergic neocortical 
innervation. In a recently published paper the effect of simvastatin on hippocampal 
long-term potentiation (LTP) in brain slices was reported, showing that simvastatin 
inhibits LTP, most likely by inhibiting the production of geranylgeraniol. In 
addition, inhibition of mevalonate pathways produced deficiencies in spatial, 
associative and motor learning. This indicates that cholesterol by itself might be 
important for learning and memory functions, but more critical are the byproducts 
from the mevalonate pathway, such as geranylgeranyl pyrophosphate (Kotti et al., 
2006). 
It is unlikely that behavioral alteration of lovastatin-treated animals can be 
attributed to direct drug effect since statins are rapidly cleared from the brain 
within 6 hours after drug administration (Johnson-Anuna et al., 2005). We 
performed all behavioral testing 7 days after the last lovastatin administration. 
However, the exact underlying mechanisms of how statins can affect the brain 
remain to be elucidated (Wolozin, 2004). Statins such as lovastatin are able to cross 
the blood brain barrier and reach the cerebral cortex within one hour after drug 
administration but are significantly reduced 6 hours later after a single drug 
application. It is not clear whether the effects of statins as found in the present 
study can be directly associated with cholesterol dependent processes in brain tissue. 
Brain cholesterol analyses in several studies showed conflicting results. Long-term 
treatment of simvastatin for 3 months did not change the total cholesterol levels in 
the brain although the plasma total cholesterol levels were strongly reduced (Li et 
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 al., 2006). Other studies report reduced brain cholesterol levels in young C57Bl/6J 
mice treated for 3 weeks with simvastatin and pravastatin, but such a decline of 
cholesterol concentrations was not observed in the brains of mice treated with 
lovastatin (Johnson-Anuna et al., 2005). 
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 2 In conclusion our data provide evidence for a neuroprotective role of lovastatin against NMDA-induced lesions of the MNB. Importantly, this beneficial effect was shown to be dependent on activation of the PKB/Akt pathway. Furthermore, 
lovastatin administration was able to attenuate impaired memory functions that can 
be associated with cholinergic cortical denervation that result from the damaged 
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Previous studies have shown that tumor necrosis factor-alpha (TNF-) induces 
neuroprotection against excitotoxic damage in primary cortical neurons via 
sustained nuclear factor-kappa B (NF-κB) activation. The transcription factor NF-κB 
can regulate the expression of small conductance calcium-activated potassium (KCa) 
channels. These channels reduce neuronal excitability and as such may yield 
neuroprotection against neuronal overstimulation. In the present study we 
investigated whether TNF--mediated neuroprotective signalling is inducing 
changes in the expression of small conductance KCa channels. Interestingly, the 
expression of KCa2.2 channel was up-regulated by TNF- treatment in a time-
dependent manner whereas the expression of KCa2.1 and KCa2.3 channels was not 
altered. The increase in KCa2.2 channel expression after TNF- treatment was 
shown to be dependent on TNFR2 and NF-κB activation. Furthermore, activation 
of small conductance KCa channels by NS309 or CyPPA induced neuroprotection 
against a glutamate challenge. Treatment with the small conductance KCa channel 
blocker apamin or KCa2.2 channel siRNA reverted the neuroprotective effect 
elicited by TNF-. We conclude that treatment of primary cortical neurons with 
TNF- leads to increased KCa2.2 channel expression which renders neurons more 


























 3.1 INTRODUCTION 
 
TNF-α is a proinflammatory cytokine involved in a wide range of cellular responses 
including inflammation, cellular differentiation and apoptosis. TNF-α per se can be 
synthesized and released in the brain by several types of cells, including astrocytes, 
microglia, and neurons. TNF-α was shown to be up-regulated in a number of 
neurodegenerative disorders including Alzheimer’s disease, stroke, and multiple 
sclerosis. It exerts its biological functions through the stimulation of two receptors, 
TNFR1 and TNFR2. Both TNFR1 and TNFR2 induce activation of the NF-κB 
pathway (Eisel et al., 2006; Marchetti et al., 2004). However, the activation kinetics 
of NF-κB stimulation reveals characteristic differences: while activation of the 
TNFR1 pathway leads to a transient NF-κB stimulation, TNFR2 signalling 
promotes persistent and long lasting NF-κB activation (activation that even persists 
up to 24 h of TNF-α treatment)(Marchetti et al., 2004).  
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Several studies showed that TNF-α is able to promote neuroprotection against 
glutamate-induced excitotoxicity in cortical neurons (Cheng et al., 1994; Marchetti 
et al., 2004). Until now, the molecular mechanisms underlying the neuroprotective 
effects of TNF-α against glutamate-induced excitotoxicity are largely unknown but at 
least PKB/Akt activation and subsequent sustained NF-κB activation were shown to 
play a major role (Marchetti et al., 2004).  
 
In a recent study, small conductance Ca2+ activated potassium (KCa2.1-3) channels 
were identified as one of the downstream targets of NF-κB mediated promoter 
regulation (Kye et al., 2007). Together with intermediate conductance KCa 
channels (KCa3.1), these small conductance KCa channels form one of the two 
subgroups of KCa channels (Wei et al., 2005). They differ from the other subgroup 
(KCa1.1, KCa4.1/4.2 and KCa5.1 channels) in that they are voltage insensitive, and 
open in response to low (< 1 mM) intracellular Ca2+ levels by virtue of calmodulin, 
which is constitutively bound to the C-terminal region. The small conductance KCa 
channels are sensitive to apamin, which distinguishes them from all other KCa 
channels. Small conductance KCa channels are important regulators of neuronal 
excitability. In many central nervous system neurons, small conductance KCa 
channel activity dampens excitability by contributing to the afterhyperpolarization, 
affecting interspike intervals during a burst of action potentials as well as the length 
of the burst (Stocker, 2004). In the mammalian brain small conductance KCa 
channels are the product of three paralogous genes, namely KCNN1, KCNN2 and 
KCNN3 genes. KCa2.1 and KCa2.2 channel subunits show extensive co-
localization. They are mainly found in the entorhinal cortex, the subiculum, in 
pyramidal cortical neurons, the CA1 - CA3 region of the hippocampus and in the 
thalamus. KCa2.3 channel subunits have a complementary distribution, and are 
mainly located in the brain stem and in monoaminergic neurons (Sailer et al., 2002; 
Sailer et al., 2004). In certain neuronal cell types, small conductance KCa channels 
are present at dendritic spines where they co-localise with NMDA receptors. There, 
small conductance KCa channel activity suppresses the amplitude of evoked 
synaptic potentials by inhibiting NMDA receptor-dependent activation (Faber et al., 
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2005; Lin et al., 2008; Ngo-Anh et al., 2005). Thus, enhancing small conductance 
KCa channel expression during an excitotoxic insult could be protective due to 
hyper-polarization and diminished excitability. In an initial study Lee and colleagues 
showed indeed that overexpression of KCa2.2 channels can prevent kainic acid- and 
glutamate-induced excitotoxicity (Lee et al., 2003). 
In the present study we have tested the hypothesis whether increased small 
conductance KCa channel expression is part of the mechanism of TNF-α mediated 
neuroprotection against glutamate-induced excitotoxity in cortical neurons.  
 
 




Neurobasal medium and B27 supplement were purchased from Invitrogen 
(Carlsbad, CA, USA). Complete mini protease inhibitor cocktail tablets were from 
Roche (Indianapolis, IN) and mouse TNF-α was a gift from HBT (Uden, The 
Netherlands) or was purchased from Peprotech (London, UK). Cyclohexyl-[2-(3,5-
dimethyl-pyrazol-1-yl)-6-methylpyrimidin- 4-yl]-amine (CyPPA) was bought from 
Specs (Delft, Netherlands). Primary antibodies used to detect small conductance 
KCa channels were rabbit anti-KCa2.1, rabbit anti-KCa2.2 (both kindly provided by 
H-G. Knaus, (Sailer et al., 2004)), and anti-KCa2.3 (APC-025; Alomone 
Laboratories, Jerusalem, Israel). For the detection of actin a monoclonal mouse 
antibody from MP Biomedicals (691001 Irvine, CA, USA) was used. Alkaline 
phosphatase (AP)-conjugated goat anti-mouse (Applied Biosystems, Bedford, MA, 
USA) and AP-conjugated goat anti-rabbit (Applied Biosystems, Bedford, MA, USA) 
were used as secondary antibodies. The chemi-luminiscence detection kit 
(Nitroblock II and CDP-Star) was purchased from Applied Biosystems (Bedford, 
MA, USA). All other materials were from Sigma. 
 
3.2.2 Animal experiments 
 
All experiments were performed using C57BL/6J (Harlan, Horst, The Netherlands), 
TNFR1-/- or TNFR2-/- mice (Erickson et al., 1994; Pfeffer et al., 1993; Rothe et al., 
1993). TNFR1-/- or TNFR2-/- mice were kept in a C57BL/6J background for more 
then ten generations. All procedures were in accordance with the regulation of the 
ethical committee for the use of experimental animals of the University of 
Groningen, The Netherlands (Licence number DEC 4048). Mice were housed in 
standard macrolon cages and maintained on a 12 h light/dark cycle. They received 






 3.2.3 Primary cortical neuron culture 
 
Primary cortical neurons were prepared from embryonic brains (E14-16) of 
C57Bl/6J, TNFR1-/- or TNFR2-/- mice. The meninges were removed and the 
cortical neurons were separated by mechanical dissociation. Cells were plated in a 
density of 12 x 104 cells/well (96 well plates) and 2 x 106 cells/well (6 well plates) on 
poly-D-lysine pre-coated plates. Neurobasal medium with 2% (v/v) B27-supplement, 
0.5 mM glutamine, 1% (v/v) penicillin/ streptomycin and 2.5 mg/ml amphotericin 
B was used as a culture medium. After 48 h neurons were treated with 10 mM 
cytosine arabinoside for another 48 h to inhibit non-neuronal cell growth. 
Subsequently, the medium was completely exchanged and after 6 days of in vitro 
culture, the neurons were used for experiments. Neurons were incubated for the 
indicated periods of time with 100 ng/ml mouse TNF-α. Some cortical neurons 
were incubated with the NF-κB inhibitor BAY11-7082, the small conductance KCa 
channel activator NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime) or CyPPA or 
the small conductance KCa channel blocker apamin for the indicated time period 
and concentrations. BAY11-7082, NS309 and CyPPA were prepared as stock 
solution in DMSO. The final concentration of DMSO in all experiments was less 
than 0.5% vol/vol. In this concentration DMSO had no effect on glutamate-
induced cell death (data not shown). Apamin was prepared as stock solution in 
toxin buffer (100 mM NaCl, 20 mM Hepes pH = 7.4) and kept at -20° C until use. 
Excitotoxicity was induced by 1 h treatment with glutamate (50 mM). After 
treatment, the medium was completely removed and fresh medium was added to 




3.2.4 Determination of cell viability 
 
24 h after glutamate treatment neuronal viability was determined by the 
colorimetric MTT (3-(4,5-dimethylthiazol-2-yl-)2,5-diphenyltetrazolium bromide) 
assay as described previously (Mosmann, 1983). 1.25 mg/ml MTT solution was 
added to each well of a 96 well plate. After 2-4 h of incubation, cells were lysed by 
adding 120 ml of isopropyl-HCl solution (37% HCl/isopropyl alcohol: 1/166) for 
15 min. The absorbance of each well was determined with an automated ELISA 
reader (Bio-Rad, Munich, Germany) at 595 nm with a reference filter at 630 nm.  
 
3.2.5 Protein analysis 
 
Primary cortical neurons from C57Bl/6J, TNFR1-/- or TNFR2-/- mice were washed 
twice with ice cold PBS after indicated periods of time of TNF-α incubation and 
subsequently lysed by the addition of 0.15 ml lysis buffer (20 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% TritonX, 2.5 mM sodium pyrophosphate, 1 
mM sodium orthovanadate and complete mini protease inhibitor cocktail tablet 
(Roche, Indianapolis, IN, USA)). The samples were centrifuged at 9,000g for 10 
min at 4º C and the supernatants boiled for 5 min in Laemmli's sample buffer. 
Twenty mg of total protein was separated by 10% SDS-polyacrylamide gel 
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electrophoresis. Proteins were transfered to a PVDF membrane (Millipore 
Corporation, Billerica, MA, USA). Overnight the membranes were incubated with 
primary antibodies at 4º C and afterwards with AP-conjugated secondary antibodies 
(1: 10,000). Proteins were detected with an ECL detection system according to the 
manufacturer’s instructions (Applied Biosystems, Bedford, MA, USA). Actin 
(1:100,000 antibody dilution) was used as an internal control to correct for 
variations in protein content. The level of actin was not affected by TNF-α 
treatment. Integrated optical densities (IOD) were measured with the Leica DFC 
320 Image Analysis System (Leica, Cambridge, UK) and densitometric analysis was 
performed using the Leica Qwin program. For quantitative image analysis we 
determined the histogram profile of each band and the peaks corresponding to the 
immunoreactive area were measured (IOD). Quantification of IOD was done only 
with images in which saturation of the signal had not occurred. IOD measurements 
were corrected for background intensity. 
 
3.2.6 Subcellular fractionation  
 
Primary cortical neurons cultured in 6-well plates were lysed in lysis buffer (50 mM 
Tris- HCl pH 7.4, 12.5 mM EDTA, 12.5 mM EGTA, 400 mM sucrose, 0.3% (v/v) 
β- mercaptoethanol, complete mini protease inhibitor cocktail tablet). In order to 
obtain the cytosolic and membrane fraction, the subcellular components were 
separated by a series of centrifugations. In a first centrifugation step at 2,000g for 2 
min cell debris and nuclei were removed. In a second centrifugation step the 
supernatant was centrifuged at 100,000g for 60 min. The supernatant of this 
centrifugation step contained the cytosolic fraction whereas the pellet fraction was 
referred to as membrane fraction. The pellet was resuspended in 50 ml lysis buffer.  
 
 
3.2.7 siRNA experiments  
 
siRNA probes targeted to KCa2.2 channels were purchased from Dharmacon 
(Dharmacon, Inc. Lafayette, CO, USA). The target sequences for the mouse-specific 
KCa2.2 channel Accell SMARTpool siRNA mixture were as follows: 
CUAGAGACUUUGAUUGGUA (A-049792-13), 
CGAUCAUCCUGCUUGGUCU (A-049792-14), GUAUUUUCUUCAUCU 
GCUU (A-049792-15), CGUUUUGUUAUGAAGACUU (A- 049792-16).  
A non-targeting Accell siRNA pool (D-001910-10) was used as a control in all 
siRNA transfection experiments. Primary cortical neurons were transfected with 
Accell siRNAs in Accell delivery media (B-005000) according to the manufacturer’s 
instructions. Primary cortical neurons grown on 96-well plates were treated with 
Accell siRNA probes after 4 days. Cells were cultured for 3 more days after 
transfection, then treated, lysed and subsequently analyzed for protein content. 
Accell siRNA probes were in the medium when TNF-α was applied to neurons.  
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 3.2.8 Statistical analysis 
 
Each experiment was performed with at least two different batches of neurons and 
MTT and Western blot were repeated at least twice for each batch. Results are 
represented as mean ± SEM. Statistical analysis was performed by the Student-
Neumann test with a 95% confidence interval followed by one-way ANOVA post-
hoc LSD and Dunnett test using the SPSS program. P values of <0.05 were 








3.3.1 TNF- α protects neurons against glutamate-induced excitotoxicity  
 
To assess the time-dependent effect of TNF-α pre-treatment on cortical neuronal 
cultures challenged with glutamate, we exposed cortical neurons to mouse TNF-α 
(100 ng/ml) for 2, 4, 6, 8 or 24 h. After incubation with TNF-α, cortical neurons 
were challenged with glutamate (50 mM, for 1 h). Neuronal viability was 
determined 24 h following glutamate exposure by the colorimetric MTT assay. 
Glutamate treatment alone reduced cell survival to 36.4 ± 3.2% when compared to 
untreated neurons (set to 100%). Pre-incubation of neurons with TNF-α for up to 6 
h had no significant protective effect against glutamate induced excitotoxicity 
(Figure 3.1). The number of surviving neurons gradually increased when the TNF-α 
pre-treatment lasted for more than 6 h up to 62.2 ± 6.3% cell survival after 24 h 
TNF-α treatment. Treatment with TNF-α (100 ng/ml) alone for 24 h did not 
change neuronal viability (Figure 3.1). Furthermore, TNF-α treatment after the 
glutamate challenge did not protect cortical neurons against glutamate-induced 





Figure 3.1. TNF-α -mediated neuroprotection against glutamate-induced excitotoxicity. Cortical 
neurons were treated with mouse TNF-α (100 ng/ml) for the indicated periods of time and subsequently 
challenged with glutamate (50 mM, 1 h). Neuronal survival was assessed 24 h following the exposure to 
glutamate by an MTT assay. Values represent mean ± SEM (n = 6). Statistical analysis was performed 
by the Student-Neumann test with a 95% confidence interval using the SPSS program. *P values of 
<0.05 were considered to be significant. 
 
3.3.2 TNF-α increases KCa2.2 channel expression 
 
Activation of small conductance KCa channels in cortical neurons has been shown 
to suppress hyperexcitability (Pedarzani et al., 2001). This could be a mechanism to 
enhance neuronal survival in conditions of overstimulation. Therefore, we 
determined whether TNF-α treatment leads to a change in the expression of the 
three small conductance KCa channels, KCa2.1, KCa2.2 or KCa2.3. Similar to a 
previous study in mouse brain (Sailer et al., 2004), we found that anti-KCa2.1(12-
29) antibody (1:1,000) detects three separate bands with molecular weights of 65, 58 
and 43 kDa. The affinity-purified anti-KCa2.2(538-555) antibody (1:1,000) detects a 
band with an apparent Mr value of 64 kDa whereas the serum antibody showed an 
additional unspecific band at approx. 67 kDa. The anti-KCa2.3(504- 522) antibody 
(1:1,000) recognizes a protein running at the height of 75 kDa. Glutamate 
treatment did not affect the expression of any of the small conductance KCa 
channels (data not shown), whereas treatment of cortical neurons with TNF-α (100 
ng/ml) for 2, 4, 6, 8 and 24 h had no effect on the expression of KCa2.1 and 







Figure 3.2. Exposure to TNF-α increases KCa2.2 channel expression in cortical neurons. Neurons 
were treated with mouse TNF-α (100 ng/ml) for indicated periods of time. A. Representative blot and 
bar graph showing the quantification of the 65 kDa KCa2.1 channel band. Accordingly, integrated 
optical densities for the other two KCa2.1 channel bands at 58 and 43 kDa showed no changes in 
response to the indicated TNF-α incubation times. B. Quantification and representative immunoblot for 
KCa2.2 channels with apparent Mr of 64 kDa after exposure to TNF-α for indicated periods of time. 
C. Quantification and expression of KCa2.2 channels after TNF- α (24 h) was removed from thee 
media. D. Quantification and representative immunoblot for KCa2.3 channels. Results shown 
represent mean ± SEM (n = 4). Statistical analysis was performed by the Students-t test or Student-
Neumann test with a 95% confidence interval followed by one-way ANOVA post-hoc LSD and 
Dunnett test using the SPSS program. *P values of <0.05 were considered to be significant. 
 
 
Shorter incubation of TNF-α also showed no effect on KCa2.2 channel expression 
when compared to untreated neurons. However, KCa2.2 channel expression 
increased significantly when neurons were treated with TNF-α for 6, 8, and 24 h (24 
h TNF-α: 204.6 ± 22.1% of non-treated neurons; Figure 3.2B). KCa2.2 channel 
expression returned within 3h to basal levels, when the medium was replaced with 
TNF-α free medium (Figure 3.2C). Subcellular fractioning revealed that under basal 
conditions KCa2.2 channels are located both in the cytosolic and membrane 







Figure 3.3. TNF-α treatment increases KCa2.2 channel immunoreactivity. Representative blot of 
KCa2.2 channel in the cytosolic and membrane fraction in non treated neurons and after 24 h 100 
ng/ml mouse TNF-α treatment (n = 4).  
 
 
3.3.3 TNF-α-induced upregulation of KCa2.2 channels is mediated by 
TNFR2  
 
TNF-α initiates signaling cascades by binding to its receptors: TNFR1 and TNFR2 
(Eisel et al., 2006). To investigate which of the two receptors is involved in the 
upregulation of KCa2.2 channels after prolonged TNF-α treatment, we isolated 
neurons from TNFR1-/- or TNFR2-/- mouse embryo brains. Interestingly, we could 
only observe increased KCa2.2 channel expression after TNF-α treatment in 
TNFR1-/- primary neurons (492.7 ± 13.7%), whereas the level in TNFR2-/- was 




Figure 3.4. The TNF-α dependent increase in KCa2.2 channel is dependent on TNF-R2. Primary 
cortical neurons from (A) TNF-R1-/- and (B) TNF-R2-/- mice were incubated with 100 ng/ml mouse 
TNF-α for 2-24 h, lysed and KCa2.2 channel expression assessed using Western blotting. Results shown 
represent mean ± SEM (n = 4). Statistical analysis was performed by the Student’s-t test with a 95% 
confidence interval using the SPSS program. *P values of <0.05 versus non-treated neurons were 




 3.3.4 Inhibition of NF-κB attenuates TNF-α induced upregulation of 
KCa2.2 channel expression 
 
The activation kinetics of the transcription factor NF-κB in response to TNF-α 
treatment in neurons was shown by several groups (Kaltschmidt et al., 1999; 
Marchetti et al., 2004; Wang et al., 2005). It has been reported that long-term (24 h) 
exposure of neurons to TNF-α promotes persistent and long lasting NF-κB 
activation, which is associated with increased protection against glutamate-induced 
neurotoxicity (Marchetti et al., 2004). We confirmed these data in our experimental 
set-up showing that inhibition of NF-κB by a specific inhibitor, BAY11-7082 (10 
mM), reversed the TNF-α-mediated neuroprotective effect (Figure 3.5A). Since 
KCa2.2 channel expression is regulated by NF-κB (Kye et al., 2007), we determined 
whether the observed increase in KCa2.2 channel expression after TNF-α 
incubation was NF-κB dependent. KCa2.2 protein expression was evaluated by 
Western blot analyses in TNF-α treated neurons in the presence or absence of 
BAY11-7082. KCa2.2 levels in cortical neurons were not increased by application of 
TNF-α (100 ng/ml) when BAY11-7082 (10 mM) was co-applied (Figure 3.5B). 
BAY11-7082 treatment alone did not affect KCa2.2 channel expression. These 
findings suggest that inhibition of NF-κB prevented the TNF-α-induced increase in 







Figure 3.5. NF-kB inhibition prevents the TNF-α-induced neuroprotection and the increase in KCa2.2 
channel expression A. Neuronal survival was assessed after 24 h TNF-α (100 ng/ml) incubation 
followed by an 1 h glutamate treatment. BAY11-7082 (10 mM) was co-applied with TNF-α where 
indicated. B.Neurons were co-incubated with TNF-α and BAY11-7082 for the indicated periods of 
time. Quantification and a representative immunoblot for KCa2.2 channel protein with apparent Mr 
values detected at 64 kDa are presented. Results shown represent mean ± SEM (n = 3). Statistical 
analysis was performed by the Student- Neumann test with a 95% confidence interval followed by one-





3.3.5 Small conductance KCa channel activation leads to neuronal 
survival 
 
To investigate whether increased small conductance KCa channel activity can be 
neuroprotective, cortical neurons were treated for 30 min with different 
concentrations of NS309, an activator of small conductance KCa and intermediate 
conductance KCa (KCa 3.1) channels (Strobaek et al., 2004), followed by addition 
of glutamate (50 mM) to the medium for 1 h. NS309 strongly reduced glutamate-
induced neuronal death in a concentration-dependent manner (cell survival NS309 
100 mM and glutamate 86.8 ± 1.8% versus glutamate 46.7 ± 5%)(Figure 3.6A). In 
order to have neuroprotective properties NS309 had to be in the medium during 
the glutamate challenge. When NS309 was given before or after the glutamate 
challenge, we could not observe a neuroprotective effect of the KCa channel 
activator (Figure 3.6B).  
 
Since NS309 does not distinguish between the subtypes KCa2.1, KCa2.2 and 
KCa2.3 and also activates the related KCa3.1 channels, we repeated this experiment 
with CyPPA, a compound which is selective for stimulating KCa2.2 and KCa2.3 
(Hougaard et al., 2007). Treatment with CyPPA also led to increased neuronal 
survival upon glutamate treatment in a concentration-dependent manner although 
to a somewhat lower extent as NS309 (cell survival CyPPA 50 mM and glutamate 
52.4 ± 3.1% versus glutamate 36.9 ± 3.3%)(Figure 3.6C). Concentrations of CyPPA 
higher than 50 mM, however, appeared to be toxic to neurons.  
 
 
3.3.6 Reduced KCa 2.2 channel activity blocks TNF-α-induced neuroprotection  
 
To confirm the involvement of small conductance KCa channels in TNF-α-induced 
neuroprotection, we analyzed the viability of cortical neurons that were treated with 
100 ng/ml mouse TNF-α for 24 h and challenged with glutamate (50 mM for 1 h) 
in the presence or absence of an inhibitor of small conductance KCa channel 
activity (Figure 3.6D). As inhibitor we used apamin, an 18-amino-acid bee-venom 
toxin with a high selectivity for small conductance KCa channels. Application of 
apamin alone in a concentration of 50 mM already reduced cell survival to 73.3 ± 
2.7% whereas a concentration of 20 mM apamin had no significant effect on cell 
survival. The detrimental effect of glutamate on cell survival was also not changed 
by 20 mM apamin treatment. Glutamate-induced neuronal death was partially 
reverted by pre-incubation of TNF-α (TNF-α and glutamate 56.7 ± 2.7% cell survival 
versus glutamate 41.2 ± 1.5%), whereas suppression of small conductance KCa 
channel activity by apamin (20 mM) prevented the TNF-α induced neuroprotective 
effect (TNF-α, apamin and glutamate 42 ± 1.3% cell survival versus glutamate 41.2 







Figure 3.6. Small conductance KCa channel activation induces neuroprotection A. Cortical neurons 
were incubated with the small conductance KCa channel activator, NS309 (10 - 100 mM) for 30 min. 
Then, where indicated, neurons where challenged by adding glutamate (50 mM) to the medium for 1 h. 
After the glutamate challenge, media were completely replaced by fresh media. After an additional 24 h 
the viability of cells was verified by an MTT assay. B. NS309 was added to the neurons 30 min before, 
during and/or immediately after the glutamate challenge (50 mM, 1 h) and cell survival assessed by an 
MTT assay. C. CyPPA (25 mM and 50 mM), a positive modulator of KCa2 channels with a high 
selectivity for KCa2.3 and KCa2.2 channels, was applied alone for 30 min or the 30 min treatment 
was followed by adding glutamate to the medium for 1h where indicated. D. Cortical neurons were 
treated with TNF-α for 24 h. Afterwards neurons were challenged with glutamate (50 mM) for 1 h. 
Where indicated, the small conductance KCa channel blocker apamin was added to the medium for 30 
min before adding glutamate to the medium. Statistical analysis was performed by the Student- 
Neumann test with a 95% confidence interval. *P values of <0.05 versus glutamate treated neurons 
were considered to be significant (n = 3). 
 
 
The role of KCa2.2 channels in TNF-α- induced neuroprotection was assessed by 
pre-treating primary cortical neurons with KCa2.2 channel siRNA. Protein analysis 
of neurons pre-treated with KCa2.2 channel siRNA showed reduced KCa2.2 
channel expression levels compared to non-treated neurons or control siRNA-
treated neurons. Most important, the up-regulation of KCa2.2 channel expression 
levels observed after TNF-α treatment was abolished when neurons were pre-treated 
with KCa2.2 channel siRNA but not when pre-treated with control siRNA (Figure 
3.7A). Treatment with KCa2.2 channel siRNA alone already significantly reduced 
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the viability of the neurons (80.1 ± 2.2%) (Figure 3.7B). TNF-α-induced 
neuroprotection against a glutamate challenge was completely abolished when 
neurons were pre-treated with KCa2.2 channel siRNA. In control siRNA-treated 







Figure 3.7. KCa2.2 channel siRNA pre-treatment abolishes TNF-α-induced neuroprotection Cortical 
neurons were pre-treated with KCa2.2 siRNA or control siRNA. After 2 days of incubation with 
siRNA, 100 ng/ml TNF-α was added to the medium for 24 h. Neurons which were not treated with 
TNF-α served as controls. A. Representative blots of KCa2.2 channel expression. B. Neuronal survival 
assessed by an MTT assay. TNF-α was applied for 24 h and followed by an 1 h exposure to 50 mM 
glutamate where indicated. Values represent mean ± SEM (n = 6). Statistical analysis was performed by 
the Student- Neumann test with a 95% confidence interval using the SPSS program. *P values of <0.05 





In the present study we have demonstrated that a TNFR2 and NF-κB-dependent 
increase in KCa2.2 channel expression in cortical neurons contributes to the 
neuroprotective effect of TNF-α against glutamate-induced excitotoxicity. TNF-α has 
been implicated as contributing to both neuroprotection and neurodegeneration, 
depending on the tissue and experimental paradigm (Chao and Hu, 1994; Cheng et 
al., 1994; Hermann et al., 2001; Marchetti et al., 2004; Zou and Crews, 2005). In 
our in vitro model of glutamate-induced cell death of primary cortical neurons, 
TNF-α was shown to have neuroprotective properties. Although the involvement of 
TNFR2, PKB/Akt and NF-κB was already suggested (Dolga et al., 2008; Fontaine et 
al., 2002; Marchetti et al., 2004), only limited data are available on potential 
neuroprotective downstream targets of NF-κB. In our study, the time-dependent 
neuroprotective effect of TNF-α against a glutamate challenge was paralleled by a 
selective increase in KCa2.2 channels, whereas the expression of KCa2.1 and 
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 KCa2.3 channels remained unaffected. More specifically, TNF-α treatment resulted 
in a translocation and increased expression of KCa2.2 channels at the cell surface. 
The increased expression of KCa2.2 channels after TNF-α treatment was mediated 
by TNFR2, which corresponds well with our previous findings that TNFR2 
mediates TNF- α-induced neuroprotection (Dolga et al., 2008; Fontaine et al., 2002; 
Marchetti et al., 2004). In addition, NF-κB was shown to be involved in the 
enhanced expression of KCa2.2 channels after TNF-α treatment. BAY11-7082, a 
specific inhibitor of NF-κB, blocked the TNF-α mediated increase in KCa2.2 
channel levels and was also shown to block TNF- α/TNFR2 mediated 
neuroprotection (Marchetti et al., 2004). NF-κB might interact with two NF-κB 
binding sites, which were recently reported as regulatory parts of the murine 
KCa2.2 promoter (Kye et al., 2007). The specific small conductance KCa channel 
blocker apamin blocked the neuroprotective effect of TNF-α against glutamate-
induced excitotoxicity. Small conductance KCa channels have different affinities for 
apamin with KCa2.2 proteins being the most sensitive, KCa2.3 intermediate and 
KCa2.1 being the least sensitive to apamin (Finlayson et al., 2001; Strobaek et al., 
2000). Given the finding that in cortical neurons KCa2.1 and KCa2.2 channels are 
more abundant than KCa2.3 channels (Sailer et al., 2002; Sailer et al., 2004) and 
KCa2.2 channels are more sensitive to apamin than KCa2.1 channels (D'Hoedt et 
al., 2004), reduction of TNF-α mediated neuroprotection by apamin could be 
mainly attributed to the inhibition of KCa2.2 channels. This was confirmed by our 
findings using KCa2.2 channel siRNA. Reduced KCa2.2 channel expression after 
KCa2.2 channel siRNA treatment abolished TNF-α mediated neuroprotection. The 
neuroprotective function of small conductance KCa channels became evident by 
the finding that the small conductance KCa channel activators, NS309 and CyPPA, 




NS309 facilitates Ca2+-dependent activation of small and intermediate conductance 
KCa channels, being most potent on intermediate KCa channels and 10–20 times 
less active on the small conductance KCa channel subtypes (Strobaek et al., 2004). 
CyPPA is a selective positive modulator of KCa2.2 and KCa2.3 channels, which 
does not affect KCa2.1 or KCa3.1 channels (Hougaard et al., 2007). Although we 
can not exclude the involvement of KCa2.3 channel activity in the neuroprotective 
effect elicited by CyPPA, the distribution profile of KCa2.2 and KCa2.3 in cortical 
neurons (Sailer et al., 2002) again suggests a major role of KCa2.2 in the CyPPA-
induced neuroprotective effect. The neuroprotective effect of CyPPA was similar to 
the neuroprotective effect of TNF-α whereas the effect of NS309 was much larger. 
This result may be explained by a possible neuroprotective effect of KCa3.1 channel 
activation in NS309 treated-neurons. Based on our results we can only speculate on 
how increased KCa2.2 channel expression can contribute to the neuroprotective 
effect elicited by TNF-α. However a KCa2.2-mediated decrease in neuronal 
excitability is likely to be part of the mechanism. Indeed, the neuroprotective 
potential of KCa2.2 has also been observed in an earlier study showing that 
overexpression of KCa2.2 channels in cultured hippocampal neurons increases 
cellular survival against a kainic acid challenge by blunting the kainic acid-induced 
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increase in excitability (Lee et al., 2003). Several studies showed a colocalization of 
KCa2.2 channels with NMDA receptor subunits in dendritic spines (Faber et al., 
2005; Lin et al., 2008; Ngo-Anh et al., 2005). Glutamate treatment of neurons 
triggers ionotropic glutamate (e.g. NMDA, AMPA) receptor dependent activation 
which leads to excessive Ca2+ influx into the cell. KCa2.2 channels can be activated 
by this Ca2+ influx. It was shown that the repolarizing effect of KCa2.2 channel 
activity can oppose the depolarizing effect of AMPA receptor activity, favouring 
Mg2+ reblocking of NMDA receptors and thus reducing the Ca2+ transient (Faber et 
al., 2005; Lin et al., 2008; Ngo-Anh et al., 2005). In this way KCa2.2 channels may 
decrease glutamate-induced excitotoxicity. We hypothesize that increased KCa2.2 
channels expression/activity may lead to decreased susceptibility to glutamate-
induced excitotoxicity via its coupling with NMDA receptors. However, based on 
the results by Houzen and colleagues (Houzen et al., 1997), it can be suggested that 
an increase in KCa2.2 channels is not the only mode of neuroprotection against 
glutamate-induced excitotoxicity. They reported that the neuroprotective effect of 
TNF-α against NMDA-induced toxicity can be attributed to an increase in outward 
potassium current (A-current) density in rat cortical neurons. From these findings, 
it may be concluded that the neuroprotective effect of TNF-α against glutamate-
induced toxicity is mediated by a concomitant increase in outward potassium 
current (A-current) density. The A-current is shown to be involved in the regulation 
of the neuronal firing rates in such a way that an increase in A-current density 
reduces cell excitability (Houzen et al., 1997). Interestingly, the increase in A-
current density was inhibited by cycloheximide, a blocker of gene translation. 
Therefore, it was concluded that the effect of TNF-α might be mediated by de novo 
synthesis of channel protein itself and/or modulating proteins associated with the 
channel activities. 
Altogether, the TNF-α/TNF-R2/NF-κB pathway may recruit several downstream 
targets in order to produce neuroprotective effects (Mattson, 2005) and the present 
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N-Methyl-d-aspartate (NMDA) receptor-mediated excitotoxicity is thought to 
underlie a variety of neurological disorders, and inhibition of either the NMDA 
receptor itself, or molecules of the intracellular cascade, may attenuate 
neurodegeneration in these diseases. Calpain, a calcium-dependent cysteine 
protease, has been identified as part of such an NMDA receptor-induced excitotoxic 
signaling pathway. The present study addressed the question of whether inhibition 
of calpain can prevent neuronal cell death and associated behavioral deficits in a 
disease-relevant animal model, which is based on excitotoxic lesions of the 
cholinergic nucleus basalis magnocellularis of Meynert. Excitotoxic lesions of the 
nucleus basalis with NMDA induced a markedly impaired performance in the novel 
object recognition test. Treatment with the calpain inhibitor (A-705253), dose-
dependently prevented the behavioral deficit. Subsequent analysis of choline 
acetyltransferase in the cortical mantle of the lesioned animals revealed that 
application of A-705253 dose-dependently and significantly attenuated cholinergic 
neurodegeneration. Calpain inhibition also significantly diminished the 
accompanying gliosis, as determined by immunohistochemical analysis of microglia 
activation. Finally, inhibition of calpain by A-705253 and the peptidic calpain 
inhibitor N-acetyl-Leu-Leu-Nle-CHO did not impair long-term potentiation in 
hippocampal slices, indicating that calpain inhibition interrupts NMDA 
excitotoxicity pathways without interfering with NMDA receptor-mediated signaling 
involved in cognition. We conclude that inhibition of calpains may represent a 
valuable strategy for the prevention of excitotoxicity-induced neuronal decline 
without interfering with the physiological neuronal functions associated with 










 4.1 INTRODUCTION 
Calpains in the central nervous system are Ca2+-dependent cysteine proteases, which 
can modulate the conformation, localization, and activity of various proteins. 
Calpain-induced modifications have a profound affect on biological processes as 
different as cell cycle progression and vesicular trafficking. They are an integrative 
part of several signaling cascades, but they can also contribute to apoptotic and 
necrotic cell death in pathological conditions. For this reason, calpains have been 
discussed extensively as target for therapeutic interventions in a number of 
neurodegenerative disease that are associated with neuronal loss (for review, see 
Huang and Wang, 2001; Goll et al., 2003; Zatz and Starling, 2005).  Chapter 
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In that respect, it has recently been shown that inhibition of calpains prevents 
excitotoxic neuronal cell death in vitro (Caba et al., 2002; Ray et al., 2006) and in 
vivo (Chiu et al., 2005; Takano et al., 2005). Excitotoxicity is caused by an 
overstimulation of N-methyl-d-aspartate (NMDA) receptors, and there is now 
growing evidence that calpain cleaves several downstream targets that are critical for 
the progression of excitotoxic neuronal degenerative processes (Wu et al., 2004; 
Hou et al., 2006).  
We have recently introduced a highly specific low-molecular-weight inhibitor of 
calpain, A-705253, which does not affect the multifunctional proteasome complex 
(Lubisch et al., 2003). Selectivity against the proteasome is necessary to evaluate the 
role of calpain, because the ubiquitin-proteasome system also contributes to some 
neurodegenerative diseases (Rubinsztein, 2006; Pan et al., 2008). By using such a 
specific calpain inhibitor, we addressed the questions of whether inhibition of 
calpain-mediated cascades would 1) prevent neurodegeneration in a model relevant 
for neurodegenerative diseases, 2) maintain the behavioral function of the affected 
brain area, and 3) affect normal NMDA receptor-dependent physiology. To analyze 
the neuroprotective effect of calpain inhibition, we used an established model of 
excitotoxicity-induced nucleus basalis magnocellularis (NBM) degeneration in rats 
(Horváth et al., 2000; Harkany et al., 2001, 2002). The NBM in rats is analogous to 
the nucleus basalis of Meynert in humans. Cholinergic fibers originating from the 
NBM extensively project to the neocortical mantle and play an essential role in the 
attention phase of information storage processing (Blokland 1995; Van der Zee and 
Luiten 1999). Lesioning of the NBM in rodents causes a degeneration of 
cholinergic cortical projections, which inevitably leads to severe cognitive deficits in 
affected rats and mimics the characteristic loss of forebrain cholinergic innervation 
in Alzheimer's disease (Bartus et al., 1982; Gaykema et al., 1992). Compounds that 
interfere with downstream calcium-associated intracellular pathways initiated by 
glutamate-induced calcium influx may well affect signaling cascades that are crucial 
for memory processes. To assess whether calpain inhibition would affect normal 
NMDA-dependent physiology, we also examined long-term potentiation (LTP) in 
hippocampal slices.  
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In this study, we present data showing that calpain inhibition prevents NMDA-
induced neurodegeneration of NBM and associated decrease of cortical cholinergic 
innervation. Furthermore, calpain inhibition attenuates cognitive deficits that occur 
as a result of such neurodegeneration. Normal NMDA receptor-dependent 
physiology is not affected, indicating that only those downstream cascades are 
interrupted, which contribute to cellular pathology.  
 
4.2 MATERIAL AND METHODS 
4.2.1 Materials  
A-705253 (Lubisch et al., 2003) was solubilized in 0.9% sodium chloride with a pH 
between 5 and 5.5, and injected intraperitoneally in doses of 1, 3, and 10 mg/kg 
b.wt. NMDA (Sigma-Aldrich, St. Louis, MO) solution was prepared in phosphate-
buffered saline (PBS) solution (pH7.4) in a concentration of 60 nmol per 1 μl. The 
selective noncompetitive NMDA receptor antagonist (+)-MK-801 hydrogen maleate 
(Sigma-Aldrich) was dissolved in 0.9% sodium chloride for intraperitoneal injection 
in a dose of 2.5 mg/kg. N-Acetyl-Leu-Leu-Nle-CHO (ALLN; Calbiochem, San 
Diego, CA) stock solutions were prepared in dimethyl sulfoxide.  
4.2.2 Animals and Surgical Procedure 
Eight-month-old male Wistar rats (8–11 per group; Harlan, Borchen, Germany) 
were anesthetized with an intraperitoneal injection of sodium pentobarbital (60 
mg/kg b.wt.). All care and treatments were carried out in accordance with the 
European Communities Council Directive on the use of experimental animals. 
One microliter of the freshly prepared solution of NMDA (60 nmol) in PBS was 
applied by a Hamilton microsyringe into the right nucleus basalis (anterior-posterior 
coordinate, -1.5 mm; lateral, 3.2 mm) at two dorsoventral positions, 6.2 and 7.0 
mm ventral to the dura. Sham controls followed the same surgical procedures, but 
they were injected with the same quantity of the PBS alone. For more 
methodological details, we can refer to our earlier report (Luiten et al., 1995).  
4.2.3 Drug Administration 
A-705253, MK-801, or vehicle were applied 1 h before NMDA injection, which was 
followed by a second application 12 h after surgery and 2 daily injections for the 
next 2 days. MK-801 was also injected 1 h before and 12 h after surgery, but it was 
given only once per day for the two postsurgery days (at 2.5 mg/kg).  
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 At postoperative day 12, the animals were transcardially perfused under deep 
pentobarbital anesthesia with a fixative solution of 4% paraformaldehyde in 0.1 M 
phosphate buffer, pH 7.4, after a short prerinse with heparinized saline. The brains 
were removed, post-fixed for 2 days in the same fixative, and stored in phosphate 
buffer at 0°C, then cryoprotected by 30% sucrose for 4 days, and sectioned on a 
cryostat microtome at a thickness of 20 μm. Free-floating brain sections were 
processed for immunocytochemical staining.  
4.2.4 ChAT Staining of Cholinergic Fibers 
An immunostaining procedure was applied to visualize choline acetyltransferase 
(ChAT)-positive cholinergic neurons in NBM and their projection axon 
ramifications in the target brain areas, i.e., in the parietal neocortex. Every eighth 
section was stained for ChAT and CD11b as a microglia marker. Goat anti-ChAT 
primary antibody (Chemicon, Temecula, CA) was used in a 1:500 dilution. 
Biotinylated rabbit anti-goat antibody and Vectastain ACB kit was obtained from 
Vector Laboratories (Burlingame, CA). The staining was completed with nickel-
enhanced diaminobenzidine reaction in the presence of H2O2.  
Chapter 
 4 
4.2.5 Visualization of Microglial Activation by CD11b Antibody 
Mouse anti-rat integrin αM [CD11b] monoclonal antibody (Chemicon) was used in 
a dilution rate of 1:1500 to recognize activated microglia. The biotinylated 
secondary antibody and the ABC kit were obtained from Vector Laboratories (see 
above). Diaminobenzidine reaction was enhanced by nickel ammonium sulfate, as 
described above.  
4.2.6 Quantification of Cholinergic Fiber Density 
The quantification procedure for cholinergic fiber density is established in our 
laboratory and was published several times in the past (Horváth et al., 2000; 
Harkany et al., 2001). In brief, the parietal neocortex, topographically 
corresponding to the anterior-posterior site of the NMDA lesion in the NBM and 
with the highest level of cholinergic fiber loss, was analyzed for fiber density with 
the Quantimet 600HR (Leica, Wetzlar, Germany) computer program. The exact 
measurement took place in the superficial sublayer of the layer V cortical area, 
which receives the highest density of cholinergic innervation. Three brain sections 
were analyzed per animal, and the results were averaged. Fiber density in percentage 
surface area of positively stained fibers was computed in both sides of the brain 
section. The ChAT-positive fiber density ipsilateral to the lesion was compared with 
the intact contralateral side, and the percentage loss was calculated as an indicator 
of cholinergic neuron and fiber degeneration.  
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4.2.7 Magnitude of Microglial Reaction 
Microglial activation around the lesion was remarkably localized and could be 
quantified with a computerized technique that measured the size of the brain region 
infiltrated by the activated microglia (Quantimet; Leica). Area of microglia 
activation was manually delineated and measured at the level of NBM injection 
indicated by the overstained injection channel. Here again, three sections were 
selected from a total of 10 to 12 for measurements. The selection of sections and 
measurements were unbiased and carried out blindly.  
4.2.8 Behavioral Testing 
4.2.8.1 Small Open-Field Behavior  
Seventy-two hours postsurgery, the behavior of the animals was assessed in a light-
independent small open-field paradigm (Nyakas et al., 1991). Animals were placed 
into individual Perspex arenas, 24 × 24 cm in diameter with 30-cm high transparent 
walls, for 25 min. Six rats were observed simultaneously, and every 10 s the 
following behaviors were scored by a sampling technique: 1) rearing; 2) sniffing with 
head turning; 3) walking; 4) grooming; and 5) immobility (resting). Ambulation was 
also expressed by a combined score of rearing, sniffing, and walking (ambulation = 3 
× rearing + 1 × sniffing + 2 × walking scores). The representative scores of each 
behavioral component were summed up in 5-min blocks and analyzed statistically.  
4.2.8.2 Novel Object Recognition 
Novel object recognition was assessed 5 days postsurgery. A day before testing novel 
object recognition ability, the rats were placed into a cylindrical open-field arena of 
80-cm diameter surrounded by a 60-cm high reflective aluminium wall for 3 min. 
During this period, the rats were allowed to habituate to the experimental 
surroundings. The next day, during the 1st session of the novel object recognition 
test, the rats were allowed to explore the same open-field apparatus for 5 min while 
two identical objects (A + A) were placed into the arena. During the 2nd session, 
carried out 3 h after the 1st session, one of the two objects was replaced by a novel 
one (B + A). The ratio of visiting the novel versus known objects illustrated the 
object recognition ability, i.e., the attention behavior. The total period spent with 
exploration of the objects during the 1st and 2nd sessions were recorded. The 
recognition ability of the novel object at the 2nd session was calculated in the 
following way: duration of exploration of the novel (B) object was divided by the 




 4.2.9 Electrophysiology 
Seven to 8-week-old male Wistar rats (Harlan) were decapitated, and 400-μm 
transverse hippocampal slices were prepared with a self-constructed tissue chopper. 
The slices were transferred to a submerged recording chamber and adapted for at 
least 1 h at 33°C in artificial cerebrospinal fluid (124 mM NaCl, 4.9 mM KCl, 1.3 
mM MgSO4, 2.5 mM CaCl, 1.2 mM KH2PO4, 25.6 mM NaHCO3, and 10 mM 
glucose 10, pH7.4).  
The Schaffer collateral was locally stimulated by a monopolar stimulation electrode 
(impedance 20 - 150 Ω; Sprint Metall Work, Reichshof, Germany) using a constant 
current, biphasic stimulus generator (voltage, 1–5 V; impulse duration, one polarity 
0.1 ms and whole impulse 0.2 ms) (2100; AM-Systems Isolated Pulse Stimulator; 
AM-Systems, Carlsborg, WA). Field excitatory postsynaptic potentials (fEPSPs) were 
recorded from the stratum radiatum with glass electrodes (borosilicate glass with 
filament, 1–5 MOhm, diameter: l.5 mm, tip diameter: 3–20 μm) filled with 
experimental solution. The field potentials were filtered by a low-pass filter (5 kHz). 
For the statistical analysis of the experiments, the slope of the fEPSP was 
determined. Recording, analysis, and supervision of the experiments were 
performed by means of a software program (PWIN), which was developed at the 
Leibniz Institute for Neurobiology (Department of Neurophysiology) in Magdeburg, 
Germany. LTP was induced using a theta burst stimulation protocol (four times two 
paired pulses were applied in intervals of 200 ms, the interval between the paired 
pulses was 10 ms, and the width of a single pulse was 0.2 ms).  
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4.2.10 Effect of A-705253 on Spectrin Cleavage in Hippocampal Slice 
Cultures 
Hippocampal slices were prepared from 9 to 11-day-old Wistar rats. Slices, 350-μm 
thick, were placed on Millicell single-well PCF inserts (Millipore, Schwalbach, 
Germany) in 6-well cell culture plates (Greiner Bio-One GmbH, Frickenhausen, 
Germany) and kept in an incubator for 8 days at 34°C with 5% CO2 air. The slices 
were cultured in medium A [25 mM HEPES, pH 7.3, 40% basal medium Eagle 
with Earle's salt, 25% horse serum, 25% Earle's balanced salt solution, 1 mM 
GlutaMAX (Invitrogen GmbH, Karlsruhe, Germany), and 28 mM glucose] for the 
first 3 days. Thereafter, medium A was replaced with Neurobasal A medium 
(Neurobasal A medium, 1 mM GlutaMAX, and 25 mM glucose; Invitrogen 
GmbH), and the slices were kept in culture for an additional 5 days. Neurobasal A 
medium was replaced twice a week.  
After cultivation of the hippocampal slices for 8 days, the medium was aspirated 
and replaced with 1 ml of Neurobasal A medium. A total of 0.001 ml of different 
A-705253 inhibitor solutions at 10, 1, and 0.1 mM was added, respectively. After a 
30-min incubation at 34°C with 5% CO2 air, NMDA was added (10 μM final 
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concentration) and incubated for 5 h at 34°C with 5% CO2 air. After this time, the 
slices were collected in 1.5-ml Eppendorf tubes and solubilized by the addition of 
0.025 ml of lysis buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 10% sucrose, 0.1% CHAPS, 1 mM dithiothreitol, 1:25 CompletePlus 
(Roche Diagnostics GmbH, Mannheim, Germany), and 1:100 phosphatase 
inhibitor cocktail set II (Calbiochem-Merck Biosciences GmbH, Darmstadt, 
Germany). Slices were homogenized with a plastic pistill and kept on ice for 5 min. 
The insoluble material was removed by centrifugation for 5 min at 13,000 rpm and 
4°C, and the supernatant was collected. Supernatant protein concentrations were 
determined with MicroBCA (Pierce Inc., Rockford, IL). Samples (equal total 
protein of 20 μg/lane) were mixed with NuPAGE LDS sample buffer 4× (Invitrogen 
GmbH), heated for 5 min at 95°C, and thereafter resolved by 4 to 12% SDS ± 
polyacrylamide gel electrophoresis (Invitrogen GmbH). After transfer of proteins to 
nitrocellulose membranes, the proteins were analyzed by immunoblotting using a 
murine monoclonal antibody (mAB 1622; Chemicon) specific for spectrin and 
calpain-mediated spectrin breakdown products (SBDPs) followed by a peroxidase-
conjugated secondary sheep anti-mouse antibody (A6782; Sigma-Aldrich) and a 
peroxidase substrate. To determine the percentage inhibition, the integrated optical 
density of the SBDPs in the presence and absence of inhibitor was determined 




4.3.1 Calpain Inhibition Markedly Attenuates Degeneration of 
Cholinergic Fibers after Excitotoxic Lesion of the Nucleus Basalis 
Magnocellularis  
We analyzed the effect of calpain inhibition on the cholinergic innervation of the 
parietal neocortex after induction of an excitotoxic insult to the nucleus basalis 
magnocellularis in rats. Immunostaining visualized ChAT-positive cholinergic 
innervation fibers in the parietal neocortex (Figure 4.1, 4.2), and fiber density was 
measured in the superficial sublayer of the layer V as described in Horvath et al. 
(2000). The ChAT-positive fiber density ipsilaterally to the lesion was compared 
with the intact contralateral side and the percentage of fiber loss in the various 
experimental groups summarized in Figure 4.3. Injection of NMDA to the NBM 
decreased the density of the ChAT-positive fibers in the parietal cortex by 50%. 
Application of 2.5 mg/kg MK-801 nearly completely prevented this decrease. The 
calpain inhibitor A-705253 dose-dependently protected the cholinergic neurons and 
their projection fibers against the excitotoxic injury and reduced the fiber 
degeneration with 44 and 49% with 3 and 10 mg/kg, respectively. Application of 
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 10 mg/kg A-705253 did not affect the density of the cholinergic innervation, when 






Figure 4.1. Anatomical description of studying the cholinergic system after NBM lesion with NMDA. 
A, the posterior part of the NBM was lesioned, and most of the magnocellular cholinergic neurons are 
absent after lesion (lower left panel, which is the magnification of the nucleus basalis area outlined by 
dashed lines at A). The parietal neocortex of lesioned rat represents a marked loss of ChAT-positive 
fibers (middle left panel). The precise anatomical region between parietal cortex area 1 (Par1; primary 
somatosensory cortex) and parietal cortex area 2 (Par2; supplementary somatosensory cortex) (Zilles 
1985), where most of the areas were sampled for quantitative measurements of fiber density, is outlined 
by dashed lines. B and the right panels represent the nonlesioned control side of the same rat. The bar in 




Figure 4.2. Photomicrographs of cholinergic innervation of the parietal neocortex in 5 groups of 
animals: sham-operated and vehicle-treated, NMDA-treated and vehicle-injected, NMDA-treated and A-
705253-injected in three different doses of 1, 3, and 10 mg/kg (labeled 1, 3, and 10, respectively). 
Quantitative measurement of fiber density was performed between the two arrows in the superficial part 
of layer V. The bar at the right represents 100 μm.  
 
Figure 4.3. Attenuation of cholinergic neurodegeneration by calpain inhibitor A-705253. Groups are 
sham-lesioned and NMDA-treated, and they received injections with either the vehicle or the different 
doses of A-705253 (1, 3, and 10 mg/kg) or MK-801 (MK). **, p < 0.01 versus sham-lesioned and 
saline-treated groups; not significant from sham-0; ##, p < 0.01 versus NMDA-injected and vehicle-
treated groups.  
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 4.3.2 Calpain Inhibition Decreased Microglia Activation after Excitotoxic 
Lesion of the Nucleus Basalis Magnocellularis  
We further sought to examine whether calpain inhibition would prevent microglial 
activation that normally accompanies neurodegenerative processes. Therefore, we 
measured the area of microglial activation at the level of the NBM injection by 
staining microglia for integrin. Injection of NMDA strongly increased this area, 
which corresponds to the spread of the neurotoxin in the injection locus (Harkany 
et al., 2000) (Figures. 4.4 and 4.5). When rats were treated with calpain inhibitor A-
705253, the area of activation was dose-dependently decreased, and it reached 
significance at a dose of 3 mg/kg. The NMDA receptor antagonist MK-801 also 





Figure 4.4. Photomicrographs show the extent of activated microglia reaction at the level of brain 
injection indicated by the stained injection channel in representative rats of five different experimental 
groups: sham-operated and vehicle-treated (sham-0), NMDA-treated and vehicle-injected (NMDA-0), 
NMDA-treated and A-705253-injected in three different doses of 1, 3, and 10 mg/kg (NMDA-1, 
NMDA-3, and NMDA-10, respectively). For quantitative measurement of the extent of microglia 
activation, the total surface area was quantified that was infiltrated by activated microglia. In the right 
upper panel, individual activated microglia are shown to be immunoreactive for CD11b with higher 




Figure 4.5. Attenuation of microglia activation by calpain inhibitor A-705253. Groups are sham-
lesioned and NMDA-treated, and they received injections with either the vehicle (0 mg) or the different 
doses of A-705253 (1, 3, and 10 mg/kg) or MK-801 (MK). *, p < 0.05 and **, p < 0.01 versus 
sham-lesioned and saline-treated group; ns, not significant from the sham group; #, p < 0.05 and ##, p 
< 0.01 versus NMDA-injected and vehicle-treated groups.  
4.3.3 Calpain Inhibition As Well As NMDA Lesioning Does Not Affect 
Behavior in the Small Open-Field Test  
We further examined whether NMDA lesioning of the NBM or the drug treatment 
itself would influence the rats ability to perform spontaneous behavior in an open-
field test (experiments were performed blindly). No significant effects of the NMDA 
lesion and of the treatment with A-705253 were recorded at day 4 after the lesion. 
The different components of ambulatory behavior, i.e., rearing, walking, and 
sniffing with head movements, were not different from sham-treated control levels 
(data are not shown). Time spent with grooming and immobility was also unaltered 
(Figure 4.6). Ambulation in general was not influenced by the different 
experimental manipulation. Therefore, the general condition to perform 








Figure 4.6. Components of behavioral activity in small open field are shown. Ambulation expressed as 
a combined score of rearing, walking, and sniffing is depicted in A, grooming is depicted in B, and 
immobility is depicted in C. Scores collected by behavioral sampling every 10 s for 25 min are shown in 
blocks of 5 min. No statistically significant difference could be obtained between groups.  
 
4.3.4 Calpain Inhibition Attenuated Cognitive Deficits Occurring after 
Excitotoxic Lesion of the Nucleus Basalis Magnocellularis 
After habituation to the open-field box, attention was tested at day 6 (5 days after 
surgery; experiments were performed blindly). The results obtained are shown in 
Figure 4.7A. Spontaneous exploration of different objects placed in the open-field 
arena was not influenced by the lesion or by the treatments. MK-801-treated rats 
explored somewhat less, but this change was not significant. The objects were 
placed on the floor of the open field, and thus they could be approached by 
horizontal ambulation. This was not different among the groups.  
Recognizing the novel object in contrast to the familiar one was markedly decreased 
by the NMDA lesion (Figure 4.7B). Treatment with A-705253 dose-dependently 
prevented the deficit. ANOVA revealed a significant difference between sham 
control and lesioned and A-705253-treated groups (p < 0.005). The smallest dose of 
A-705253 was ineffective. The dose of 3 mg/kg attenuated the effect of the NMDA 
lesion, but the interference just approached statistical significance (p = 0.074). 
However, performance of this group was closer to the values of sham controls (p = 
0.104). The highest dose of 10 mg/kg completely prevented the effect of lesion (p < 
0.005). The NMDA-lesioned group that was treated with MK-801 also displayed an 





Figure 4.7. Exploratory behavior in the novel object recognition test. A, the duration of exploration of 
objects irrespective of their nature; B, the relative preference of novel object exploration compared with 
the familiar object. The different treatments did not influence object exploration in general. The NMDA 
lesion decreased attention toward the novel object, and A-705253 treatment interfered with the lesion 
effect. The dotted line at 50% represents the chance level. xx, p < 0.01 versus sham-operated control; *, 
p < 0.05 and **, p < 0.01 versus NMDA-lesioned group.  
 
 
4.3.5 Calpain Inhibition Did Not Affect NMDA Receptor-Dependent 
LTP 
 
To examine whether general NMDA receptor-mediated physiological functions and 
related intracellular signaling cascades were affected by calpain inhibition, we 
analyzed LTP during administration of A-705253 in hippocampal slices (Figures 
4.8, A and C). Calpain inhibition by A-705253 did not affect LTP at 100 nM, 
which is comparable with brain levels of A-705253 at the dose of 10 mg/kg. We 
also tested the peptidic inhibitor ALLN for possible effects on LTP (Figure 4.9, A 
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 and B), but we did not detect any LTP suppression. Basic synaptic transmission was 
also unaltered, as assessed by the input/output relation (Figures 4.8B and 4.9C). To 
determine whether the LTP protocol used in this study was indeed NMDA 
receptor-dependent, we used the same LTP induction paradigm during treatment 
with the NMDA receptor blocker APV (Figure 4.9D). LTP was completely blocked 
under this condition, indicating that the LTP induction with our tetanization 





Figure 4.8. Effect of A-705253.13 (100 nM) on the potentiation of the fEPSPs after a weak tetanus. 
A, averaged LTP time course. When applied 45 min before until 10 min after a weak tetanus, A-
705253.13 (100 nM) did not affect LTP elicited by weak tetanization (control: n = 10 slices, 5 
animals; A-705253.13: n = 10 slices, 5 animals; p = 0.742, repeated measures ANOVA). B, 
input/output relation.  C, original traces taken before (solid line) and after the tetanus (dotted line). 





Figure 4.9. Effect ALLN and AP-V on the potentiation of the fEPSPs after a weak tetanus. A, 
averaged LTP time course under ALLN (left panel). When ALLN (6 μM) was applied 60 min before 
until 120 min after tetanization (6 μM), LTP was not affected (dimethyl sulfoxide control: n = 10 
slices, 5 animals; ALLN: n = 10 slices, 5 animals; p = 0.230, repeated measures ANOVA). Right 
panel, input/output-relation. B, original traces taken before (solid line) and after the tetanus (dotted 
line). C, averaged LTP time course under APV. When APV (AP-V) (25 μM) was applied 20 min 
before until 10 min after tetanization, LTP was completely suppressed (control: n = 5 slices, 3 animals; 
APV: n = 5 slices, 3 animals). Open circles, control; filled circles, compound.  
 
4.3.6 Calpain Was Activated by NMDA in Hippocampal Slice Cultures 
and Dose-Dependently Inhibited by A-705253  
To examine whether application of NMDA activates calpain in neurons, and 
whether A-705253 sufficiently inhibits the activated calpain, we cultured rat 
hippocampal slices and exposed them to NMDA in the presence or absence of 
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 different concentrations of A-705253. Spectrin was cleaved under 10 μM NMDA 
treatment into its spectrin degradation products of 150/145 kDa (Figure 4.10A), 
indicating that calpain was indeed activated in neurons treated with NMDA. 
Application of A-705253 dose-dependently prevented calpain activation, as 
indicated by a decrease of SBDPs. The calculated IC50 is 408 nM = 29 nM for free 




Figure 4.10. Spectrin cleavage in rat hippocampal slice cultures for the determination of calpain 
activity. A, immunoblot of slice cultures treated with 10 μM NMDA in the absence and presence of 
calpain inhibitor A-705253 (CI) using an antibody directed against spectrin and spectrin degradation 
products. The 150/145-kDa spectrin degradation bands are shown in the image. Control lanes are 
untreated cultures. B, IC50 for calpain inhibition by A-705253 determined by graphical analysis of the 
150/145-kDa band signal intensities at different inhibitor concentrations. The NMDA band was used 
as 100%.  
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4.4 DISCUSSION 
Excitotoxic cell death has been discussed as a common principle for several 
progressive neurological disorders (Lipton and Rosenberg, 1994; Harkany et al., 
2000; Mattson, 2004). Inadequate control over NMDA receptor stimulation causes 
excessive calcium influx into neurons, activating a subset of intracellular Ca2+-
dependent signaling cascades. As a result, affected cells perish, can eventually die, 
and consequently the functionality of affected brain areas is impaired. During this 
process, Ca2+-activated calpain cleaves several proteins that are involved in cell death 
signaling. For example, Wu et al. (2004) provide data that cleavage of calcineurin by 
calpain contributes to neuronal degeneration. Xu et al. (2007) could show that 
truncation of mGluR1α by calpain is essential to excitotoxicity. Furthermore, 
collapsin response mediator-protein 3 triggers neuronal death after cleavage by 
calpain (Hou et al., 2006). In a more chronic model, Kim et al. (2007) could show 
that degeneration of cortical neurons in vitro depends on calpain cleavage of p35. If 
calpain is part of such degenerative cascades, then inhibition of calpain should 
attenuate neuronal decline. Indeed, Caba et al. (2002) could show that inhibition 
of calpain was neuroprotective in hippocampal slice cultures exposed to NMDA 
receptor overstimulation. In vivo, Chiu et al. (2005) revealed that calpain inhibition 
should reduce neurodegeneration in the rat retina. For these reasons, calpain has 
been discussed as a target for neurodegenerative disorders (Huang and Wang, 2001; 
Zatz and Starling, 2005; Saez et al., 2006).  
The data presented here strongly suggest calpain that inhibition by A-705253 is 
neuroprotective in a model of NMDA-induced cholinergic cell lesion. After such 
cholinergic basal forebrain damage by NMDA and subsequent cholinergic cortical 
denervation, learning behavior was compromised as assessed in a novel object 
recognition test, in which a dose-dependent protective effect of A-705253 on 
behavioral decline was demonstrated. Anatomical findings further confirmed the 
neuroprotective effect of calpain inhibition. Both the degree of cholinergic 
denervation in the parietal cortex and the extent of microglia activation around the 
injection in the NBM were markedly and dose-dependently attenuated by the 
inhibitor. The effective dose was shown to inhibit calpain in vivo, as determined by 
experiments on tau phosphorylation in the rat brain (data not shown). The present 
findings support the conclusion that inhibition of calpain not only prevents 
neuronal decline in an animal model of excitotoxicity, but it also attenuates 
accompanying behavioral deficits and neuropathology, including gliosis.  
Most of the previous studies on calpain inhibition used peptidic inhibitors that are 
not specific for calpain. Furthermore, due to low solubility, these compounds had 
to be applied at high concentrations, which again may have resulted in unspecific 
side effects. The compound used in the present study was recently introduced by 
Lubisch et al. (2003), and it has a high inhibitory potency for calpain (K i = 27 nM) 
without affecting the proteasome (K i > 10,000 nM) and caspases (K i > 10,000 nM). 
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 Therefore, the observed neuroprotective effects are probably mediated by inhibition 
of calpain and not by reducing proteasome or caspase activity. This finding is 
important in light of the fact that the proteasome complex contributes to a variety 
of neurodegenerative disorders (Rubinsztein, 2006; Pan et al., 2008). A-705253 has 
previously been shown to rapidly and effectively penetrate myocardial tissues, and it 
exerts its effects on cellular targets within minutes after perfusion (Neuhof et al., 
2003, 2004), making it an ideal compound for studying calpain in vivo.  
Excitotoxicity-induced neurodegeneration is caused by an overactivation of the 
NMDA receptor (Liu et al., 2007; von Engelhardt et al., 2007). Consequently, 
blockade of the NMDA receptor has been widely discussed and tested as a 
pharmacological target for excitotoxicity-induced neurodegeneration (Harkany et 
al., 1999; Lipton 2004; Gardoni and Di Luca, 2006). However, one of the caveats of 
this approach is that a functional NMDA receptor is indispensable for a variety of 
physiological and behavioral brain functions, including synaptic plasticity, long-term 
potentiation, and memory performance (Lynch, 2004; Fedulov et al., 2007), and it 
is well established that blockade of the NMDA receptor impairs cognition (Morris, 
1989; Fedulov et al., 2007). In the study presented here, calpain inhibition by A-
705253 was similarly effective as MK-801 against the excitotoxic insult. This 
indicates that blocking the calpain-mediated downstream pathway in specific 
neurotoxic conditions can be as effective in suppressing the NMDA receptor. 
Therefore, we investigated whether calpain inhibition would also prevent or affect 
normal physiological function of the NMDA receptor, as does MK-801. To address 
this question, we examined LTP in the hippocampal CA1 region under exposure to 
A-705253. LTP at the Schaffer collateral requires functional NMDA receptors 
(Harris et al., 1984; Reymann et al., 1989). We did not detect any LTP impairment 
during calpain inhibition, allowing the conclusion that normal NMDA receptor 
function and downstream calcium-dependent mechanisms of synaptic plasticity are 
not affected by A-705253 treatment. The concentration used effectively inhibited 
calpain in hippocampal slices as well as cultured neurons, as determined by tau and 
dynamin degradation as well as tau hyperphosphorylation (data not shown). LTP 
during application of the peptidic calpain inhibitor ALLN also yielded LTP equal to 
controls. To ensure that our LTP protocol indeed induces NMDA receptor-
dependent LTP, the NMDA blocker (2R)-amino-5-phosphonovaleric acid (APV) was 
applied under the same protocol. Under this condition, LTP was completely 
prevented. Therefore, it is unlikely that calpain is involved with all of the cascades 
induced by NMDA receptor activation, and it may thus be a more appropriate 
target for neuroprotection than the NMDA receptor itself.  
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With the exception of traumatic brain injury and stroke, most neurodegenerative 
diseases progress slowly over a period of many years. The excitotoxic insult used in 
this model induced a more rapid decline, and behavioral deficits were already 
measurable after days. At this point, it is not known whether calpain inhibition 
would also prevent a more chronic neurodegeneration of the nucleus basalis, as 
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observed in Alzheimer's disease. Further experiments are needed to evaluate 
whether calpain inhibition can also counteract a chronic loss of cholinergic cells.  
Taken together, this study shows that inhibition of calpain 1) is sufficient to prevent 
NMDA-induced degeneration of NBM and its associated cholinergic fiber 
projections, 2) attenuates behavioral deficits associated with such lesion, and 3) 
does not interfere with the physiological role of the synaptic NMDA receptor. 
These findings indicate that inhibiting calpain could be an attractive 
neuroprotective strategy, without interfering with physiologically relevant NMDA 
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Amyloid- (A) is toxic to neurons and such toxicity is – at least in part – mediated 
via the NMDA receptor. Calpain, a calcium dependent cystein protease, is part of 
the NMDA receptor-induced neurodegeneration pathway, and we previously 
reported that inhibition of calpain prevents excitotoxic lesions of the cholinergic 
nucleus basalis magnocellularis of Meynert. The present study reveals that 
inhibition of calpain is also neuroprotective in an in vivo model of A oligomer-
induced neurodegeneration in rats. A-induced lesions of the nucleus basalis 
induced a significant decrease in the number of cholinergic neurons and their 
projecting fibers, as determined by analysis of choline acetyltransferase in the 
nucleus basalis magnocellularis and cortical mantle of the lesioned animals. 
Treatment with the calpain inhibitor A-705253 significantly attenuated cholinergic 
neurodegeneration in a dose-dependent manner. Calpain inhibition also 
significantly diminished the accompanying neuroinflammatory response, as 
determined by immunohistochemical analysis of microglia activation. 
Administration of -amyloid markedly impaired performance in the novel object 
recognition test. Treatment with the calpain inhibitor, A-705253, dose-dependently 
prevented this behavioral deficit.  
In order to determine whether pre-treatment with the calpain inhibitor is necessary 
to exhibit its full protective effect on neurons we induced A toxicity in primary 
neuronal cultures and administered A-705253 at various time points before and 
after A oligomer application. Although the protective effect was higher when A-
705253 was applied before induction of A toxicity, calpain inhibition was still 
beneficial when applied up to 1 hour post-treatment. 
We conclude that inhibition of calpains may represent a valuable strategy for the 






 5.1 INTRODUCTION 
 
According to the amyloid--hypothesis of Alzheimer’s disease (AD) accumulation of  
A in brain parenchyma – possibly in its soluble form – causes a degeneration of 
neurons and their processes in brain areas involved in memory formation (Selkoe et 
al., 2008). Among the first regions to be affected are the hippocampus and the 
nucleus basalis of Meynert. The latter provides the majority of cholinergic input to 
neocortical structures and plays an essential role in attention and information 
storage (Blokland 1995; Van der Zee and Luiten 1999). Damage and the selective 
degeneration of the nucleus basalis of Meynert provides the morphological correlate 
of the cortical cholinergic deficiency in AD. The loss of this discrete cholinergic 
neuronal population leads to an impairment of higher cortical functions, which is 
directly related to the progressive deterioration of memory and attention, and 
cognitive processes in affected patients. 
 
A number of studies suggest that A-induced toxicity in AD is caused by excessive 
glutamate stimulation, over activation of the NMDA receptor, and subsequent 
calcium accumulation in the postsynaptic neuron (Harkany et al., 2000; Molnar et 
al., 2004; Mattson et al., 2000). Recently, the pathology of A has been correlated 
to oligomeric forms of the peptide (for review see Walsh and Selkoe, 2007), and 
studies indicate an involvement of the NMDA receptor also in oligomer toxicity 
(Shankar et al., 2007). Although the exact mechanism of this process is not fully 
understood, there is evidence that calpains, Ca2+-dependent cystein proteases, are 
components of the downstream cascade. Inhibition of calpains prevents excitotoxic 
neuronal cell death in vitro (Caba et al., 2002; Ray et al., 2006) and in vivo (Chiu et 
al., 2005;  Takano et al., 2005), and there is evidence that calpain cleaves several 
downstream targets that are critical for the progression of excitotoxic 
neurodegeneration (Hou et al., 2006; Wu et al., 2004). Calpains have therefore 
been discussed as a target for interference in the neurodegenerative diseases that are 
associated with neuronal loss (for review see Huang and Wang, 2001; Goll et al., 
2003, Zatz and Starling, 2005). 
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Using a specific low molecular weight inhibitor, A-705253 (Lubish et al. 2003), we 
have recently shown that inhibition of calpain completely prevents NMDA-induced 
excitotoxic lesions of the nucleus basalis magnocellularis (NBM), the rat analog of 
the nucleus basalis of Meynert in humans. A-705253 also fully protected from 
behavioral deficits that accompany such lesions (Nimmrich et al., 2008). Although 
excitotoxicity is likely to contribute to the pathology of AD, this study did not reveal 
whether neuronal decline could also be prevented, if the insult was induced by A. 
To provide this missing link we assessed whether calpain inhibition would protect 
from A-induced degeneration of the NBM, and whether such treatment would 
protect from associated cognitive decline of the rats.  
As oligomeric A is now thought to underlie the pathology of the disease, we 
generated A-oligomers in vitro and used such oligomer preparation - rather than 
the monomeric peptide - to induce NBM degeneration in rats. Lesioning of the 
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NBM causes a decline of cholinergic projections, mimicking the characteristic loss 
of forebrain cholinergic innervation in AD (Bartus et al., 1982; Gaykema et al., 
1992).  
Here we present data showing that calpain inhibition prevents A oligomer-induced 
neurodegeneration of NBM and associated decrease of cortical cholinergic 
innervation. Furthermore, calpain inhibition attenuates cognitive deficits that occur 
as a result of such neurodegeneration.  
NMDA receptor activation is an early step in the excitotoxicity cascade, and 
compounds targeting the NMDA receptor have to be administered in close time 
proximity of the toxic stimulus. Calpain activation lies further downstream in this 
cascade, thus offering an opportunity to interfere with cell death signalling at later 
time points. We therefore added to this study an in vitro analysis of the time course 
of the calpain application relative to the point of insult. Calpain inhibition is also 




5.2 MATERIAL AND METHODS 
 
5.2.1 Calpain inhibitor  
 
Calpain inhibitor A-705253 was solubilized in DMSO (Sigma-Aldrich, St. Louis, 
USA)  and stored as 1 M stock at -20 °C. Working stock solutions with different 
concentrations of A-705253 were prepared in ultrapure water containing 0.9% 
sodium chloride with a pH between 5 and 5.5. The solution was prepared freshly 
before use.  
 
5.2.2 Preparation of A-oligomers 
 
Oligomeric A42 was prepared as was described by Dahlgren et al. (2002). In short, 
solid A42 peptide (EZBiolabs, Carmel, USA) was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP)(Sigma-Aldrich, St. Louis, USA) to a concentration of 
1 mM.  The peptide solution was aliquoted and the HFIP removed by evaporation 
in a SpeedVac (Savant Instruments, Hyderabad, India). The dry peptide films were 
stored at -20 °C until further processing. Before use A42 films were dissolved in 
anhydrous DMSO to 5 mM and subsequently diluted in neurobasal medium to a 
final concentration of 100 μM (stock solution). The stock solution was incubated at 
4 °C for 24 h to enable A42 oligomerization. 
 
5.2.3 Animals  
 
All animals were purchased from Harlan (Horst, The Netherlands). For the in vivo 
experiments, we used male Wistar rats of 3.5 months of age. For the in vitro 
experiments we used female C57BL/6J mice (12 weeks old). During the experiment 
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 animals were kept under normal laboratory conditions in an air-conditioned room 
(21 ± 2°C) with a 12/12h light dark cycle (lights on at 07.00 h) with food and tap 
water ad libitum. All care and treatments were carried out in accordance with the 
European Communities Council Directive on the use of experimental animals. 
 
 
5.2.4 Nucleus basalis lesion  
 
Surgery was performed as described in Luiten et al. (1995). The animals were 
anaesthetized with Nembutal (sodiumpentobarbital, 60 mg/kg i.p.). The 
coordinates for the injection in the nucleus basalis magnocellularis (NBM) were 1.5 
mm posterior to bregma, 3.2 mm lateral to midline as defined by the atlas of 
Paxinos and Watson (1986).  A 5 L Hamilton syringe was lowered into the brain, 
followed over 10 min by two injections of 0.5 L of the freshly prepared solution of 
A1-42 oligomers (250 pmol each) diluted in 0.01 mM phosphate buffer pH 7.4 
unilatterally at two dorsoventral positions, 6.0 mm and 6.7 mm ventral to the dura. 
The final injected amount of the peptide therefore was amounted to 500 pmol per 
animal. For sham-operated animals two times 0.5 l phosphate buffered 
physiological saline solution were infused (0.01 mM pH 7.4 PBS) containing 
equivalent amount of DMSO, which served for sham-injection. After each injection 
the needle was left in situ for another 10 min to allow for diffusion and to limit 
spread of the solution during withdrawal of the needle. Brain injections were 
performed only in the right hemisphere and the left hemisphere was left 
undisturbed and served for the self-control side for the histological examinations. 
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The animals received the calpain inhibitor A-705253 intraperitoneally in doses of 1, 
3, and 10 mg/kg of body weight, one hour before, 12 hours after and twice a day 
for two consecutive days after surgery (for experimental design see Figure 5.1). 
 
5.2.5 Small open-field behavior 
 
A moderate novelty-induced behavioral activation and habituation to a dimly lit 
home-cage like novel environment was tested in this paradigm (Nimmrich et al., 
2008). The test also reflected the general behavioral condition after experimental 
manipulations, since it was performed 3 days after the surgery. Every 10 seconds the 
following behaviors were scored by behavioral sampling technique: a) rearing, b) 
sniffing with head turning, c) walking, d) grooming, and e) immobility (resting). 
Exploration was expressed by a combined score of rearing, sniffing and walking 
(exploration = 3 x rearing + 1 x sniffing + 2 x walking scores). The representative 
scores of each behavioral component were summed up in 5 min blocks and 




Figure 5.1. Schematic outline of the experimental setup for the in vivo experiments. Rats received in 
total 6 intraperitoneal injections of the calpain inhibitor A-705253 or saline. The first injection was 
given 1 hour prior to unilateral A lesions into the nucleus basalis magnocellularis, the other 5 
injections followed within two consecutive days after the lesion. From the fourth day on (after the lesion) 
the rats were subjected to different behavioral tests. Ten days after the lesion the animals were 
transcardially perfused and the brains removed for immunohistochemical analysis. 
 
 
5.2.6 Novel Object Recognition  
 
Testing the ability of rats to recognize a novel object in an otherwise familiar 
environment represents a sensitive and discriminating test to assess memory 
performance. Novel object recognition was measured in a conventional cylindrical 
open-field box of 80 cm diameter, in which the floor was divided into 20 sectors 
and surrounded by a 60 cm high reflective aluminum wall (Nyakas et al., 2009).  
During the first day the rats were allowed to habituate to the apparatus and their 
open-field behavior was recorded for 3 min (conventional open field). The test was 
carried out the day following to the 3 min open-field test and consisted of 2 
sessions. During the 1st session the rats were allowed to explore in the open-field 
apparatus for 5 min while two identical objects (A + A) were placed into the arena. 
During the 2nd session, carried out 2.5 hrs after the 1st session, one of the two 
objects was replaced by a novel one (B + A). The ratio of visiting the novel versus 
known objects indicated the object recognition ability, i.e. attention behavior. The 
number and the period in sec spent with exploration of the objects during the 1st 
and 2nd sessions were recorded. The recognition ability of the novel object at the 2nd 
session was calculated in the following way: duration of exploration of the novel (B) 
object was divided by the duration of exploration of both novel (B) and familiar (A) 
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 objects and expressed in percentage. The criterion to pass the test was that both 
objects had to be visited at least 5 times during the first session representing 
sufficient interest for object exploration. From the 57 animals only one failed to 
perform the test, thus statistical analysis was conducted on 56 animals. 
 
5.2.7 Brain tissue processing  
 
At postoperative day 10 the animals were transcardially perfused under deep 
pentobarbital anesthesia with a fixative solution of 4 % paraformaldehyde in 0.1 M 
phosphate buffer pH 7.4 after a short pre-rinse with heparinized saline. The brains 
were removed, post fixed for two days in the same fixative and stored in phosphate 
buffer at 0 C, cryoprotected by 30 % sucrose for 4 days and sectioned on a cryostat 
microtome at a thickness of 20 m. Vials processed for immunostaining contained 
every 10th section at the level of NBM, i.e. the serial sections positioned 200 m 





5.2.8 ChAT staining of cholinergic fibers 
 
Immunostaining procedure was applied to visualize choline acetyltransferase 
(ChAT) positive cholinergic neurons in NBM and their axon ramifications in the 
target brain areas selecting parietal neocortex. Goat anti ChAT primary antibody 
(AB144P, Lot: LV1359401; Chemicon International, Temecula, CA, USA) was 
used in dilution 1:500. Biotinylated rabbit anti goat antibody and Vectastain ACB 
kit was obtained from Vector Laboratories (CA, USA). The staining was completed 
with nickel-enhanced diaminobenzidine (DAB) reaction in the presence of H2O2.  
 
5.2.9 Microglial activation  
 
Mouse anti rat integrin M [CD11b] monoclonal antibody (CLB1512, Lot: 
0604026553; Chemicon International, Temecula, CA, USA) was used as first 
antibody in a dilution rate of 1:1500 to recognize activated microglia. The 
biotinylated second antibody and the ABC kit were obtained from Vector Labs (Ca, 
USA, see above). DAB reaction was enhanced by nickel ammonium sulfate.  
 
5.2.10 Quantification of cortical cholinergic innervation  
 
Reduction in cholinergic fiber density and cholinergic neurons  
The quantification procedure for cholinergic fiber density in the parietal neocortex 
was established in our laboratory and described in detail in a series of previous 
publications (Horvath et al., 2000; Harkany et al., 2001; Dolga et al., 2009). Briefly, 
parietal neocortex which is topographically the target of afferent cholinergic 
pathway from the NBM sites where the A42 oligomers were injected, was analyzed 
for ChAT positive fiber density with a Quantimet 600HR (Leica, Germany) image 
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analysis program. The exact measurement took place in the superficial sublayer of 
the layer V cortical area representing the densest zone of cortical cholinergic 
innervation. In addition we determined the number of ChAT positive neurons in 
the NBM. Three brain sections were analyzed for each experimental animal and the 
results were averaged. Percent surface area of positively stained fibers against zero 
background and number of positively stained neurons were computed in both sides 
of the brain section. The ChAT positive fiber density and NBM cell count 
ipsilaterally to the lesion was compared to the intact contralateral side and the 
percent decrement was calculated as an indicator of cholinergic degeneration. 
 
5.2.11 Magnitude of microglial reaction 
 
The magnitude of microglial activation was quantified with by image analysis 
measuring the extent of CD11b-immunoreactive microglia in a specific volume at 
the level of the lesion site (total infiltration volume). Therefore, a series of positively 
stained sections were used to reconstruct the extent of activation area. At each 
section the surface area of core structure around the injection channel and the size 
of infiltration area were measured with the Quantimet 600 system (Leica, Germany) 
by means of manual delineation of the affected area. Based on these measurements 
the total volume of the infiltrated brain area was computed: (x1+x2+…xn)  200 μm; 
where ‘x’ was the cross-sectioned stained area in μm2 and 200 μm was the distance 
between two consecutive sections. The volume of affected brain area was expressed 
in μm3. 
 
5.2.12 Primary cortical neuron culture 
 
Primary cortical neurons were prepared from embryonic brains (E14) of C57BL/6J 
mice. The cortices were carefully dissected, meninges were removed and the 
neurons separated by trituration. Cells were plated on poly-D-lysine pre-coated 
plates at a density of 1.2 x 105 cells/well (96 well plates). Neurobasal medium 
supplemented with 2 % (v/v) B27-supplement, 0.5 mM glutamine, 1 % (v/v) 
penicillin/streptomycin was used as a culture medium. After 48 h neurons were 
treated with 10 μM cytosine arabinoside for another 48 h to inhibit non-neuronal 
cell growth. Subsequently, the medium was completely exchanged with fresh 
medium and after 6 days of in vitro culture, the neurons were used for experiments.  
 
5.2.13 Treatment of cells 
 
The neuroprotective effect of A-705253 was assessed by incubating neurons 
(cultured in 96 well plates) for 24 h with 25 μM or 50 μM oligomeric A in the 
presence or absence of different concentrations of A-705253. After the treatment 
the cell viability was determined by an MTT-assay. All treatments were performed in 
triplicates and the experiments were repeated at least two times. 
 
88 
 5.2.14 Determination of cell viability by MTT-assay 
 
Neuronal viability was determined by the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl-)2,5-diphenyltetrazolium bromide] assay as described previously (Mosman et al., 
1983). 1.25 mg/ml MTT solution was added to each well of a 96 well plate. After 2 
h of incubation, cells were lysed in DMSO. The absorbance of each well was 
measured with an automated ELISA plate reader (Bio-Rad, Munich, Germany) at 




The Statistica 8 package was applied for one-way ANOVA evaluation of the results 
of independent groups which was followed by Dunnett post-hoc t-test to reveal 
differences between two selected groups. The level of p<0.05 was accepted as 









5.3.1 A-705253 protects neurons against A-induced toxicity in vitro. 
 
To investigate the neuroprotective properties of A-705253 against A-induced 
toxicity, we treated primary cortical neurons with different concentrations (0.04 μM 
– 5 μM) of the calpain inhibitor and challenged with 25 μM or 50 μM of oligomeric 
A42 for 24 hours. Our results show that the calpain inhibitor A-705253 in the 
present condition protects primary cortical neurons against oligomeric A42. 
Moreover, we found that concentrations in the range of 1 μM of A-705253 in the 
current experimental setup is most effective (Figure 5.2A).  
 
Furthermore, we were interested if the temporal dynamics of the treatment is 
important for the neuroprotective effect. Therefore we applied 1 μM A-705253 2h 
and 1 h before, 1 h and 2 h after, or together with the A42 challenge. We found 
that pre-treatment, or simultaneous treatment of A-705253 with A42 were fully 
protective against A induced toxicity (Figure 5.2B). Interestingly, when neurons 
were treated one hour after the insult, calpain inhibition still exerted a significant 
neuroprotective effect. However, application of the compound could not prevent 




Figure 5.2.  A) Neuroprotection was determined by co-incubating increasing concentrations of calpain 
inhibitor A-705253 with 25 μM or 50 μM A42 for 24 h. B) The effect of the time point of treatment 
relative to the insult was assessed by incubating primary cortical neurons were with 1 μM A-705253 for 
2h and 1h before, after or together with 20 μM oligomeric A for 24 h. Cell viability determined by 
MTT-assay. Bars indicate the mean cell viability in % relative to untreated controls ± S.E.M. (*p < 




 5.3.2 Calpain inhibition prevents Aβ-induced degeneration of cholinergic 
fibers and neurons after lesion of the Nucleus Basalis Magnocellularis.   
 
Recently, we demonstrated that the inhibition of calpain can protect cholinergic 
neurons against an NMDA-initiated excitotoxic insult (Nimmrich et al., 2008). 
Although excitotoxicity is likely to contribute to the pathology of AD, this study did 
not reveal whether neuronal decline could also be prevented, if the insult was 
induced by A.  
To assess the sensitivity of cholinergic neurons to A-induced toxicity we injected 
oligomeric A42 into the NBM and quantified the loss of cholinergic neurons and 
their cortical innervations that originate from the NBM (Figure 5.3) (Gaykema et al.,  
1992). Cholinergic neurons and fibers were visualized with the cholinergic marker 
choline-acetyl transferase (ChAT, EC3.2.1.6) (Harkany et al., 2000). The fiber 
density was measured in the superficial sublayer of the layer V as described earlier 




The cholinergic fiber density (Figure 5.3A and B) and the number of neurons 
(Figure 5.3C and D) ipsilaterally to the lesion was compared with the intact 
contralateral side respectively. The percentage of fiber and neuronal loss in the 
various experimental groups is summarized in Figure 5.4. Injection of oligomerized 
A42 into the NBM led to a loss of 40.6 ±2.3 % in cholinergic neurons, which is a 
26.78 % higher depletion compared to sham injection (Figure 5.3C, D and 5.4A) 
and a concomitant decrease of 26.4±3.4 % in cholinergic fiber density (18.03 % 
compared to sham injected control) in the cortex (Figure 5.4B, C). Pre-treatment 
with 3 and 10 mg/kg of the calpain inhibitor A-705253 significantly prevented the 
A-induced cell death and cholinergic fiber loss, respectively. The smallest dose of 1 
mg/kg A-705253 was ineffective. The density of cholinergic neurons and fiber 






Figure 5.3. Anatomical description of studying the cholinergic system after NBM lesion with 
oligomerized A1-42 . The upper panel shows ChAT positive fibers in the parietal neocortex of the 
lesioned rat. A) A1-42 lesioned side B) ipsilateral control side. The A1-42  injection site in the NBM 














Figure 5.4.  Cholinergic neurons in the NBM and their innervation of the parietal neocortex was 
measured in 6 groups of animals: vehicle treated and sham-lesioned (Sham); sham-lesioned  injected with 
10mg/kg A-705253 (Sham + 10 mg);  vehicle treated and A1-42 -lesioned (A);  A1-42 -lesioned and 
injected with A-705253 in doses of 1 and 3 mg/kg (labled Aβ + 1 or 3 respectively). A) A1-42 
injection into the NBM resulted in decrease in cholinergic neurons. B) Decrease in cholinergic fiber 
density in the parietal neocortex after sham-injection and in the cholinergic NBM region. A1-42 -
injection (A) increased the decline of cholinergic neurons and cortical innervation, which was not 
modulated by the smallest dose of 1 mg/kg, but greatly attenuated at 3 mg/kg. *p<0.01 vs. Sham; 
#p<0.01 vs. Ab.  C) Representative photomicrographs of cholinergic innervation of the parietal 
neocortex. Quantitative measurement of fiber density was performed between the two arrows in the 




5.3.3 Reduced microglia activation in A-705253 treated rats. 
 
In neurodegenerative diseases, microglial activation is an early sign that often 
precedes neuronal death and sustained local inflammatory responses. For that 
reason we determined the effect of calpain inhibition on microglia activation. We 
calculated the amount of CD11b immunoreactive microglia, as a measure of brain 
inflammation, in a specific volume at the level of the lesion site (infiltration 
volume) (Fig 5.5B). Injection of oligomerized A42 resulted in a strong activation of 
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microglia at the infusion site (Fig 5.5C), which was significantly reduced in animals 
treated with 3 mg/kg A-705253 as measured by CD11b expression (Fig 5.5A). 
 
5.3.4 Calpain inhibition as well as NBM lesion does not affect explorative 
behavior in rats.  
 
We further examined whether drug treatment or the A-induced NBM lesion had 
an effect on the explorative behavior of the animals. Therefore, the rats were tested 
in a small open field and a conventional open field paradigm to asses explorative 
behavior. Neither the drug treated nor the A-induced NBM lesioned animals 
showed any significant differences in behavior in the tested paradigms. Analysis of 
the different ambulatory behaviors in the open field tests, i.e. rearing walking, 
sniffing were not different from sham-treated rats. Exploration time, immobility as 
well as time spent grooming was also unaffected and reflects the behavior of healthy 
animals in such a paradigm (Figure 5.6 A-C).  
 
 
5.3.5 A-705253 prevents A-induced memory deficits in a novel object 
recognition paradigm. 
 
Cholinergic neuronal projections from the NBM are well known to directly 
modulate neocortical attentional and memory functions. The novel object 
recognition task is a learning task which depends, in part, on proper neocortical 
information processing. In a previous study we could show that a lesion of the 
NBM in rats leads to attention and memory impairments in a novel object 
recognition paradigm (Nimmrich et al., 2008). Therefore, we used this behavioral 
test to investigate whether the preservation of cortical cholinergic function by 
calpain inhibitor A-705253 can prevent the cognitive deficits induced by A-
mediated lesion of the NBM.  
 
The novel object recognition test sensitively assesses attention, or discrimination 
ability between a novel object placed nearby to a familiar one in a habituated 
environment. The A42-lesioned group showed less attention towards the novel 
object as compared to the controls treated with vehicle. The amyloid-injected and 
drug treated groups performed all better than the lesioned control, and even the 
dose of 1 mg/kg A-705253 was effective in preventing A42-induced memory 






Figure 5.5. Extent of microglia activation after A1-42 injection decreased under treatment with A-
705253. A) Representative photomicrographs show the extent of microglia activation at the level of the 
brain injection site measured in 6 groups of animals: vehicle treated and sham-lesioned (Sham); sham-
lesioned  injected with 10mg/kg A-705253 (Sham + 10 mg);  vehicle treated and A1-42 -lesioned (A);  
A1-42 -lesioned and injected with A-705253 in three different doses of 1, 3 and 10 mg/kg (labled A + 
1, 3 or 10 respectively). The volume of total microglia infiltration volume around the injections (PBS or 
oligomers) is shown in B) (*p<0.05 vs. Sham and #p<0.05 vs. A). C) High-magnification image 















Figure 5.6. Behavioral activity was compared in a small open field paradigm. Exploration is expressed 
as a combined score of rearing, walking and sniffing in A), grooming is depicted in B), and immobility 
is shown in C). Scores were collected by behavioral sampling every 10 s for 25 min. No statistical 
difference could be observed between the groups.  
Attention was estimated by measuring novel object recognition ability in a habituated open field. The 
results shown in D). Fifty percent performance means chance level since both the novel and familiar 
objects are explored by equal amount of time. A1-42 -lesioned and vehicle-treated rats performed 
significantly worse than controls (Sham) (*p<0.05; Dunnett post hoc test). Treatment with different 
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ned elusive.  
Soluble, oligomeric forms of A42 are increasingly associated with the 
neuropathological mechanisms of AD. Whereas the toxicity of A oligomers has 
been demonstrated in multiple studies, mainly in vitro, the mode of action of those 
peptide aggregates remains largely unknown. However, a greater understanding of 
the underlying process of amyloid toxicity is pressing in order to develop 
medication that specifically interferes with the A-induced disease cascade. A 
number of authors reporting in vitro studies have suggested that the pathological 
effect of A oligomers is mediated by the NMDA receptor (Shankar et al., 2007; 
Kelly and Ferreira, 2006; DeFelice et al., 2007), and that over activation of the 
NMDA receptor should be considered as a common principle for some major 
neurological diseases, including AD (Lipton and Rosenberg, 1994; Harkany et al, 
2000; Mattson, 2004). Stimulation of the NMDA receptor leads to excessive entry 
of calcium into the cell, which activates proteases that are involved in cell death 
signaling. Calpain is a calcium-activated cysteine protease that has been implicated 
to contribute to NMDA-mediated excitotoxic cell death in various studies. For 
example, inhibition of calpain is neuroprotective after NMDA-exposure in 
hippocampal slice cultures (Caba et al., 2002). In vivo, calpain inhibition reduces 
neurodegeneration in the rat retina after NMDA-injection (Chiu et al, 2005). 
Calpain has therefore been discussed as target for neurodegenerative disorders 
(Huang and Wang, 2001; Zatz and Starling, 2005; Saez et al., 2006). Using the 
specific calpain inhibitor A-705253 we recently reported that inhibition of calpain 
prevents NMDA-induced lesioning of the NBM in rats, whereas physiological 
NMDA-cascades remained unaffected (Nimmrich et al., 2008). However, although 
these studies suggested that calpain inhibition can prevent excitotoxic 
neurodegeneration in various in vitro and animal models, evidence that calpain 
inhibition could be protective against A42 oligomer-induced neuronal 
deterioration remai
 
The present study provides now evidence that calpain inhibition is neuroprotective 
against A oligomer-induced cholinergic cell lesion. Injection of oligomeric A to 
the nucleus basalis caused a strong deterioration of cortical cholinergic projections 
leading to deficits in learning behavior. Behavioral decline was prevented by 
application of the calpain inhibitor A-705253. The neuroprotective effect of calpain 
inhibition was also shown by morphological analysis: Cholinergic denervation in 
the parietal cortex and the extent of microglia activation around the injection in the 
NBM were greatly attenuated by A-705253. The present findings expand previous 
findings in animal models of excitotoxicity, and allow the conclusion that 
inhibition of calpain is effective in vivo against neurodegeneration triggered by 
oligomeric A. Interestingly, our in vitro studies indicate that calpain inhibition is 
not only effective when the compound is applied prior to the insult. Efficacy of A-
705253 against A-induced cell damage was demonstrated – albeit less pronounced 
– up to 1 hour after administration of A. This indicates that the A-induced cell 
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death cascade – once initiated – may not instantly kill the neuron, but requires 
some time until degeneration is irreversible. If this holds true also for other acute 
forms of neurodegeneration, this could offer a promising avenue for the treatment 
of acute neurodegenerative disorders. It is likely that drugs targeting the NMDA 
receptor may only be effective up to the time of the insult. At least from studies on 
long-term potentiation (LTP), a neurophysiological paradigm considered to mimic 
neuronal memory processing, it is known that NMDA receptor-related cascades 
cannot be reversed by NMDAR blockers once the cascade is initiated. This could be 
the reason why patients suffering from acute neurodegenerative processes do not 
benefit from current pharmacological treatment: the drug is administered once the 
NMDAR-dependent cell death cascades have already started. Future studies need to 
reveal whether inhibition of calpain is also effective in vivo after NBM-lesioning, 
which is currently hampered by the fact that the time of A diffusion to target cells 
cannot exactly be determined. The time point of treatment, however, may be less 
relevant for more chronic neurodegenerative diseases, like those accompanying 
amyloidoses. In any case, calpain inhibition might be superior to drugs targeting the 
NMDA receptor for another reason: calpain inhibition does not affect physiological 
processes like LTP (Nimmrich et al., 2008). Thus, it is likely that calpain inhibition 
does not interfere with memory processes, but indeed contributes solely to the 
prevention of cognitive deficits. This is also indicated by the fact that the highest 
dose of A-705253 did not impair rat memory in several tasks (e.g. novel object 
recognition test) (Nimmrich et al., 2008).  
 
The compound used here was introduced by Lubish and co-workers (Lubish et al., 
2003) and does not affect caspases or the proteasome (Ki calpain=27 nM; Ki 
proteasome>10000 nM; Ki caspases>10000 nM). Therefore, it is likely that the 
protective effects against A-oligomer toxicity are mediated by inhibition of calpain, 
and not by reducing proteasome or caspase activity. The proteasome complex 
(Rubinsztein, 2006; Pan et al., 2008) as well as caspases (Cribbs et al., 2004) 
potentially contribute to neurodegeneration, and a discrimination from these 
targets mandatory. It is likely that A-705253 has fully reached the target in our 
experiments as it rapidly penetrates tissues, affecting its cellular target within 
minutes after perfusion (Neuhof et al., 2003; Neuhof et al., 2004). It also effectively 
prevented A-induced toxicity at doses previously shown to inhibit calpain 
(Nimmrich et al., 2008). It should be noted that A-705253 also inhibits other 
molecules like cathepsin B to some extend. We therefore cannot fully exclude that 
at least some of the observed protective effects may be attributed to mechanisms 
other than calpain inhibition. In reverse, it is also possible that the reduction of 
efficacy at higher concentration is caused by inhibition of other proteins. Future 
synthesis of more selective compounds is highly desirable for dissecting the 
molecular components of neuroprotection. 
 
The model presented here reflects some essential hallmarks of the AD pathology. 
The NBM is one of the early regions to be affected during AD and the overall 
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 neuropathology in this model, including cholinergic denervation and microglial 
activation, features much of the pathology found in AD patients.  
 
Beyond this, A oligomers– rather than amyloid plaques or monomeric amyloid- - 
are thought to underlie the neurotoxic initiator of the disease. They occur in 
patients prior to plaque formation and correlate much better with cognitive deficits 
than amyloid plaques. A oligomers have been extracted from brains of AD 
patients and correlate well with the severity of the disease. A oligomers are 
therefore – to the best of our knowledge – currently the most appropriate 
conformation of -amyloid to induce pathology. The oligomer preparation used 
here has been introduced by Stine and colleagues (Stine et al., 2003) and was shown 
to be toxic to neurons (Lambert et al., 1998). They also impair LTP (Lambert et al., 
1998; Trommer et al., 2004) and have been demonstrated to exhibit their 
pathogenic action via the NMDA receptor (Lacor et al., 2007). The preparation is 
similar in their biophysical properties to brain derived A oligomers, underlining 
their physiological relevance (Gong et al., 2003). In spite of all similarities to AD it 
must be noted, however, that the experimental model presented here involves a 
rather rapid decline of neurons and thus differs from the slowly progressive 
neurodegeneration observed in AD. It would be challenging to examine whether 
calpain inhibition also prevents more chronic neurodegeneration processes, which 
is currently only feasible in transgenic mouse models. Most of these transgenic 
models, however, suffer from a lack of neurodegeneration and decline of 
cholinergic fibers. Hence, it may be an adequate approach to combine the effect of 
calpain inhibition on neurodegeneration in an acute in vivo model, and the 
prevention of other deficits – like synaptic decline – in chronic mouse models. The 
latter effects were explored by Battaglia and colleagues using another, less specific 
calpain inhibitor, E64 (Battaglia et al., 2003), who showed that long-term (5 mo) 
intraperitoneal application of E64 in APP(K670N/ M671L)/PS1(M146L) mice 
prevented synaptic impairment as measured by LTP. Chronic calpain inhibition 
also attenuated the development of deficits in spatial behavior of these mice.  Thus, 
it is likely that calpain inhibition serves to protect from acute and chronic neuronal 




Interestingly, protection from behavioral deficits in our study is more sensitive to 
calpain inhibition than the prevention of cholinergic denervation and microglia 
activation. A significant improvement in cognitive function measured by novel 
object recognition was already accomplished with 1 mg/Kg of A-705253 whereas 
the best protection from A-induced cholinergic denervation was achieved with a 
dose of 3 mg/kg. This did not further improve with the highest dose of 10 mg/kg 
(data not shown). This suggests that the efficacy of calpain inhibitor A-705253 
reaches a plateau at 3 mg/kg in our in vivo model.  
 
In addition, the highest dose (10 mg/Kg) A-705253 did not significantly prevent 
microglia activation. This could indicate that neither cholinergic denervation nor 
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microglia activation do fully contribute to the behavioral outcome measured by the 
novel object recognition test. It is very likely that the microglia reaction might 
follow a different dose-response course, which might facilitate other molecular 
pathways, specific for microglia independent from functional changes behind the 
behavioural effects.  
Whether the effect on behavior at 1 mg/kg may be due to an improvement of 
physiological function (and hence remain undetected by neuroanatomical analysis) 
should be assessed in further studies. Recent data showing the involvement of 
calpain in A-mediated dysfunction of the synaptic vesicle machinery (Ferreira et 
al., 2005, Kelly and Ferreira, 2006) could support such view. 
In summary the presented study add evidence that calpain inhibition significantly 
decreases acute A oligomer-induced degeneration of NBM and its associated 
cholinergic fiber projections, and attenuates behavioral deficits associated with such 
lesions. Furthermore, in vitro data suggest that inhibition of calpain is still effective 
when performed shortly after the insult. Our findings indicate that inhibiting 
calpain could be a promising strategy for the therapeutic intervention of amyloid-  
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Inflammatory processes are a hallmark of many chronic diseases including 
Alzheimer’s disease and Diabetes mellitus. Fairly recent statistical evidence 
indicating that type two diabetes increases the risk of developing Alzheimer’s disease 
has led to investigation of the potential common processes that could explain this 
relation. Here, we review the literature on how inflammation and the inducible 
nuclear factor NF- (kappa) B might be involved in both Diabetes mellitus and 





































 6.1 INTRODUCTION 
 
Since the beginning of the 20th century, there has been a continuous knowledge-
based improvement in healthcare in most industrialized societies. As a result, 
people in these affluent societies live longer, which has led to an increase in 
prevalence of age-related neurodegenerative diseases such as stroke and dementia. 
Diabetes mellitus (DM) has long been known as a risk factor for all vascular 
diseases, including vascular dementia. Indeed, the epidemiological relationship was 
recently explored in several large-scale studies. Furthermore, population-based 
cohort studies, such as the Rotterdam study have shown that patients with type 2 
DM (T2DM) are approximately twice as likely to develop Alzheimer’s disease (AD), 
independent of vascular factors (Leibson et al., 1997; Ott et al., 1999). The fact that 
neurodegenerative diseases are often associated with metabolic diseases such as DM 
suggests an underlying or aggravating metabolic basis. Here, we will provide a survey 
of the multiple levels of interactions between metabolic diseases and AD, and vice 
versa, and the particular role of inflammatory processes in these interactions. 
Although inflammation can be considered at least initially as a reaction of tissue 
against various stressors, chronic inflammation can be seen as part of the 
pathological process. A number of studies have shown both that inflammatory 
signaling in peripheral organs can influence central nervous system (CNS) 
functions, while reversely the CNS can have profound effects on peripheral 
functions. To partially illustrate these multiple mechanisms of interaction, we focus 
in this review on the transcription factor family NF-B, which plays a major role in 
the initiation of the innate and adaptive immune response. This review 





6.1.1 Inflammation and Diabetes Mellitus  
Involvement of inflammation in DM was first recognized more than a century ago, 
when Ebstein observed that the anti-inflammatory drug sodium salicylate 
dramatically reduced glucosuria in DM patients (Ebstein, 1876).  Following the 
classification of type-1 (i.e., insulin-dependent) and type-2 (i.e., non-insulin-
dependent) DM, other, more distinctive inflammatory processes were thought to 
play a role, especially in the aetiology of T2DM. T2DM, which is characterised by 
an insufficient release of insulin from pancreatic beta-cells to overcome insulin 
resistance in target tissues, is usually associated with increased levels of markers and 
mediators of inflammation and acute-phase reactants such as fibrinogen, C-reactive 
protein (CRP), interleukin-6 (IL-6), plasminogen activator inhibitor-1 (PAI-1), sialic 
acid, and white cell count. An additional connection between inflammation, 
obesity, and T2DM in which obese patients exhibited an elevated level of cytokines 
that caused hepatic insulin resistance (Fig. 1) (Pradhan et al., 2001). In fact that 
T2DM is a comorbidity of increased visceral adiposity has stimulated interest in the 
role of adipose tissue as a mediator of inflammatory processes underlying the 
development of T2DM. Indeed, the proinflammatory cytokine tumor necrosis 
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factor- alpha (TNF-), which is produced and secreted by adipose tissue, was found 
to induce insulin resistance through local and potentially systemic effects on 
metabolism (Feinstein et al., 1993; Hotamisligil et al., 1993). Subsequent to the idea 
that fat tissue was a site for the production of cytokines and other bioactive 
substances, the concept quickly developed beyond TNF- to include leptin, IL-6, 
resistin, monocyte chemo attractant protein-1 (MCP-1), angiotensinogen, retinol-
binding protein-4, serum amyloid A (SAA), and others (Fried et al., 1998; Steppan 
et al., 2001; Zhang et al., 1994). Furthermore, TNF-, IL-6, MCP-1, visfatin, and 
PAI-1 are highly expressed in activated macrophages and/or other peripheral tissue, 
as well as in the brain. At this moment, it is not known if cytokines are produced by 
the adipocytes themselves or by monocytes which have invaded adipose tissue 
(Weisberg et al., 2003). This knowledge gap has engendered an intense debate. 
 
 
Figure 6.1. Inflammation as a central event in the pathogenesis of AD and DM. Ageing, diet, genetic 
risk or other unknown factors can directly or indirectly lead to the pathological changes underlying both 
diseases. However, chronic inflammation may amplify the pathogenic processes through sustained NF-
B activation and elevated cytokine levels, which eventually lead to insulin resistance and DM, or result 
in increased A production and microglia activation, which are symptomatic of AD.  
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 6.1.2 Inflammation in Alzheimer’s Disease 
 
The idea that neuroinflammatory factors play a role in the etiology of AD dates 
back to 1910, when Fischer reported that the extracellular deposition of a “foreign” 
substance in the cerebral cortex induced both a local inflammatory response and 
the formation of cerebral plaques (Fischer, 1910). Due to the inadequate detection 
methods at the time, it was not possible to identify the precise structure of this 
“foreign” substance or to establish the ultimate proof for the involvement of 
inflammatory molecules was. Today, however, it is well known that the major 
component of the “foreign” substances is the amyloid beta protein (A). The A 
peptide is the result of a proteolytic cleavage of the amyloid  precursor protein 
(APP). This precursor protein can be processed in two different ways: via 
amyloidogenic- or via non-amyloidogenic-processing. Non-amyloidogenic processing 
involves cleavage within the A sequence by -secretase, which prevents the 
formation of A. On the other hand the amyloidogenic pathway is mediated by 
sequential cleavage of APP by -secretase (BACE) and -secretase, which results in 
the generation of A1-40 and A1-42 species (Gandy, 2005; Mattson, 2004).  
This A peptide plays a central role in the neuroinflammation hypothesis of AD, 
which states that A accumulation results in increased levels of inflammatory 
molecules (e.g. cytokines, chemokines, complement proteins) produced by 
chronically activated glia. This leads to neuronal damage, which in turn induces 
further glial activation, and results in a detrimental cycle of neuroinflammation and 
neurodegeneration (Griffin et al., 1998).  
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 6  TNF- is one of the most prominent pro-inflammatory cytokines significantly 
increased in AD and it plays a central role in initiating and regulating the cytokine 
cascade during inflammatory responses (Akiyama et al., 2000; Fillit et al., 1991). For 
example, TNF- increases the expression of adhesion molecules on the vascular 
endothelium, which allows leukocytes and immune cells to infiltrate areas of tissue 
damage and infection (Perry et al., 2001). TNF- exerts its biological functions via 
two distinct receptors: TNF receptor 1 (TNF-R1) and TNF receptor 2 (TNF-R2). 
The 55 kDa TNF-R1 (p55/60) is a membrane-receptor and is expressed in most 
tissues where it can be stimulated by both the membrane-bound and the soluble 
form of TNF-. The functions of TNF-R1 range from inducing apoptosis and 
differentiation to NF-B-mediated cell survival (Hu, 2003). Similar to TNF-R1, also 
the 75 kDa TNF-R2 (p75/80) is a membrane-receptor, but because of its low affinity 
to soluble TNF- it can be fully activated only by membrane-bound TNF-. The 
functions of TNF-R2 are as complex as those of TNF-R1 and are still not revealed in 
all its detail. It is known that the action of the TNF receptors is strongly dependent 
on the cell type. For instance, TNF-R2 is able to amplify apoptotic signals from 
TNF-R1 in cancer cell lines (Wajant, 2003) but has also been reported to mediate 
neuroprotection, as shown in a model for glutamate-induced excitotoxicity 
(Marchetti et al., 2004). TNF-R2 exerts its protective properties when pre-stimulated 
with TNF-, which suggests a neuroprotective role in the CNS (Dolga et al., 2008; 
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Marchetti et al., 2004). In AD patients, TNF-R1 levels are increased (Fillit et al., 
1991), whereas TNF-R2 (Taoufik et al., 2007) levels are decreased.  
Recently, it was demonstrated that overexpression of TNF-R1 promotes A-induced 
neuronal death in an APP overexpressing mouse model for AD (Li et al., 2004). In 
contrast, such mice lacking TNF-R1 have a decreased amyloid plaque burden, lower 
expression of -secretase (BACE), and improved learning abilities compared to 
controls (He et al., 2007). Interestingly, the stimulation of both TNF receptors can 
lead to the activation of NF-B, which has binding sites in the promoter regions of 
both the APP and the BACE gene (Grilli et al., 1996). Mutations in the NF-B 
promotor region of BACE lead to a significant decrease in promotor activity of 
TNF- activated glia cells or A exposed neurons, which indicates an activating role 
of NF-B in BACE expression (Bourne et al., 2007). In this way, NF-B activation 
can lead to increased APP expression and enhanced amyloidogenic APP processing. 
Elevated APP and BACE expression will ultimately lead to increased A 
production, which can in turn activate glia cells and enhance neuroinflammatory 
processes.  
 
6.1.3 Inflammation and the NF-B Family  
 
Inflammation is defined as the local response to tissue injury (Cone, 2001), and NF-
B is considered as a primary regulator of inflammatory processes. The NF-B 
family of transcription factors is an evolutionarily conserved signalling system that 
plays an important role in many biological processes in addition to inflammation. 
NF-B was first described in B cells, but it was later shown to exist in an inactive 
cytosolic form in all cell types, including the nervous system (O'Neill and 
Kaltschmidt, 1997). NF-B also plays a central role in the initiation and 
amplification of inflammation by responding to proinflammatory stimuli such as 
TNF- or interleukin-1 (IL-1) (Hayden et al., 2006; Karin and Greten, 2005; Tak 
and Firestein, 2001). As illustrated in Figure 6.1, aberrant regulation of NF-B leads 
to the development of many pathological states especially those involving acute 
inflammation such as AD and DM (Kaltschmidt et al., 1997; Katarina et al., 2007). 
However, NF-B is not the only transcription factor activated under inflammatory 
conditions. Activation of other transcription factors such as PPAR and STAT-1 









 6.2 Involvement of NF-B in Diabetes Mellitus and Alzheimer’s Disease 
 
6.2.1 The NF-B family 
 
Different members of the NF-B family have been identified in mammalian cells: 
p65 (RelA), RelB, c-Rel, p50/p105 (NF-B1), and p52/p100 (NF-B2). NF-B1 and 
NF-B2 are synthesized as large precursors, p105 and p100, which are post-
translationally processed to the DNA-binding subunits p50 and p52, respectively. 
All members of the NF-B family have an N-terminal 300 amino acid Rel homology 
domain that allows DNA binding, dimerization, and nuclear localization in 
common (Baeuerle and Henkel, 1994). NF-B proteins are present in unstimulated 
cells such as homo- or heterodimers bound to the inhibitor of the kAPP a B (IB) 
family of proteins IB, IB, IB, IB, IBNS, Bcl-3, and the p100 and p105 
precursor proteins. Association with IB prevents the nuclear translocation of the 
NF-B:IB complex.  
Currently, two NF-B activation pathways have been identified (Fig. 2). 
Classical/canonical NF-B activity is stimulated by proinflammatory cytokines, such 
as TNF- and IL-1, as well as by pathogen-associated molecular patterns (PAMPs). 
The binding of these ligands to their respective receptors, i.e. the TNF-R, Toll-like 
receptor (TLR) and the interleukin-1 (IL-1) receptor (IL-1R) superfamilies, causes 
activation of various cellular signaling pathways such as the protein kinase C (PKC), 
mitogen-activated protein (MAP) kinase kinase kinase-1 (MEKK1), and also the 
PKB/Akt signaling pathway, all of which have the potential to phosphorylate the 
IB kinase (IKK) complex. IKK consists of two catalytic subunits (IKK and IKK) 
and a regulatory subunit (IKK). In the canonical pathway, the activated IKK 
complex predominantly acts through IKK in an IKK-dependent manner to 
catalyze the phosphorylation of IBs. Upon phosphorylation, IB releases NF-B, 
allowing it to translocate to the nucleus and to initiate gene transcription (Figure 
6.2a). The most commonly released NF-B dimer in this pathway is the p50–RelA 
dimer (Ghosh and Karin, 2002). 
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The alternative/non-canonical activation pathway is activated by certain members of 
the TNF cytokine family but not by TNF- itself and is strictly dependent on IKK 
(Senftleben et al., 2001). The target for IKK homodimers in this pathway is NF-
B2/p100 (Figure 6.2b). 
Recent results strongly suggest that the canonical and non-canonical pathways to 
NF-B activation have distinct regulatory functions. Whereas the classical pathway 
was found to be mostly involved in innate immunity and maintaining survival of 
immune cells, the alternative pathway is an important player in adaptive immunity 
and the development and organization of secondary lymphoid organs and B-cell 





Figure 6.2. The activation of NF-B transcription factors occurs through two main pathways: a) the 
canonical and b) the non-canonical NF-B activation pathway. During canonical signalling upstream 
mediators activate the IB kinase (IKK) complex to phosphorylate inhibitory IB proteins, leading to 
their ubiquitination and degradation. NF-B dimers are then free to bind to DNA and to activate gene 
transcription. Alternative, non-canonical NF-B signalling is mediated by NF-B Inducing Kinase 
(NIK), which induces the partial proteolytical degradation of p100 to p52. RelB, together with p52, 
translocates to the nucleus and transactivates their target genes.  
 
NF-B regulates several promoters containing variations in a highly divergent 
consensus DNA-binding sequence. Variations in the DNA-binding site APP ear to 
confer regulatory specificity for NF-B family members by two general mechanisms. 
The sequence of the site can determine which coactivators form productive 
interactions with the bound NF-B dimer (Leung et al., 2004). This mode of 
specificity occurs independently of any inherent difference in DNA binding by 
distinct dimers. A second mechanism conferring specificity of transcriptional 
regulation involves differential affinity of NF-B dimer combinations for different 
DNA-binding sequences sites. NF-B signalling can be switched off through 
multiple mechanisms, including the new synthesis of IB protein.  
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 The activation and nuclear translocation of classical NF-B dimers (mostly p50–
RelA) is associated with increased transcription of genes encoding chemokines, 
cytokines, adhesion molecules [intercellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), and endothelial–leukocyte adhesion 
molecule 1 (ELAM)], all of which are factors that produce secondary inflammatory 
mediators (Ghosh et al., 1998). NF-B regulates proliferation and apoptosis by 
controlling the expression of the cellular inhibitors of apoptosis (cIAP1, cIAP2, and 
XIAP) (Deveraux and Reed, 1999); (Wang et al., 1998), the TNF receptor associated 
factors (TRAF1 and TRAF2) (Wang et al., 1998), the bcl-2 homologue A1/Bfl-1, 
and IEX-IL (Wu et al., 1998). Interestingly, NF-B activation can thus lead to the 
expression of the same cytokines that can also regulate its activity, such as IL-1 and 
TNF-. This results in a positive auto-regulatory loop contributing to the 
amplification of the inflammatory response and the persistence of chronic 
inflammation at local sites. 
 
6.2.2 NF-B and Diabetes 
 
After Ebstein’s discovery (Ebstein, 1876) and somewhat later investigation by 
Williamson (Williamson, 1901), the role of salicylates in the treatment DM were 
long forgotten, in part because the fact that the well-established effects of low doses 
of salicylates to block cyclo-oxygenase enzyme activation of prostaglandin synthesis 
(Simmons et al., 2004), were far below the concentration of salicylates necessary to 
induce effects on glucose homeostasis  (Mitchell et al., 1997).  High doses of 
salicylates, however, had been found to inhibit NF-B (Mitchell et al., 1997), and its 
upstream component, IB kinase- (IKK-). Cai and colleagues (Cai et al., 2005) 
were able to induce a T2DM phenotype in mice by selectively expressing IKK in 
hepatocytes, characterized by hyperglycemia and insulin resistance. A definitive role 
for the IKK/NF-B in glucose homeostasis was substantiated when targeted 
deletion of IKK- in obese and diabetic mice completely reversed insulin resistance 
in these animals (Hundal et al., 2002; Shoelson et al., 2003; Yuan et al., 2001).  
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Evidence in support of a critical role of NF-B in the pathogenesis in early stages of 
DM can be described as threefold (regarded as activators, effectors, and as 
modulators of the NF-B activity).  
 
First, in DM, the increase in NF-B activators promotes vascular complications. 
Thus far, at least four molecular mechanisms have been implicated in glucose-
mediated vascular diseases. These mechanisms include: glucose-mediated activation 
of protein kinase C (PKC) isoforms; increased formation of glucose-derived 
advanced glycation endproducts (AGEs); the aldose-reductase (AR) pathway; and 
increased formation of reactive oxygen species (ROS). Furthermore, all of these 
pathways have been demonstrated to increase NF-B activity. Hyperglycemia leads 
to the activation of different isoforms of PKC in accordance with tissue types, thus 
determining the specific kind of DM-induced organ damage (Ibrahim et al., 2008). 
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Activation of the AR pathway is necessary for high-glucose-induced TNF- synthesis 
and release. In DM, high-glucose mediated TNF- release has been shown to cause 
cardiovascular complications (Ramana et al., 2007). Although targeting PKC 
isoforms and AR products has proven to be a difficult and challenging task, 
targeting glucose-derived AGE- receptor for advanced glycation endproducts 
(RAGE) products became more feasible with the availability of RAGE knockout 
mice and a competitive decoy for AGEs, soluble RAGE (sRAGE). Diabetic RAGE 
overexpressing transgenic mice showed exacerbated neuropathy, while inhibition of 
AGE formation prevented these vascular cell derangements (Bierhaus et al., 2004; 
Toth et al., 2008). On the the other hand, it was found that RAGE knockout mice 
were resistant to DM-induced neuropathy. In human DM patients, NF-B 
activation is a time consuming process and is associated with increased transcription 
of the p65 subunit of NF-B (Bierhaus et al., 2001). These findings were paralleled 
by in vitro studies, in which it was shown that RAGE-expressing cells induced 
sustained translocation of p50/p65 subunits of NF-B from the cytoplasm into the 
nucleus. RAGE ligands induce NF-B activation by initial degradation of IB 
proteins, followed by new synthesis of the p65 subunit of NF-B, although IB 
and IB are also generated. These findings indicate an important function of de 
novo synthesized p65 subunit in prevailing the NF-B auto-inhibitory effects, thus 
inducing a sustained NF-B activation in hyperglycemic conditions (Bierhaus et al., 
2001). Several reports have shown that IKK, which is responsible for the activation 
of NF-B, was also increased in insulin-resistant cells (Yuan et al., 2001) (Shoelson 
et al., 2003).  
The importance of IKK in insulin resistance was provided by data accumulated 
from IKK (+/-) heterozygous mice. Whereas IKK (-/-) homozygous mice died in 
embryonic stages due to massive apoptosis in the liver, IKK (+/-) heterozygous 
mice were reported to exhibit a stronger insulin sensitivity compared with their 
littermates (Yuan et al., 2001). 
 
Second, inhibition of NF-B effectors, such as iNOS or ICAM proteins mediates 
beneficial effects reducing DM-induced degeneration of retinal capillaries (Chu and 
Ali, 2008). In retinas of  mice exhibiting streptozotocin-induced DM, the 
concentrations of NO, of iNOS, the nitration of proteins and leukostasis were 
significantly increased when compared with non-diabetic mice (Zheng et al., 2007). 
Interestingly, in diabetic iNOS-/- mice not all of the above-mentioned abnormalities 
were detected. In addition, retinas from stretozotocin-induced DM mice were 
significantly thinner than from non-diabetic control mice, whereas no retinal 
defects were observed in diabetic iNOS  -/- mice. Administration of the iNOS 
specific inhibitor, N(G)-nitro-L-arginine methyl ester, reduced DM-mediated 
leukostatis within retinal vessels and blood-retinal barrier permeability (Leal et al., 
2007). These studies showed that iNOS enzymes play a crucial role in the 
pathogenesis of vascular lesions detected in early stages of diabetic retinopathy (Leal 
et al., 2007; Zheng et al., 2007).  
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 Third, compounds known to inhibit the NF-B pathway also inhibit the 
development of the DM retinopathy or neuropathy. In addition to the augmented 
oxidative stress-mediated cellular damage, type 2 DM patients usually present 
defects of cellular antioxidant defense mechanisms, such as the glutathione redox 
system, vitamin C-vitamin E cycle, and the -lipoic acid (LA)/dihydrolipoic acid 
(DHLA) redox pair (Evans et al., 2002). Antioxidants inhibit the activation of NF-
B and the development of inflammatory responses in several tissues, including 
retinas of diabetic animals (Kowluru et al., 2003). Consistent with these findings, 
treatment with antioxidants significantly suppressed the NF-B activity and reduced 
plasma markers for lipid oxidation (Hofmann et al., 1998). LA treatment of diabetic 
neuropathy restored the LA pool, increased the insulin sensitivity (Jacob et al., 
1999), raised intracellular glutathione levels (Han et al., 1997), prevented glycation 
of serum albumin (Biewenga et al., 1997) and reduced the oxidative stress-mediated 
NF- B activation (Hofmann et al., 1998). 
 
6.2.3 NF-B in Alzheimer’s disease 
 
NF-B activation as a central event of inflammation is a common feature of many 
neurodegenerative diseases such as Huntington, Parkinson, stroke, and particularly 
of AD. In the brain of AD patients, activated NF-B was found predominantly in 
neurons and glial cells in A plaque surrounding areas (Boissiere et al., 1997; 
Kaltschmidt et al., 1997; Lukiw and Bazan, 1998; Terai et al., 1996). The reactive 
astrocytes in close proximity to the A plaques produce inflammatory cytokines, 
including IL-1b and TNF-, and iNOS, which generates free radicals such as NO, 
that can be neurotoxic (Akama et al., 1998; Lee and Brosnan, 1996). Several studies 
have shown that A and/or a secreted form of APP induce an up-regulation of NF-
B activity. Some non-steroidal anti-inflammatory drugs (NSAIDs) have a direct 
effect on NF-B activity, which eventually results in decreased APP processing. 
Flurbiprofen and indomethacin, which target NF-B, have been shown to 
effectively reduce the amyloid load in vitro and also in APP  transgenic mice (Eriksen 
et al., 2003; Sung et al., 2004). The activation of NF-B leads to the expression of a 
large variety of pro-inflammatory molecules such as cytokines and chemokines, 
which could be in partly responsible for the neurotoxicity seen in AD. However, 
there are also reports that certain cytokines, e.g. TNF-, may trigger NF-B 
activation, which seems to be neuroprotective against A toxicity in cultured 
neurons (Barger et al., 1995; Barger and Mattson, 1996).  
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Both pathological hallmarks of AD (A and hyperphosphorylated tau) are capable 
to inducing NF-B activation via various mechanisms. One common mechanism is 
the activation of the AGE/RAGE signalling pathway. A and tau can undergo a 
non-enzymatic glycation and form AGEs. These AGEs, which bind to so-called 
RAGEs and can trigger NF-B dependent gene transcription. Furthermore, 
glycation of A enhances its aggregation in vitro (Vitek et al., 1994), and glycated 
tau, in addition to hyperphosphorylation, APP ears to enhance the formation of 
paired helical filaments (PHFs) (Ledesma et al., 1994; Yan et al., 1994). In addition, 
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AGEs have been reported to generate reactive oxygen intermediates, leading to the 
activation of cytokines including IL-1β and TNF-, which in turn induce the 
translocation of NF-B to the nucleus (Yan et al., 1995).  
The recently discovered prolyl isomerase protein Pin1, which accelerates the trans to 
cis or cis to trans isomerization of target proteins, is APP arently a ‘key player’ in the 
pathogenesis of AD (Lu et al., 1999; Pastorino et al., 2006). Pin1 has been shown to 
bind to both APP and phosphorylated tau, where it stabilizes the non-pathogenic 
conformations of both proteins. In AD, Pin1 levels are compromized, leading to 
increased A formation and reduced tau de-phosphorylation. In addition, Pin1 
might have a role in neuronal apoptosis of AD affected cells as well, either 
indirectly, via depletion in the levels or aberrant function of Pin1 (resulting from 
oxidation, phosphorylation or mutations) or directly, via association with specific 
signaling proteins such as NF-B. 
During TNF- treatment, Pin1 binds to the phosphorylated p65/Rel subunit on 
Thr 254 (Ryo et al., 2003), enhancing NF-B DNA binding and transactivation 
activity. Pin1 binding to p65/Rel inhibits p65 binding to IB, which prevents 
p65/Rel nuclear export and its subsequent ubiquitin mediated degradation. This 
leads to enhanced nuclear accumulation, protein stability, and transcriptional 
activity of NF-B towards its target genes, which in turn  promotes neuronal 
survival (Ryo et al., 2003).  
Furthermore, a single mutation in p65/Rel abolishes Pin1 binding and destabilizes 
the protein in HeLa and 293 cells. The source of destabilization has been found to 
be enhanced ubiquitin mediated proteasomal degradation (Ryo et al., 2003). Ryo 
and colleagues (Ryo et al., 2003) suggest that Pin1 stabilizes p65 and prevents its 
proteasomal degradation, probably by isomerizing the Thr254-Pro motif towards a 
more stable conformation, possibly indicating that in neurons in which NF-B is 
induced, Pin1 might mediates neuronal survival by stabilizing NF-B, resulting in 
the transcription of its pro-survival target genes. In addition, Pin1 has also been 
shown to bind to these anti-apoptotic NF-B target genes, possibly stimulating 
survival downstream of NF-B signaling as well (Lu et al., 2002). Thus, depletion of 
Pin1 could accelerate neuronal cell death in AD patients. Since stabilization of the 
p65/Rel subunit of NF-B by Pin1 no longer takes place, it will ultimately lead to a 
down regulation of anti-apoptotic genes and, ultimately, to cellular death.  
 
6.3 Mechanisms relating Type-2 Diabetes Mellitus and Alzheimer’s 
Disease 
 
Since the Rotterdam study and other studies linked DM with an increased risk to 
develop AD, researchers worldwide have searched for the causal mechanisms 
underlying this relationship.  Becaus the NF-B pathway plays a major role in the 
aetiology in both diseases, it seems reasonable to assume that mechanisms causing 
disturbances in this pathway are at the core of the relationship (Figure 6.3).  A 
number of issues relevant to this possibility need to be addressed.   
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 First, in addition, to their role in inflammation and immune responses, neurons 
and their neighbouring glial cells also employ the NF-B pathway for distinctive 
functions ranging from the development to the coordination of cellular responses 
to injury of the nervous system, and to brain-specific processes such as the synaptic 
signaling that underlies learning and memory. Interestingly, electrical activity within 
neurons and synaptic transmission between neurons are potent stimuli for NF-B 
activation, and such neuronal activity may account for the relatively high 
constitutive activity of NF-B in brain tissue compared with other tissues (O'Neill 
and Kaltschmidt, 1997). As in other organs, NF-B influences the expression of a 
complex array of genes in the nervous system, and, in general, these genes serve 
important functions in cellular responses to injury and in neuronal plasticity. In the 
nervous system, the cell type and the duration of NF-B activation APP ears to be a 
determining factor for the output of NF-B in neurodegenerative diseases such as 
AD. NF-B activation in neurons has been shown to promote the neurons’ survival 
and plasticity. On the other hand NF-B activation in glial cells may play a major 
role in inflammatory processes that can damage and kill neurons. Indeed, in some 
cases, the NF-B and the NF-B responsive genes may serve dual functions. In 
neuronal cells sustained activation of NF-B has been shown to induce 
neuroprotection via PI3-kinase-PKB/Akt pathway activation (Marchetti et al., 2004). 
Furthermore, NF-B cellular survival functions underlie cytokine-induced 
neuroprotective mechanisms, including transforming growth factor-beta1 (TGF-1) 
and TNF-. Although transient activation of NF-B in activated glial cells is 
beneficial for defence processes, either chronic activation or overactivation may 
exacerbate neuronal diseases as seen in AD  (Guzman and Blazquez, 2001; 




The second issue relates to the use of substrates for metabolic purposes.  Although 
the brain is preferentially utilizes glucose as the main substrate, ketone bodies may 
replace glucose as the major energy source.  The liver is the main source for elevated 
ketones in the circulation (e.g. in starvation or hypoglycemia), but glial cells are also 
suitable to engage in ketone body production via stimulation of AMP-activated 
protein kinase (AMPK), a highly conserved stress-activated kinase (Blazquez et al., 
1999; Guzman and Blazquez, 2001). Sustained glucoprivation and hypoxia, 
however, may cause neurons to release glutamate, which in turn leads to chronic 
activation of the NF-B pathway in glia cells and their pro-inflammatory actions.  
The third issue relates to the fact that glial cells require insulin for glucose uptake 
(i.e, which is comparable to peripheral tissue), whereas neuronal glucose uptake is 
independent of insulin (Wei and Yeh, 1991).  Thus, in the case of insulin 
resistance, which is underlies T2DM, this would result in a limitation of glucose 
uptake in glial cells but not in neurons.  In fact, in the case of T2DM, neurons 
often evidence elevated levels of glucose, which may cause direct deleterious effects 
via the RAGE pathway (Ramasamy et al., 2005).  A  reduction in glucose availability 
at the level of glial cells might be expected to cause augmented ketone body 
production and the chronic activation of the NF-B pathway with the resulting 
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inflammatory assaults on neuronal tissue, a scenario is somewhat comparable to the 
recent discussion by Erol (Erol, 2008). Here, we suggest a more central role for the 
NF-B pathway than has been put forward previously.  Whether this scenario can 
explain the causality, however, is still under investigation. Moroz and colleagues 
recently found that mice chronically subjected to a high-fat diet displayed all the 
characteristics of peripheral and central insulin resistance, but signs of AD were 
only marginally observed (Moroz et al., 2008). Future experiments must address 
species differences (e.g., the variation of cholesterol metabolism in mice and in 
humans (MacLean et al., 2003)), timing and lifespan or ageing (Selman et al., 2008), 
and environmental challenges (e.g., psychological stress), of all which could act as 
additional factors interacting in the causal link between T2DM and AD. One 
particularly interesting permissive mechanism linking insulin and A, which plays a 
central role in development of both diseases, is the insulin-degrading enzyme (IDE). 
In addition to defining a key role for IDE in both A and insulin metabolism in 
vivo, selective deletion of the IDE gene recapitulates some of the hallmark 
phenotypic characteristics of AD and T2DM, namely chronic elevation of cerebral 
A, as in AD, and hyperinsulinemia and glucose intolerance, as in T2DM (Farris et 
al., 2003).  The state of chronic inflammation has great influence on the 
metabolism of A and insulin. For example, in AD chronic inflammation and 
augmented NF-B, activation leads eventually to elevated A levels, activation of 
glia cells, and increased cytokine release. Furthermore, pro–inflammatory cytokines 
can directly reduce the expression of IDE (Yamamoto et al., 2008), which would 
compromise the clearance of A and promote its aggregation. In T2DM, elevated 
levels of pro inflammatory cytokines such as TNF- are known to induce insulin 
resistance in peripheral tissues by reducing insulin receptor substrate (IRS-1) 
phosphorylation (Peraldi and Spiegelman, 1997) (Figure 6.3). 
 
 Perez and colleagues (Perez et al., 2000) reported that the IDE activity may be 
reduced in AD patients compared to controls.  IDE levels are reduced in diabetic 
APP transgenic mice that have increased cerebral A levels compared to non 
diabetic APP transgenic controls (Ho et al., 2004). Clinical studies show that IDE 
levels are decreased in the hippocampi of AD patients who have the Apolipoprotein 
4 (Cook et al., 2003). In thist context, it is interesting to note that hippocampal 
volume is reduced in AD patients several years before any symptoms can be 
















Figure 6.3. Schematic representation of molecular pathways linking the pathogenesis of T2DM and 
AD. Conditions such as oxidative stress, pro-inflammatory cytokines, activated RAGE, and insulin 
receptor stimulation can directly or indirectly, lead to sustained activation of NF-B (p50/p65). Upon 
phosphorylation IB becomes degraded and NF-B can translocate into the nucleus to initiate NF-B 
dependent gene transcription (e.g. TNF-, IL-6, IL-1, iNOS, COX-2, BACE, APP ). A monomers 
and oligomers activate RAGE, whereas insulin and the A protein compete for binding to the insulin 
receptor. Pro–inflammatory cytokines can directly reduce the expression of IDE, which would 
compromise the clearance of A and insulin in the extracellular domain. A, amyloid beta peptide; 
APP , Amyloid beta precursor protein; AKT, protein kinase B/AKT; BACE, beta-secretase; -sec, 
gamma-secretase; IDE insulin degrading enzyme; IKK, inhibitor of B kinase; IB, inhibitor of B; 
IRE, insulin response element; LRP-1, Low density lipoprotein-related protein 1; NEP, neprilysine; PI3-
K, phosphoinositide-3 kinase; RAGE, receptor for advanced glycation end products; ROS, reactive 
oxygen species; TNF-, tumor necrosis factor –alpha; TNF-R, TNF receptor; Dashed arrow: indirect 






A recent paper showed that impaired insulin signaling can also lead to tau 
hyperphosphorylation in an animal model for DM (Planel et al., 2007). Insulin and 
insulin-like growth factor-1 stimulation reduces tau phosphorylation and promotes 
tau binding to microtubules. These effects of insulin and insulin-like growth factor-
1 are mediated through inhibition of glycogen-synthase kinase-3 via the 
phosphatidylinositol 3-kinase/protein kinase B signaling pathway (Schubert et al., 
2004). It is known that insulin and the A protein compete for binding to the 
insulin receptor (Xie et al., 2002) A, co-immunoprecipitates with the insulin 
receptor, and interferes with the autophosphorylation of the insulin receptor 
induced by insulin that affects downstream targets such as Erk/MAPK, CaMKII 
and PKB/Akt (Townsend et al., 2007; Zhao et al., 2008). Insulin resistance or 
hypoinsulinaemia cause elevated glucose levels which in turn leads to increases in 
AGEs. As the RAGE activates NF-B, it is conceivable that such an inflammatory 
precondition might increase the risk for the onset of AD.   
All of these mechanisms reflect the variety of links between T2DM and AD and 
how this linkage might lead to pre-conditions favouring the development of AD. 
However, it is also conceivable that central signal mechanisms preceding the phase 
of clinical symptoms of AD might also aggravate or favour T2DM . 
 
 
6.4 Conclusions and future perspectives 
 
It is clear from the reviewed literature that inflammatory processes are playing 
essential roles in the etiology of T2DM and AD.  Aberrant regulation of the 
inflammatory pathway involving NF-B, which includes TNF- dependent 
(canonical) and TNF- independent (non-canonical) mechanisms, directly underlies 
insulin resistance in peripheral tissue as well as in astrocytes in the brain.  Since 
insulin resistance in the periphery can lead to glucose intolerance, neuronal 
inflammatory processes triggering (or triggered by) the NF-B pathway may be 
propagated even further via stimulation of the AGE/RAGE signaling pathway.  
Therefore, it might be expected that alleviating symptoms of T2DM may be an 
effective way to treat AD. Indeed, recent clinical trials with the insulin sensitizer 
rosiglitazone -i.e., an agonist for the peroxisome proliferator-activated receptor 
gamma (PPAR), whose biological actions are to regulate glucose and lipid 
metabolism and suppress inflammatory gene expression) have shown a significant 
improvement in memory and cognition in AD patients (Landreth et al., 2008). The 
currently used multi-target-directed ligand (MTDLs), usually including a mix of 
inhibitors of acetyl-choline esterase (AChE) and of mono-amine oxidase (MAO) 
(Cavalli et al., 2008) may be complemented with ligands (NSAIDs, PPAR agonists) 
that improve metabolic functions of neurons and microglia, in order to delay of 









LPYFDa neutralizes Aβ-induced memory 
impairment and toxicity 
 
Ivica Granic1, Marcelo F. Masman1, Cornelius Mulder1, Ingrid M. 
Nijholt1,4, Pieter J.W. Naude1,3, Ammerins de Haan1, Emóke Borbély2, 
Botond Penke2, Paul G.M. Luiten1,3, Ulrich L.M. Eisel1 
 
1Department of Molecular Neurobiology, University of Groningen, P.O. Box 14, 9750 AA Haren, The 
Netherlands; 2Department of Medical Chemistry, University of Szeged, Dóm Square 8, 6720 Szeged, 
Hungary; 3 Department of Biological Psychiatry, and 4Department of Neuroscience, Section Anatomy, 





















Misfolding, oligomerization and aggregation of the amyloid-beta (Aβ) peptide is 
widely recognized as a central event in the pathogenesis of Alzheimer’s disease (AD). 
Recent studies have identified soluble Aβ oligomers as the main pathogenic agents 
and provided evidence that such oligomeric Aβ aggregates are neurotoxic, disrupt 
synaptic plasticity and inhibit long-term potentiation (LTP). A promising 
therapeutic strategy in the battle against AD is the application of short synthetic 
peptides which are designed to bind to specific Aβ-regions thereby neutralizing or 
interfering with the devastating properties of oligomeric Aβ species. In the present 
study we investigated the neuroprotective properties of the amyloid sequence 
derived pentapeptide LPYFDa in vitro as well as its memory preserving capacity 
against Aβ42-induced learning deficits in vivo. In vitro we could show that neurons in 
culture treated with LPYFDa are protected against Aβ42-induced cell death. 
Moreover, in vivo LPYFDa prevented memory impairment tested in a contextual 
fear conditioning paradigm in mice after bilateral intrahippocampal Aβ42 injections. 
We thus showed for the first time that an anti-amyloid peptide like LPYFDa can 

































Progressive neurodegeneration and cognitive decline are typical features of 
Alzheimer’s disease (AD), the most common form of dementia (Haass and Selkoe, 
2007). Besides the formation of neurofibrillary tangles, it is widely acknowledged 
that the aggregation of amyloid β (Aβ) initiates a complex series of events that 
ultimately results in neuronal cell death particularly in forebrain regions, which is 
paralleled by the cognitive and behavioral decline that is characteristic for 
pathogenesis of AD. Aβ is generated by sequential proteolytic cleavage from the 
amyloid-β precursor protein (APP) by beta-, and gamma-secretases (amyloidogenic 
processing). Alternatively APP can be cleaved by -secretase within the Aβ sequence 
which prevents the generation of Aβ peptide. Once released, Aβ due to its physico-
chemical properties has the strong tendency to misfold, oligomerize and to 
aggregate into fibrils and plaques (Wisniewski et al., 1997). 
Although amyloid plaques represent a major hallmark of AD, they correlate poorly 
with the progression of the disease (Forman et al., 2007). Interestingly, more recent 
studies have identified soluble Aβ–oligomer assemblies as the main pathogenic 
agents which, in contrast to plaques, do correlate well with the mental decline 
observed in AD patients (Haass and Selkoe, 2007; Lue et al., 1999; McLean et al., 
1999; Naslund et al., 2000; Wang et al., 1999). Furthermore, soluble Aβ oligomers 
have been shown to be neuro- and synaptotoxic, and to inhibit long-term 
potentiation (LTP) (Chang et al., 2006; Chapman et al., 1999; Shankar et al., 2008; 
Walsh and Selkoe, 2007; Wasling et al., 2009). Acute application of oligomeric Aβ 
leads to internalization of glutamatergic AMPA and NMDA receptors and finally to 
synaptic downscaling (Hsieh et al., 2006; Shankar et al., 2007). However, it should 
be appreciated that next to its pathological properties, Aβ notably in very low 
physiological concentrations, may have important roles in synaptic plasticity and 
normal brain functioning (Pearson and Peers, 2006; Puzzo et al., 2008; Wasling et 
al., 2009). The endogenous level of Aβ in the brain is regulated by synaptic activity 
in vivo, suggesting a dynamic feedback loop involving APP metabolism and Aβ that 
may modulate synaptic activity (Haass and Selkoe, 2007). Recently, Garcia-Osta and 
coworkers showed that depletion of endogenous Aβ by a single intrahippocampal 
(i.h.) administration of anti- Aβ -antibody leads to disrupted memory retention in 
rats (Garcia-Osta and Alberini, 2009). During the pathogenesis of AD the 
equilibrium of Aβ generation and Aβ clearance is disturbed, which eventually leads 
to elevated Aβ levels, increased Aβ aggregation and impaired memory function 
(Wasling et al., 2009).  
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Multiple therapeutic strategies have been developed since the second half of the 
previous century (Harkany et al., 2000). Unfortunately, most of the currently 
available therapies target only the symptoms since acting on presumed downstream 
neurotoxic pathogenic mechanisms without tackling the cause and thus hardly able 




using immunotherapy in order to remove Aβ- from the brain were highly promising 
(Schenk et al., 1999). However, clinical trials with active immunization against Aβ 
were halted due to severe brain inflammation and premature  death of several 
patients (Hock et al., 2003; Orgogozo et al., 2003).  
Consequently, as a therapeutic strategy compounds were developed that could 
inhibit or delay the development of Aβ aggregation, fibrillization, and/or plaque 
formation and were thus potentially capable of protecting neurons from Aβ toxicity. 
As part of this approach small peptides derived from the Aβ sequence were 
designed such as the pentapeptide LPYFDa which seemed to offer a promising 
starting point to develop potential drugs that can somehow revert the devastating 
impact of Aβ aggregates. The advantage of such compounds, in comparison to other 
putative therapeutic approaches for AD such as vaccination, is that they specifically 
target the abnormal conformation of Aβ without interfering with any possible 
physiological function of the soluble, monomeric Aβ peptide. 
There have been numerous attempts to develop treatments developed to interfere 
with various key steps in the amyloidogenic process. Promising putative treatments 
may be those designed to inhibit steps that precede Aβ peptide aggregation, by 
blocking production of the toxic soluble Aβ oligomers in the first place, or by 
reversing, somehow, the toxic effect of these oligomers.  
In the present study we established an in vivo model in the mouse for Aβ induced 
memory impairment through a single bilateral injection of oligomeric Aβ42 into the 
hippocampus and explored in this model whether LPYFDa can be beneficial against 
the Aβ-induced cognitive deficits. Furthermore, we investigated the neuroprotective 
properties of Aβ-derived synthetic beta-sheet breaker peptide Leu-Pro-Tyr-Phe-Asp-
amide (LPYFDa) (Datki et al., 2004; Juhasz et al., 2009; Szegedi et al., 2005) against 
the neurotoxic effects of soluble Aβ42 oligomers in cultured mouse primary cortical 
neurons (PCN). Finally, we employed molecular modeling and docking experiments 








The beta-sheet breaker LPYFDa was synthesized in our laboratories by a solid-phase 
procedure involving the use of Merrifeld resin and Boc chemistry. Purity control 
and structure verification were carried out by amino acid analysis and mass 
spectrometry as previously described (Zarandi et al., 2007). The control peptide 
(scrP), which is a scrambled version of the LPYFD peptide (Pro-Asp-Tyr-Leu-Phe-
amide), and Aβ −1  42 (Aβ42) were purchased from EZBiolab Inc. (Carmel, USA). 
Anti-Aβ antibody (6E10) was obtained from Covance (Emeryville, USA). Other 
compounds used in this study were purchased from Invitrogen (Carlsbad, USA) or 





7.2.2 Preparation of Aβ-oligomers 
 
Oligomeric Aβ42 was prepared as was described by Dahlgren and colleagues 
(Dahlgren et al., 2002). In short, the synthetic Aβ42 peptide was initially dissolved in 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to a concentration of 1 mM. The peptide 
solution was divided into aliquots and the HFIP removed by evaporation under 
vacuum (SpeedVac; Savant Instruments, Hyderabad, India). The dry peptide films 
were stored at -20°C until further processing. Before use, the dry film Aβ42 was 
dissolved in anhydrous DMSO to 5 mM followed by bath sonication (Decon, Hove 
Sussex, UK) for 10 min, subsequently diluted in neurobasal medium to a final 
concentration of 100 μM (stock solution) and incubated at 4°C for 24 h to enable 
Aβ42 oligomerization. The aggregation state and the secondary structure of the 
oligomeric Aβ42 preparation were examined by sodium dodecyl sulfate (SDS) - 
PAGE Western blotting and Circular Dichroism (CD) spectrometry (Figure 7.1). 
 
7.2.3 Gel electrophoresis and Western Blot Analysis 
 
Gel electrophoresis and Western blot analysis were adopted from Stine et al., 2003 
(Stine et al., 2003). Briefly, unheated samples in SDS sample buffer were applied to 
10-20% tris-tricine gradient gels (Bio-Rad, Munich, Germany), electrophoresed 
using tricine running buffer and subsequently transferred to 0.45-μm polyvinylidene 
difluoride membranes (Millipore, Bilerca, USA). Membranes were blocked with 1% 
I-Block (Tropix, Bedford, USA) in Trisbuffered saline containing 0.0625% Tween-
20. Blots were incubated with primary antibody 6E10 over night (1:2000; mouse 
monoclonal against Aβ residues 1–16; Covance Emeryville, USA). 
Immunoreactivity was detected using enhanced chemiluminescence (Pierce 
Biotechnology, Rockford, USA) and imaged on an Kodak X-Ray film (Eastman 
Kodak Company, Rochester, USA) (Figure 7.1A). Molecular weight values were 
estimated using the PageRuler (Fermentas International, Ontario, Canada) pre-




7.2.4 CD spectrometry 
 
CD measurements were performed at 25 °C on a CD Spectrometer Model 62DS 
(AVIV Associates Inc., Lakewood, USA) using a quartz cell of 0.1-cm pathlength. 
All spectra were averages of four scans; the resolution was 1 nm. The oligomerized 
Aβ was diluted in PBS to a concentration of 25 μM. The samples were sonicated for 
10 min immediately after dissolution. CD spectra were expressed as mean residue 
ellipticity []MR in units of deg cm2 dmol−1, (Figure 7.1B). The percentages of 







7.2.5 Molecular Modeling 
 
7.2.5.1 Stochastic Conformational Search. EDMC calculations 
 
The conformational space was explored using the method previously employed by 
Liwo et al. (Liwo et al., 1996) which includes the electrostatically driven Monte 
Carlo (EDMC) method (Ripoll and Scheraga, 1988, 1990) implemented in the 
ECEPPAK (Letoha et al., 2005) package. Conformational energy was evaluated 
using the ECEPP/3 force field (Nemethy G, 1992). Hydration energy was evaluated 
using a hydration-shell model with a solvent sphere radius of 1.4 Å and atomic 
hydration parameters that have been optimized using nonpeptide data (SRFOPT) 
(Vila et al., 1991; Williams et al., 1992). In order to explore the conformational 
space extensively, we carried out 10 different runs, each of them with a different 
random number. Therefore, we collected a total of 5000 accepted conformations. 
Each EDMC run was terminated after 500 energy-minimized conformations had 
been accepted. The parameters controlling the runs were the following: a 
temperature of 298.15 K was used for the simulations. A temperature jump of 
1,000 K was used; the maximum number of allowed repetitions of the same 
minimum was 50. The maximum number of electrostatically predicted 
conformations per iteration was 400; the maximum number of random-generated 
conformations per iteration was 100; the fraction of random/electrostatically 
predicted conformations was 0.30. The maximum number of steps at one increased 
temperature was 20; and the maximum number of rejected conformations until a 
temperature jump is executed was 100. Only trans peptide bonds (  180°) were 
considered. All accepted conformations were then clustered into families using the 
program ANALYZE (Meadows et al., 1994; Pohorille and Pratt, 1990) by applying 
the minimal-tree clustering algorithm for separation, using all heavy atoms, energy 
threshold of 30 kcal.mol-1, and RMSD of 0.75 Å as separation criteria. This 
clustering step allows a substantial reduction of the number of conformations and 
the elimination of repetitions. A more detailed description of the procedure used 
here is given in section 4.4 Computational Methods of reference (Masman et al., 
2009b). 
 
7.2.5.2 Docking Studies 
 
Two models for Aβ were used as target systems; the monomeric Aβ42 elucidated by 
Crescenzi et al (monomeric model) (Crescenzi et al., 2002), PDB code 1IYT, and 
the pentameric aggregate Aβ42 developed by Masman et al (pentameric model) 
(Masman et al., 2009a). The structures were prepared for docking study as follows: 
for the Aβ42 molecules, water molecules were removed from the PDB file and 
hydrogen atoms were added; Gasteiger charges, atomic solvation parameters and 
fragmental volumes were merged to the target system. For both LPYFDa and scrP, 
the structure of the most populated family (results from the EDMC calculations) was 
taken as initial conformation. Gasteiger charges were assigned and non-polar 




The docking energy grid was produced with the auxiliary program AutoGrid. The 
grid dimensions were 60x60x60 for the monomeric model, and 90x60x60 for the 
pentameric model, points along the x-, y- and z-axes, with points separated by 
0.375Å. The grids were chosen to be sufficiently large to cover significant portions 
of the putative binding sites. The center of the pentapeptide was positioned at the 
grid center. All graphic manipulations and visualizations were performed by means 
of the AutoDock Tools (Sanner, 1999) and the Chimera (Pettersen et al., 2004) 
programs, and ligand docking with AUTODOCK 4 (Morris et al., 2009). The 
Lamarckian genetic algorithm was utilized and the energy evaluations were set at 
2.5x106. A total of 250 accepted conformations were collected. Other parameters 
were set to default values. 
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 7  Figure 7.1 A) Oligomeric preparation of Aβ42 was examined by Western blot using the anti-Aβ antibody 6E10 (1:2000). Bands correspond to monomeric up to tetrameric forms of A42. B) CD 
spectrum of () A42 in PBS after 24 hours incubation at 4 °C.() fitted line data using K2D2 
program. C) Schematic outline of the experimental procedure in vitro. PCN from C57BL6 mouse 
embryos (E14) were cultured for 6 days and then treated for 24 h with different concentrations of 
oligomerized Aβ42, beta-sheet breaker peptides or combinations of both. On day 7 medium was 
completely exchanged and 24 h later the cell viability was assessed by an MTT reduction assay. D) 
Schematic outline of the experimental setup in vivo. C57BL/6J mice were cannulated 7 days prior i.h. 
injection with oligomerized Aβ42 and/or beta-sheet breaker peptides. One hour after the injection the 
animals were trained in a contextual fear conditioning paradigm. 24 h after the training session memory 
performance was assessed. Cannula position was evaluated by methylene blue injection after the 
behavioural test. E) Representative coronal brain sections of a bilateral dorsal hippocampal (i.h.) 









7.2.6 Primary cortical neuron culture 
 
Primary cortical neurons were prepared from embryonic brains (E14) of C57Bl/6J 
mice. The cortices were carefully dissected, meninges were removed and the 
neurons separated by trituration. Cells were plated on poly-D-lysine pre-coated 
plates at a density of 1.2 x 105 cells/well (96 well plates). Neurobasal medium 
supplemented with 2% (v/v) B27-supplement, 0.5 mM glutamine and 1% (v/v) 
penicillin/ streptomycin was used as a culture medium. After 48 h neurons were 
treated with 10 μM cytosine arabinoside for another 48 h to inhibit non-neuronal 
cell growth. Subsequently, the medium was completely exchanged and after 6 days 
of in vitro culture, the neurons were used for experiments.  
 
7.2.7 Treatment of cells 
 
Possible toxicity of LPYFDa, its control peptide scrP and Aβ42 oligomers was 
determined by incubating neuronal cultures for 24 h with different concentrations 
of the peptide solutions. The neuroprotective effect of LPYFDa was assessed by 
incubating neurons (cultured in 96 well plates) for 24 h with 20 M oligomeric Aβ 
in the presence or absence of different concentrations of LPYFDa or control 
peptide. After the treatment, the medium was completely exchanged, and 24 h 
later, the cell viability was determined by an MTT-assay (Figure 7.1C). All 
treatments were performed in triplicates and the experiments were repeated at least 
two times. 
 
7.2.8 Determination of cell viability by MTT-assay 
 
Neuronal viability was determined by the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl-)2,5-diphenyltetrazolium bromide] assay as described previously (Mosmann, 
1983). 1.25 mg/ml MTT solution was added to each well of a 96 well plate. After 2 
h of incubation, cells were lysed in acidic propan-2-ol solution (37% HCl/ propan-2-
ol: 1/166). The absorbance of each well was measured with an automated ELISA 





Behavioral experiments were performed with 9–12 weeks old male C57Bl/6J mice 
(Harlan, Horst, The Netherlands). Individually housed mice were maintained on a 
12 h light/dark cycle (lights on at 7.00 a.m.) with food (Hopefarms, standard rodent 
pellets) and water ad libitum. A layer of sawdust served as bedding. The animals 
were allowed to adapt to the housing conditions for 1–2 weeks before the 
experiments started. The procedures concerning animal care and treatment were in 
accordance with the regulations of the Ethical Committee for the use of 





7.2.10 Animal surgery 
 
Double guide cannulae type C235 (Plastics One, Roanoke, USA) were implanted in 
the brain using a Kopf stereotactic instrument during Hypnorm/Midazolam (10 
ml/kg, i.p.) anesthesia under aseptic conditions as previously described (Nijholt et 
al., 2008) with anteroposterior (AP) coordinates zeroed at Bregma directed toward 
both dorsal hippocampi (i.h.), AP -1.5 mm, lateral 1 mm, depth 2 mm (Franklin 
and Paxinos, 1997). Each double guide cannula with inserted dummy cannula and 
dust cap was fixed to the skull with dental cement (3M ESPE AG, Seefeld, 
Germany). Administration of 1 mg/ml finadyne (2.5 mg/kg s.c.) before the surgery 
served as analgesic. The animals were allowed to recover for 6–7 days before the 
behavioral measurements started.  
 
7.2.11 Intrahippocampal injections 
 
Bilateral i.h. injections were performed under short isofluran anesthesia using a 
Hamilton microsyringe fitted to a syringe pump unit (TSE systems, Bad Homburg, 
Germany) at a constant rate of 0.3 μl/min (final volume: 0.3 μl per side). The 
amount of injected A42 was of 15, 30 or 60 pmol and LPYFDa as well as the control 
peptide scrP in an amount of 150 pmol into the dorsal hippocampus. PBS (pH 7.5) 
served as vehicle. One hour after the injection the animals were subjected to a 
training session in a fear conditioning paradigm (Figure 7.1D). The number of 




7.2.12 Fear conditioning 
 
Fear conditioning was performed in a plexiglas cage (44 x 22 x 44 cm) with constant 
illumination (12 V, 10W halogen lamp, 100–500 lux). The training (conditioning) 
consisted of a single trial. Before each individual mouse entered the box, the box 
was cleaned with 70% ethanol. The mouse was exposed to the conditioning context 
for 180 s followed by a scrambled footshock (0.7 mA, 2 s, constant current) 
delivered through a stainless steel grid floor. The mouse was removed from the fear 
conditioning box 30 s after shock termination to avoid an aversive association with 
the handling procedure. Memory tests were performed 24 h after fear conditioning. 
Contextual memory was tested in the fear conditioning box for 180 s without 
footshock presentation. Freezing, defined as the lack of movement except for 
respiration and heart beat, was assessed as the behavioral parameter of the defensive 
reaction of mice by a time-sampling procedure every 10 s throughout memory tests. 
In addition, mean activity of the animal during the training and retention test was 







7.2.13 Histology  
 
Immediately after the behavioral test mice were injected i.h. with methylene blue 
solution during sodium-pentobarbital anesthesia (0.1 ml/ 10g, i.p.). Brains were 
removed and serially sectioned at 50 μm. Sections were stained on glass for 5 min in 
0.1% nuclear fast red solution. To identify the location of the injection, sections 
were analyzed using light microscopy. Only data from animals in which the proper 
intrahippocampal site of injection was confirmed, were evaluated (Figure 7.1E).  
 
7.2.14 Statistical analysis 
 
Behavioral data were analyzed by analysis of variance (ANOVA) followed by the 
Bonferroni post-hoc test to determine statistical significance. For statistical analysis 
of the MTT assays, an unpaired Student’s t test with unequal variance was used. A 
p-value < 0.05 was considered to be statistically significant. Data are presented as 





7.3.1 Characterization of the oligomeric Aβ42  
 
The state of aggregation of the oligomeric Aβ42 preparation was determined by 
Western blot analysis. The results confirmed that the Aβ42 preparation consisted of 
a mixture of small molecular weight Aβ42 oligomers from monomeric to tetrameric 
Aβ42 (Figure 7.1A). In addition we used CD spectrometry to characterize the 
secondary structure of Aβ42 in solution. We could show that our oligomeric Aβ42 
preparation consists of 43.02% β-sheets, 5.40% -helix and 51.58% random-coil 
conformation (Figure 7.1B), which shows a good correlation to the conformation 
behavior of Aβ42 aggregates observed by Masman et al (Masman et al., 2009a). 
 
 
7.3.2 Molecular modeling and Stochastic Conformational Search. EDMC 
calculations 
 
To have a better view at the molecular lever, it is crucial to assess the 
conformational behavior of the pentapeptides in solution. Therefore, LPYFDa and 
scrP were selected for energy calculations to determine the biologically relevant 







Calculations yielded a large set of conformational families for each peptide studied. 
The total number of conformations generated was 62515 and 65056, for LPYFDa 
and scrP respectively, whereof 5000 conformations for each pentapeptide were 
accepted. In the clustering procedure, an R.M.S.D (Root Mean Square Deviation) 
of 0.75 Å and a E of 30 kcal mol-1 were used. The number of families after 
clustering was 220 and 323, for LPYFDa and scrP, resp. The total number of 
families accepted with a relative population higher than 0.50% was 10 and 25, for 
LPYFDa and scrP, resp. that  sum up to ca 90% of all conformations. All low-energy 
conformers of pentapeptides studied here were then compared to each other. The 
comparison involved the spatial arrangements, relative energy and populations. The 
LPYFDa evaluation showed that the most populated family (50.04%) is also the 
energetically preferred one, while its second most populated family (15.36%) has a 
relative energy of 0.03 kcal mol-1 above the global minimum. This small energetic 
difference is due to a slight reorientation of the side-chain of the residue Phe (see 
Figure 7.2A), while the rest of the structure showed approximately the same 
orientation. On the other hand, the most populated family of scrP (22.92%) 
showed a relative energy of 1.18 kcal mol-1 above the global minimum and a relative 
population of 6.38%. It was observed that LPYFDa is confrontationally, generally 
more restricted than scrP, with a preference to form folded structures, while scrP 
tended to form semi-extended or fully-extended conformations. Spatial views of 




Table 7.1: Conformational search and clustering results for LPYFDa and scrP optimized at the 
EDMC/SRFOPT/ECCEP/3 level of theory. Total (Etot, kcal mol-1) and relative (E, kcal mol-1) 
energies are also shown. All conformational families shown here have relative population (%PF) higher 
than 0.5%. 
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 7     LPYFDa Electrostatic Random Thermal Total Generated a 4233 58242 40 62515 
Accepted b 535 4431 34 5000 
     
Family NF c %PF d Etot  E 
1 2502 50.04 -70.79 0.00 
2 768 15.36 -70.76 0.03 
3 370 7.40 -69.43 1.36 
4 262 5.24 -70.12 0.66 
5 261 5.22 -69.31 1.47 
6 247 4.94 -70.25 0.54 
7 62 1.24 -69.37 1.42 
8 47 0.94 -70.13 0.66 
9 35 0.70 -69.75 1.03 
10 30 0.60 -68.45 2.34 
    scrP 
Electrostatic Random Thermal Total 
Generated a 4288 60708 60 65056 
Accepted b 362 4595 43 5000 




Family NF c %PF d Etot E 
1 1146 22.92 -49.71 1.18 
2 635 12.70 -50.16 0.73 
3 478 9.56 -49.95 0.93 
4 329 6.58 -50.88 0.00 
5 272 5.44 -49.66 1.22 
6 250 5.00 -49.94 0.94 
7 190 3.80 -50.19 0.69 
8 116 2.32 -49.71 1.17 
9 114 2.28 -50.57 0.31 
10 101 2.02 -49.44 1.44 
11 97 1.94 -49.63 1.26 
12 88 1.76 -50.23 0.65 
13 60 1.20 -50.25 0.64 
14 53 1.06 -49.47 1.41 
15 51 1.02 -49.81 1.07 
16 48 0.96 -49.39 1.50 
17 45 0.90 -48.58 2.30 
18 39 0.78 -48.78 2.10 
19 39 0.78 -48.22 2.66 
20 38 0.76 -48.97 1.91 
21 37 0.74 -49.23 1.65 
22 32 0.64 -49.74 1.14 
23 30 0.60 -48.90 1.98 
24 27 0.54 -49.03 1.86 
25 26 0.52 -49.07 1.81 
a Number of conformations generated electrostatically, randomly and thermally during the 
conformational search. 
b Number of conformations accepted from those generated electrostatically, randomly and thermally 
during the conformational search. 
c NF represents the total number of conformational families as result of the clustering run. 
d %PF represents the percent relative population based on a total of 5000 accepted conformations. 
 
 
7.3.3 Docking Studies  
 
7.3.3.1 Monomeric Model  
 
Two potential binding sites were found by using a single blind docking run (results 
not shown) on the monomeric Aβ42 molecule (PDB code 1IYT), which comprises 
two -helix moieties (residues 8-25 and 29-39) connected by a loop (residues 26-28). 
Site I encompasses the residues 21-26 containing Glu22 and Asp23, which were 
previously identified as residues for aggregation of the oligomers (Buchete and 
Hummer, 2007; Masman et al., 2009a). Site II includes residues 6-12 located in the 
portion of the molecule that loses all structural organization after oligomer 
formation, thus forming the so-called disordered region. In table 7.2 the two most 
populated families of the complexes of LPYFDa and scrP with the monomeric Aβ42 
are summarized. LPYFDa showed lower binding energies, while site II was in 
general energetically preferred over site I but families on site II poorly populated. In 








Figure 7.2. Stereoview of selected conformations for LPYFDa and scrP optimized at 
EDMC/SRFOPT/ECCEP/3 level of theory. (A) overlapping of the two most populated and 
energetically preferred families of LPYFDa, family 1 (E = 0.00 cal.mol-1, white) and family 2 (E = 
0.03 kcal.mol-1, pink) . (B) Family 4 with a relative energy (E) of 0.00 kcal.mol-1 and (C) Family 1 





7.3.3.2 Pentameric Model  
 
As previously reported by Masman et al. (Masman et al., 2009a), the Aβ42 aggregates 
contain two β-sheet moieties (β1, residues 18-26 and β2, residues 31-42) organized 
into a parallel interchain orientation, which were proposed as intermolecular 
binding sites for the pentameric conformation. Moreover, a third possible site for 
interactions with ligand molecules was postulated, which involves the β1 and β2 
portions of the chain located at the edge of the aggregate. This site is orientated into 












Table 7.2: The two most populated families of LPYFDa and scrP found by docking simulations on the 
monomeric and pentameric A42 peptide and the corresponding binding energies (EB) of the complexes. 
The binding constant (KB) and the relative populations (%P) are also shown.  
   LPYFDa scrP 
































































































         
a KB is calculated in with the equation KB=exp((G*1000.)/(Rcal*TK), where G is the 
docking energy, Rcal is 1.98719 and TK is 298.15 
 
Table 7.2 shows the two most populated families of the complexes of LPYFDa and 
scrP with the pentameric Aβ42. For all the sites proposed, LPYFDa showed lower 
binding energies than scrP. Interestingly, both pentapeptide LPYFDa and scrP, 
revealed an energetic preference for site β1. LPYFDa was designed on the basis of 
Soto’s pentapeptide LPFFD, which derives from the amino acid sequence Leu17-Val-
Phe-Phe-Ala21 of Aβ42, being the β1 portion of the aggregate. Figure 7.3 shows the 
atomic details of the interactions of the best complex (family β1 1, in table 7.2) 
found between LPYFDa and the pentameric Aβ42. It can be appreciated that the N-
terminal of LPYFDa formed a double salt bridge with the Glu22’s of the second and 
third chain of the aggregate. Also, a second salt bridge links the Lys16 to the Asp 
residue of LPYFDa. All salt bridges, indicated with a block-arrow that points to the 
positive member of the interaction, revealed an interacting distance of 
approximately 3.5 Å. All the ligand-target contacts are depicted as wireframe 




and Val18 of the aggregate, and the residues Leu, Pro and Phe of the pentapeptide 
LPYFDa. This hydrophobic pocket is indicated with a dashed line.  
 
Figure 7.3. A steric view of binding between the pentameric A42 model and LPYFDa. Salt bridges are 





7.3.4 LPYFDa is neuroprotective against oligomeric Aβ42 in vitro 
 
Part of our study was to assess the neuroprotective potential of the beta-sheet 
breaker LPYFDa against Aβ-induced toxicity. Therefore, we first determined the 
toxic effect of the Aβ42 oligomer preparation in vitro on cultured primary cortical 
neurons (PCN). Neuronal cultures were exposed to increasing concentrations of 
oligomerized Aβ42 for 24 h, followed by an MTT-reduction assay to assess cell 
viability. The results showed a clear Aβ-induced, dose dependent decrease in cell 
survival reaching significance at concentrations higher than 10 μM (Figure 7.4A). 
For the subsequent experiments we used oligomeric Aβ42 at a concentration of 25 
μM as a toxic stimulus.  
Second, we investigated if LPYFDa or the control peptide scrP exhibited any 
toxicity to PCN and whether the beta-sheet breaker peptides were capable to 
overcome the toxic effect of oligomeric Aβ42. For this purpose PCN were exposed to 
different concentrations of LPYFDa or scrP alone, Aβ42 alone (25 μM) or beta-sheet 
breaker peptides and Aβ42 together for 24 h. The results showed that LPYFDa and 




Furthermore, the control peptide scrP was not able to protect the neurons from Aβ-
induced toxicity (Figure 7.4C). In contrast, we could demonstrate a dose dependent 
neuroprotective effect of LPYFDa against Aβ-induced toxicity, reaching significance 




Figure 7.4. Cell viability of PCN as determined by an MTT-assay. Neurons treated with increasing 
concentrations of A) Aβ42 or B) pentapeptides LPYFDa and scrP incubated for 24 h. Neuroprotection 
by C) scrP or D) LPYFDa was determined by co incubating increasing concentrations of the 
pentapeptides with 25 μM Aβ42 for 24 h. Bars indicate the mean cell viability in % relative to 
untreated controls ± SEM. (* = significant at p < 0.05). 
 
 
7.3.5 A single intrahippocampal injection of oligomeric Aβ42 induces 
cognitive deficits in contextual fear conditioning 
 
One hour prior to the training session in a contextual fear conditioning paradigm 
C57BL/6J mice received a single injection of oligomeric Aβ42 (15, 30 or 60 pmol) 
or vehicle. Injections did not affect locomotion or the shock reaction during 
training (data not shown). The vehicle injected animals displayed an average relative 
freezing behavior of 58.9± 2.9% which did not differ from untreated control 
animals (61.1± 2.4 %). The mice injected with Aβ42 showed a dose dependent 




freezing of 50.0±4.2 % which was not significantly different from the vehicle-
injected animals. However, the mice injected with 30 pmol and 60 pmol of Aβ42 
had significantly reduced freezing scores compared to the vehicle group (36.2± 
4.6%; p=0.024 and 33.3± 5.3%; p=0.037).  
Next, we investigated whether LPYFDa is able to revert the Aβ-induced memory 
deficits. Therefore, we injected mice with 150 pmol LPYFDa or 150 pmol of the 
non specific control peptide scrP in the presence or absence of 30 pmol 
oligomerized Aβ42 into the hippocampus. The LPYFDa and the scrP injected mice 
showed an average freezing of 61.1± 5.0% and 63.0± 5.5% which did not 
significantly differ from the untreated (61.1± 2.4%) or vehicle injected group (58.9± 
2.9%).  
However, LPYFDa co-injected with Aβ42 was able to abolish the Aβ42 oligomer-
induced memory impairment (57.4± 5.2% vs 36.2± 4.46%; p=0.039). Co-injection 
of Aβ with the control peptide scrP, which resulted in an average freezing score of 
48.0± 4.9%, did not significantly reverse the Aβ-induced memory deficits (Figure 
7.5B). 
These results indicate that LPYFDa can reverse the detrimental effects of Aβ42 






Figure 7.5. Effect of Aβ42 and LPYFDa on contextual fear conditioning. A) A single i.h. injection of 
oligomeric Aβ42 led to a dose dependent significant decrease in conditioned fear when compared to a 
vehicle injection. B) Co-injection of Aβ42 with LPYFDa prevented the Aβ-induced memory impairment 
significantly, whereas the non-specific control peptide scrP failed to revert memory deficits. Bars indicate 
the mean relative freezing score in % ± SEM. Differences were determined by ANOVA (* = significant 









In the present study we could show that Aβ42 oligomers are toxic to primary cortical 
neurons in culture in a dose-dependent manner (Figure 7.4A). These results are in 
line with studies by Dahlgren and colleagues, who reported that the oligomeric 
form of Aβ42 is 10 fold more toxic when compared to the fibrillar form (Dahlgren et 
al., 2002). These and our present findings support the growing general view that in 
particular oligomeric Aβ42 peptides contribute to the progressive neuronal loss and 
the associated memory impairment observed in AD patients. Indeed, several studies 
showed that elevated levels of soluble oligomeric Aβ correlate strongly with 
cognitive decline in AD patients (McLean et al., 1999; Wang et al., 1999). Walsh et 
al. observed that a low-n oligomeric assembly of naturally secreted human Aβ alters 
hippocampal synaptic plasticity by inhibiting long-term potentiation (Walsh et al., 
2002). Also the number of dendritic spines was dramatically decreased when 
neurons were incubated with Aβ oligomers, but not with monomers (Walsh et al., 
2002). However, the loss in spines could be reverted by treating neurons with an 
anti-A antibody (Shankar et al., 2007).  
A possibility to counteract the injurious effects of oligomeric A is by modulating 
its aggregation. Crucial for the aggregation process of the A molecule are the 
hydrophobic residues (amino acids 17-21: LVFFA) within the internal region of the 
Aβ peptide. Experiments by Hilbich and colleagues revealed that replacement of 
those hydrophobic residues by hydrophilic residues results in impaired fibril 
formation (Hilbich et al., 1992). These and other findings eventually led to the 
concept of beta-sheet breakers as therapeutic strategy for AD as proposed by Soto et 
al. (Soto, 1999; Soto et al., 1996). The initially synthesized compounds were 
peptides of 11 to 5 amino acids targeting the center region of the Aβ peptide and 
evolved to compounds like LPFFD (iAβ5) and/or LPYFDa. These pentapeptides are 
partially homologous to this hydrophobic center region and bind with a relatively 
high affinity to Aβ (Hetenyi et al., 2002a; Permanne et al., 2002; van Groen et al., 
2009) by similar intermolecular interactions, leading to a competitive replacement 
of Aβ molecules. A major drawback with peptide drugs for neurological disorders is 
their rapid degradation in vivo by proteolytic enzymes and their poor blood-brain 
permeability (Adessi and Soto, 2002). These issues were overcome by chemical 
modifications, like C-terminal amidation and N-terminal carboxylation, which 
resulted in increased half life in vivo and rapid brain up-take (Permanne et al., 
2002).  Although, our knowledge of the biochemistry in respect to catabolism and 
brain uptake of certain aggregation inhibitor peptides has developed greatly in 
recent years, the detailed mechanisms of action are still poorly understood. 
Therefore, it is essential to elucidate and study the three dimensional structure of 
the Aβ peptide/aggregation inhibiting peptide complex to gain more insight into 
the molecular dynamics of the Aβ aggregation process.  
We used computational modeling and docking experiments to address this 
question. Interestingly our docking results showed that LPYFDa binds preferably to 
the β1 portion of the aggregate (Table 7.2 and Figure 7.3), which has a good 




wild-type sequence Leu17-Val-Phe-Phe-Ala21 of Aβ42, which is contained in this 
portion of the aggregate. Our docking results did not show any binding preference 
of LPYFDa (nor scrP) for the monomeric or the pentameric Aβ.  
In the present study we showed that the pentapeptide LPYFDa can protect cultured 
neurons from oligomeric Aβ-induced cell death. Datki et al. reported similar results 
on neuronal-like cell lines, e.g. SHSY-5Y cells. They could show that a 5-fold molar 
excess of LPYFDa protects these cells from toxic effects of fibrillar Aβ (Datki et al., 
2004; Fulop et al., 2004). In our study we could confirm that a molar excess of 
LPYFDa can prevent Aβ42 mediated neurotoxicity. Moreover, we demonstrated a 
dose-dependent protective effect of LPYFDa and that this pentapeptide already has 
significant neuroprotective properties even with a 6-fold molar excess of oligomeric 
Aβ42. Our results are also in agreement with other studies reporting protection by 
LPYFDa against the rapid neuromodulatory action of fibrillar Aβ42 demonstrated by 
in vitro and in vivo electrophysiology (Szegedi et al., 2005).  
We found that a single bilateral intrahippocampal injection of oligomeric Aβ42 
impairs memory formation if applied 1 h before the training session in a contextual 
fear conditioning paradigm. These findings are in line with several other studies, 
which consistently report on memory deficits after intracerebral injections of Aβ42 
peptides, although the experimental conditions vary in terms of the injected 
peptide, injection procedure and behavioral tasks employed (Ammassari-Teule et 
al., 2002; Christensen et al., 2008; Harkany et al., 2001; Malin et al., 2001; 
Nakamura et al., 2001; O'Hare et al., 1999). It should be noted that these injections 
obviously lead to Aβ levels beyond the basal levels necessary for proper synaptic 
functioning. Garcia-Osta showed that neutralizing endogenous Aβ by an anti-Aβ 
antibody resulted in memory impairment which implies that physiological soluble 
Aβ levels are required for proper memory function (Garcia-Osta and Alberini, 
2009), which was recently confirmed by a study of Morley et al (Morley et al., 2009) 
Chapter 
 7 The peptide LPFFD, which was designed by the Soto group was able to prevent fibrillogenesis in a rat brain model (Soto et al., 1998) and to reduce Aβ deposition a transgenic Alzheimer mouse model (Permanne et al., 2002). Most interestingly, 
iAβ5p was shown to reverse the memory impairment caused by intrahippocampal 
injections of A fibrils in rats (Chacon et al., 2004). However, these studies did not 
reveal whether impairment of learning and memory after oligomeric Aβ injections 
could be counteracted by such compounds. A novelty of our study is that we used 
Aβ oligomers instead of the less effective Aβ fibrils. Therefore, an important aim of 
our study was to establish if a compound like LPYFDa is able to prevent Aβ 
oligomer–induced learning and memory deficits. We showed that a 5-fold molar 
excess of LPYFDa to Aβ could overcome the detrimental effects of Aβ oligomers on 
memory. Thus, we provide evidence that so-called beta-sheet breaker peptides such 
as LPYFDa bear therapeutic potential against Aβ-induced memory impairment. 
Moreover, it was recently demonstrated that intraperitoneally administered LPYFDa 
is able to cross the blood brain barrier and protects synapses against excitatory 
action of fibrillar Aβ (Juhasz et al., 2009).  
The mechanism how these pentapeptides exert their protective effects on cell death 





actions of Aβ reported here, namely, the neuronal degeneration following 
application of Aβ oligomers in vitro and memory loss following injections of Aβ 
oligomers in vivo may be unrelated. In hippocampal tissue extracted one hour after 
Aβ injection we were unable to detect any caspase-3 cleavage which would indicate 
apoptotic cell death (data not shown). Furthermore, there are no studies so far that 
show toxic effects of oligomeric Aβ on neurons in vivo. Therefore, the effects on 
memory following an hour post-injection may not have a direct correlation with 
neuronal degeneration, but could simply reflect the effects of Aβ on synaptic 
integrity. It is well documented that the main effects of Aβ on synapses are 
inhibition of LTP (Chapman et al., 1999; Kamenetz et al., 2003) and elimination of 
postsynaptic glutamate receptors (Almeida et al., 2005; Chang et al., 2006; Ting et 
al., 2007). Remarkably, the Aβ induced synaptic dysfunction occurs rather rapidly, 
starting with 20 minutes after application, and does not need chronic exposure 
(Chen et al., 2000; Chen et al., 2002; Townsend et al., 2006; Wang et al., 2004). 
Furthermore, it is likely that the injected oligomeric Aβ does not remain unchanged 
in terms of its conformation, and the effects on memory may be due to changes of 
Aβ to other conformations. The importance of the Aβ conformation on memory 
was demonstrated by Lesne et al (Lesne et al., 2006), who showed that only specific 
Aβ protein assemblies in the brain are able to impair memory (Lesne et al., 2006). 
It remains elusive whether aggregation inhibiting peptides like LPYFDa directly 
bind to Aβ, and thereby prevent possible interactions between Aβ and neuronal 
membrane proteins, and in this way neutralize its toxic effect. We could consider 
two options of interaction with Aβ, 1) the pentapeptides bind to the monomeric 
Aβ, thus preventing and/or retarding the formation of toxic oligomers, and 2) the 
pentapeptides bind the Aβ oligomers already formed preventing and/or 
modulating, somehow, its neurotoxic properties. On the other hand, both above 
mentioned possibilities might act simultaneously comprising a third possible way of 
action of this peptide toward its neuroprotective effects. 
Being aware of the many possible biological pathways that these peptides might 
follow while inducing neuroprotection, it is interesting to see whether these 
peptides show a preference to bind the monomeric Aβ or its soluble oligomers. 
Previous studies using CD spectrometry and molecular docking studies have been 
carried out on LPYFDa and other so-called β-sheet breaker peptides (Datki et al., 
2004; Hetenyi et al., 2002a; Hetenyi et al., 2002b; Laczko et al., 2008) but none of 
them so far have demonstrated proof at the molecular level of the β-sheet breaking 
properties of these peptides. We also might consider the possibility that these 
peptides might act as “glue” that promote elongation to biologically inert larger 
aggregates, or conversely, bind to the monomeric Aβ and this way inhibits oligomer 
formation. By either of these actions, or both, the neurotoxicity of Aβ is decreased 
or reverted. 
In summary our findings provide evidence on how and where LPYFD interacts with 
Aβ mono- and oligomers, that LPYFDa neutralizes the neurotoxic activity of soluble 
Aβ oligomers, and in the present conditions can effectively prevent the oligomer-






Neuroprotective action and neutralization of 
Aβ42-induced memory impairment by a novel 
in silico designed N-methyl amino acid 
containing peptide 
 
Ivica Granic1, Marcelo F. Masman1, Sebastian A. Andujar2, Pieter J.W. 
Naude1, Ulrich L.M. Eisel1, Ricardo D. Enriz2, Siewert Jan Marrink3 
and Paul G.M. Luiten1 
 
1Department of Molecular Neurobiology, University of Groningen, Kerklaan 30, 9751 NN Haren, The 
Netherlands; 2Departamento de Qumica, Universidad Nacional de San Luis, Chacabuco 917, San Luis, 
Argentina 5700; 3Department of Biophysical Chemistry, University of Groningen, Nijenborgh 4, 9747 













There is overwhelming evidence that points towards the central role of the Abeta-
peptide in pathogenesis of Alzheimer's disease (AD). In particular the misfolding 
and aggregation of Aβ into soluble oligomeric assemblies is associated with synaptic 
toxicity and cognitive dysfunction. A promising therapeutic approach for AD 
treatment is to neutralize or interfere with the devastating properties of oligomeric 
Abeta species, which can be achieved by short synthetic peptides (e. g. LPYFDa) 
designed to bind to specific Abeta-regions. 
In this study, we present a novel rationally designed peptide (PN22), employing the 
in silico approach (conformational analysis, molecular dynamics and docking 
studies). The design of PN22 is based on the conformational behavior of Aβ42 
aggregates. 
Furthermore, we evaluated the therapeutic potential of the novel peptides by testing 
them for their neuroprotective properties against oligomeric Aβ42 in vitro, as well as 
their memory preserving capacity in vivo. We have been able to show that neurons 
in culture treated with PN22 are protected against Aβ42 -induced cell death. 
Moreover, PN22 prevented memory impairment tested in a contextual fear 
conditioning paradigm in mice. 
In conclusion we can demonstrate that the peptide PN22 can neutralize the 
neurotoxic effects of soluble Aβ42 oligomers in vitro and in vivo. In the latter 
condition we obtained proof of principle that short synthetic peptides can 





Alzheimer’s disease (AD) is a complex multifactorial neurodegenerative syndrome 
characterized by the patient’s memory loss and impairment of a wide range of 
cognitive abilities. This devastating disease affects more than 20 million people 
worldwide and, as a consequence of the worlds aging population, the prevalence of 
AD is expected to increase to endemic dimensions both in developed and 
developing nations (Blennow et al. 2006; Pratico and Delanty 2000). AD is the 
most extensively studied amyloid-based disease, whose main hallmarks are 
characterized by pathological high levels of amyloid deposits in frontal brain regions 
(senile or amyloid or neuritic plaques) and neurofibrillary tangles (Haass and Selkoe 
2007; Holtzman and Mobley 1991). The major components of senile plaques are 
small peptides of 39-43 amino acids called β-amyloid (Aβ) which are produced 
through endoproteolysis of the amyloid precursor protein (APP). During the 
pathogenesis of AD the equilibrium of Aβ production and Aβ clearance is 
disturbed, which eventually leads to elevated Aβ levels, increased Aβ aggregation 
and consequently impaired memory function (Wasling et al. 2009). Recent evidence 
now indicates that particularly soluble oligomeric forms of Aβ42 are to be 
considered as the most toxic form of this peptide, and correlate well with the 
progression and cognitive decline of the disease (Lesne et al. 2006; Wasling et al. 
2009) 
Due to the high incidence that AD has in the human aging population, there is an 
evident need of therapeutic agents that could at least significantly delay the course 
of the disease (Hardy and Selkoe 2002; Wolfe 2002). Several research strategies 
currently attempt to develop therapies and therapeutic agents that aim to reduce Aβ 
production, enhancing its clearance and/or preventing or retarding the 
amyloidogenic processes. Amongst them, the use of peptides or peptidomimetic 
molecules derived from the Aβ sequence is particularly appealing (Granic et al. 
2010; Soto et al. 1998; Tjernberg et al. 1996a; Wolfe 2002). Promising putative 
treatments may be those designed to inhibit steps that precede Aβ peptide 
aggregation, by blocking the production of toxic soluble Aβ oligomers in the first 
place, or by reversing, somehow, the toxic effect of these soluble oligomers 
(FIGURE 8.1). 
 In fact, some short peptides that are derived from the Aβ sequence have already 
been reported to specifically interact with Aβ and cause interferences with its 
neurotoxic effects. LPFFD (Soto et al. 1996; Soto et al. 1998), KLVFF (Hetenyi et 
al. 2002; Tjernberg et al. 1997; Tjernberg et al. 1996b), RIIGLa (Fulop et al. 2004) 
and LPYFDa (Datki et al. 2003; Datki et al. 2004; Granic et al. 2010; Juhasz et al. 
2009; Szegedi et al. 2005) are some of the promising starting points to develop 
potential drugs that can somehow reverse the negative impacts of soluble Aβ 







































Figure 8.1: Simplified schematic representation of the up-stream amyloid assembly process that leads to 
neuronal cytotoxicity. In disease states, the mechanisms of Aβ production and it clearance is unbalance 
causing that soluble Aβ monomers undergo aggregation to form various intermediates consisting of 
different forms of multimeric Aβ oligomers that, somehow, performers negative effect on brain cells. Aβ 
oligomers subsequently assemble to generate insoluble fibrils that accumulate in the affected tissues or 
organs (pathway no shown). Compounds that inhibit formation of these undesirable species may, 
therefore, be capable of protecting tissues or organs from their toxic effects. Two possible inhibition 
pathways are depicted. Pathway 1 shows an up-stream intervention of a putative drug. Thus, this drug 
may stop or retard the amyloigenic process by preventing the conformational change of the Aβ monomers 
that leads to toxic Aβ aggregates. Pathway 2 shows the intervention of a putative drug that, somehow, 
blocks the toxic effects of Aβ oligomers and might also reverse the amyloidic assembly process. 
 
In order to increase the anti-amyloidogenic properties of these peptides, a new 
strategy was recently explored with the introduction of N-methyl amino acids in 
these sequences (Cruz et al. 2004; Gordon et al. 2001; Gordon et al. 2002). 
N-Methyl amino acids have been used in several systems to control, or prevent the 
aggregation of β-sheet and β-strand peptides (Chitnumsub et al. 1999; Clark et al. 
1998; Doig 1997; Hughes et al. 2000; Nesloney and Kelly 1996; Rajarathnam et al. 
1994). The goal of this modification is to block the hydrogen bond network that 
stabilizes the β-sheet amyloid structure and this way to inhibit the formation of 
toxic oligomers and/or amyloid aggregates.   
In the present study, we report the in silico design of a new Aβ-derived synthetic 
penta-peptide Ac-Lys-Ile-Ile-Gly-Leu-NH2 (PN20) and its chemically modified 
version; Ac-Lys-(Me)Ile-Ile-(Me)Gly-Leu-NH2 (PN22), which contains alternated N-

























































Scheme 8.1: Schematic representation of the chemical structure of PN20 and PN22. Backbone 
torsional angles and the distance CαLys/C
α
Leu are also shown. For the case of PN22 the “poor and rich 
H-bonding faces” are shown. 
The protective property of these peptides against the neurotoxic effects of soluble 
Aβ42 oligomers was investigated in cultured mouse primary cortical neurons (PCN). 
Furthermore, we explored in a previously established in vivo model of Aβ injections 
directly into the hippocampus of mice whether PN22 exerts beneficial action 
against the Aβ-induced cognitive deficits (Granic et al. 2010). Ultimately, we 
intended to reveal some of the putative mechanism of action of these chemically 
modified peptides by employing molecular modeling techniques. 
These peptides were designed based on the observations of the conformational 
behavior of the Aβ42 aggregates in silico previously reported by Masman and 
coworkers (Masman et al. 2009a). The portion β2 of these aggregates, specifically 
the highly hydrophobic sequence Ala30-Ile31-Ile32-Gly33-Leu34, was the starting point 
of the present design. 
8.1.1 Rational in silico design of PN20 and PN22 
In this study we rationally designed two novel aggregation modulating peptides 
(PN20 and PN22). Their in silico design was based on the conformational behavior 
of Aβ42 aggregates, which was previously reported by Masman and coworkers 
(Masman et al. 2009a). The so-called β2 portion of these aggregates, specifically the 
highly hydrophobic sequence Ala30-Ile31-Ile32-Gly33-Leu34, was the starting point of 
this design. Due to its hydrophobic nature some chemical modifications were 
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applied to the peptides in order to increase the solubility of the final peptides. 
Thus, the first modification was the change of the Ala residue to Lys. A positively 
charged residue not only increases the water solubility of the peptides but also offers 
the possibility of targeting important negatively charged residues that play a crucial 
role in the stabilization of the aggregated Aβ42 oligomers, e.g. Glu22 and Asp23. A 
posteriori, the N- and C-terminal were blocked by acetylation and amidation 
respectively. This provides some advantages: (i) peptide ends are uncharged (no 
zwitterionic), thus we have a better control on the charges that take place in a 
biological medium; (ii) increased biological membrane permeability and cell 
penetration; (iii) the stability and resistance towards digestion by aminopeptidases is 
enhanced; and (iv) peptide ends are blocked against synthetase activities. Moreover, 
C-terminal amidation is essential to the biological activity of many neuropeptides 
and hormones (Fricker 2005; Kim and Seong 2001). These two modifications were 
our guiding principle to the design of PN20. 
In fact, a possibility to counteract the detrimental effects of oligomeric Aβ is by 
modulating its aggregation process. A very appealing strategy to endow peptides 
with aggregation modulating properties is the incorporation of non-natural amino 
acids to their sequence. Such is the case of N-methyl amino acids containing 
peptides. When the N-methyl amino acids residues are located in an alternated 
fashion into the peptide sequence, and the peptide has the possibility to form 
extended conformations, e.g. β-sheets, two different “faces” are expressed. On the 
one hand, one of the faces has all the normal H-bonding possibilities that a natural 
peptide has (the so-called “rich H-bonding face”). On the other hand, the other face 
is limited on H-bonding possibilities due to the presence of the N-methyl groups 
(SCHEME 8.1). Thus, the incorporation of N-methyl-L-isoleusine and N-methyl-
glycine (or sarcosine) in position 2 and 4 respectively, by replacement of their 
natural analogs, led us to PN22. 
 
8.2 MATERIAL AND METHODS 
8.2.1 Molecular modeling 
8.2.1.1 Stochastic and conformational search (EDMC calculations) 
The conformational space of the penta-peptides PN20 and PN22 was explored 
using the method previously employed by Liwo et al. (Liwo et al. 1996) which 
includes the electrostatically driven Monte Carlo (EDMC) method (Ripoll and 
Scheraga 1988, 1990) implemented in the ECEPPAK package. Conformational 
energy was evaluated using the ECEPP/3 force field (Némethy et al. 1992). 




radius of 1.4 Å and atomic hydration parameters that have been optimized using 
nonpeptide data (SRFOPT) (Vila et al. 1991; Williams et al. 1992). In order to 
explore the conformational space extensively, we carried out 20 different runs, each 
of them with a different random number. Therefore, we collected a total of 5000 
accepted conformations. Each EDMC run was terminated after 250 energy-
minimized conformations had been accepted. The parameters controlling the runs 
were the following: a temperature of 298.15 K was chosen for the simulations. A 
temperature jump of 50,000 K was used; the maximum number of allowed 
repetitions of the same minimum was 50. The maximum number of electrostatically 
predicted conformations per iteration was 400; the maximum number of random-
generated conformations per iteration was 100; the fraction of 
random/electrostically predicted conformations was 0.30. The maximum number 
of steps at one increased temperature was 20; and the maximum number of rejected 
conformations until a temperature jump was executed was 100. Only trans peptide 
bonds (Θ ≅ 180°) were considered. All accepted conformations were then clustered 
into families using the program ANALYZE (Meadows et al. 1994; Pohorille and 
Pratt 1990) by applying the minimal-tree clustering algorithm for separation, using 
all heavy atoms, energy threshold of 30 kcal.mol-1, and RMSD of 0.75 Å as 
separation criteria. This clustering step allows a substantial reduction of the number 
of conformations and the elimination of repetitions. A more detailed description of 
the procedure used here is given in section 4.4 Computational Methods of reference 
(Masman et al. 2009b). 
 
8.2.1.2 Molecular dynamics simulation 
The most populated conformation of PN20 and PN22 obtained from the EDMC 
were embedded in a cubic box containing SPC waters, (Berendsen et al. 1981) 
leaving at least 10 Å between the solutes and the edge of the box. The total number 
of water molecules varied between 15630 and 25919. Cl- ions were added to the 
systems by replacing water molecules in random positions, thus making the whole 
system neutral. Multiple simulations were performed for each system, starting from 
different initial random velocity distributions. Details of the equilibration 
procedure can be found in the Suppl. Information. For each system 10 ns 
production runs were obtained and analyzed. The coordinates were saved every 2 
ps. Molecular dynamics (MD) simulations were performed using the GROMACS 
3.3.2 package of programs (Van Der Spoel et al. 2005), with the OPLS-AA force 
field (Kaminski et al. 2001). The simulations were run under NPT conditions, using 
Berendsen’s coupling algorithm (Berendsen et al. 1984) for keeping the temperature 
and pressure constant (P = 1 bar, ∆P = 0.5 ps; T = 310 K, ∆T = 0.1 ps). The LINCS 
algorithm (Hess et al. 1997) was used to constrain the lengths of hydrogen 
containing bonds; the waters were restrained using the SETTLE algorithm 
(Miyamoto and Kollman 1992). The time step for the simulations was 0.002 ps and 
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the compressibility 4.8x10-5 bar-1. Van der Waals forces were treated using a 1.2 nm 
cutoff. Long-range electrostatic forces were treated using the particle mesh Ewald 
method (PME) (Darden et al. 1993). The analysis of the simulations was performed 
using the analysis tools provided in the Gromacs package. The root mean square 
deviation (RMSD) of backbone atoms, the total and potential energies were 
calculated. The root mean square fluctuation (RMSF) of the backbone atoms and 
the hydrophilic, hydrophobic and total Solvent Accessible Surface Area (SASA) 
were also determined. The total number of hydrogen bonds in the peptide group 
were quantified by counting acceptor and donor atom pairs that are not further 
apart than 0.35 nm. All molecular graphical presentations were created by VMD 
(Humphrey et al. 1996) and/or UCSF Chimera (Pettersen et al. 2004) packages. 
The standard deviation of every given value is shown in between brackets. 
 
8.2.1.3 Docking studies 
Two models for Aβ were used as target systems; the monomeric Aβ42 elucidated by 
Crescenzi et al (monomeric model) (Crescenzi et al. 2002), PDB code 1IYT, and the 
pentameric aggregate Aβ42 developed by Masman et al (pentameric model) (Masman 
et al. 2009a). The structures were prepared for docking study as follows: for the 
Aβ42 molecules, water molecules were removed from the PDB file and hydrogen 
atoms were added; Gasteiger charges, atomic solvation parameters and fragmental 
volumes were merged to the target system. For all peptides, the structure of the 
most populated family (results from the EDMC calculations) was taken as initial 
conformation. Gasteiger charges were assigned and non-polar hydrogen atoms were 
merged. All torsions were allowed to rotate during docking. The docking energy 
grid was produced with the auxiliary program AutoGrid. The grid dimensions were 
61x61x61 for the monomeric model, and 90x60x60 for the pentameric model, 
points along the x-, y- and z-axes, with points separated by 0.375Å. The grids were 
chosen to be sufficiently large to cover significant portions of the putative binding 
sites. The center of the pentapeptide was positioned at the grid center. All graphic 
manipulations and visualizations were performed by means of the AutoDock Tools 
(Sanner 1999) and the Chimera (Pettersen et al. 2004) programs, and ligand 
docking with AUTODOCK 4 (Morris et al. 2009). The Lamarckian genetic 
algorithm was utilized and the energy evaluations were set at 2.5x106. A total of 250 







8.2.2 EXPERIMENTAL SECTION 
8.2.2.1 Compounds 
The peptides Ac-Lys-Ile-Ile-Gly-Leu-NH2 (PN20), Pro-Asp-Tyr-Leu-Phe-NH2 (scrP) 
and Amyloid β − peptide 1  42 (Aβ42) were purchased from EZBiolab Inc.(Carmel, 
USA). Anti-Aβ antibody (6E10) was obtained from Covance (Emeryville, USA). 
The peptide Ac-Lys-(Me)Ile-Ile-(Me)Gly-Leu-NH2 (PN22) was purchased from 
AnaSpec Inc (San Jose, CA, USA). HPLC purity higher than 95% was described for 
all peptides used here. Other compounds used in this study were purchased from 
Invitrogen (Carlsbad, USA) or Sigma-Aldrich Corporation (St. Louis, USA). 
8.2.2.2 Preparation of Aβ-oligomers 
Oligomeric Aβ42 was prepared as described by Granic and colleagues (Granic et al. 
2010). Also, the aggregational state and the secondary structure of the oligomeric 
Aβ42 preparation were examined by sodium dodecyl sulfate (SDS)-PAGE Western 
blotting and Circular Dichroism (CD) spectrometry. For a more detailed 
description of the methodology used here, see Granic et al. (2010). 
 
8.2.3 In vitro testing 
8.2.3.1 Primary neuronal culture 
Primary cortical neurons were prepared from embryonic brains (E14) of C57Bl/6J 
mice. The cortices were carefully dissected, meninges were removed and the 
neurons separated by trituration. Cells were plated on poly-D-lysine pre-coated 
plates at a density of 1.2 x 105 cells/well (96 well plates). Neurobasal medium 
supplemented with 2% (v/v) B27-supplement, 0.5 mM glutamine and 1% (v/v) 
penicillin/streptomycin was used as a culture medium. After 48 h neurons were 
treated with 10 µM cytosine arabinoside for another 48 h to inhibit non-neuronal 
cell growth. Subsequently, the medium was completely exchanged and after 6 days 
of in vitro culture, the neurons were used for experiments. 
8.2.3.2 Treatment of cells  
Possible toxicity of the penta-peptides used here and Aβ42 oligomers was determined 
by incubating neuronal cultures for 24 h with different concentrations of the 
peptide solutions. The neuroprotective effect of PN20 and PN22 was assessed by 
incubating neurons (cultured in 96 well plates) for 24 h with 25 µM oligomeric Aβ 
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in the presence or absence of different concentrations of PN20 or PN22 peptides. 
After treatments, the medium was completely exchanged, and 24 h later, the cell 
viability determined by an MTT-assay. All treatments were performed in triplicates 
and the experiments were repeated at least two times. 
8.2.3.3 Determination of cell viability by MTT assay 
Neuronal viability was determined by the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl-)2,5-diphenyltetrazolium bromide] assay as described previously (Mosmann 
1983). 1.25 mg/ml MTT solution was added to each well of a 96 well plate. After 2 
h of incubation, cells were lysed in acidic propan-2-ol solution (37% HCl/ propan-2-
ol: 1/166). The absorbance of each well was measured with an automated ELISA 
plate reader (Bio-Rad, Munich, Germany) at 595 nm with a reference filter at 630 
nm. 
 
8.2.4 In vivo testing 
8.2.4.1 Animals 
Behavioral experiments were performed with 9–12 weeks old male C57Bl/6J mice 
(Harlan, Horst, The Netherlands). Individually housed mice were maintained on a 
12 h light/dark cycle (lights on at 7.00 a.m.) with food (Hopefarms, standard rodent 
pellets) and water ad libitum. A layer of sawdust served as bedding. The animals 
were allowed to adapt to the housing conditions for 1–2 weeks before the 
experiments started. The procedures concerning animal care and treatment were in 
accordance with the regulations of the Ethical Committee for the use of 
experimental animals of the University of Groningen (License number 
DEC4668D). 
8.2.4.2 Animal surgery 
Double guide cannulae type C235 (Plastics One, Roanoke, USA) were implanted in 
the brain using a Kopf stereotactic instrument during Hypnorm/Midazolam (10 
ml/kg, i.p.) anesthesia under aseptic conditions as previously described (Nijholt et 
al. 2008) with anteroposterior (AP) coordinates zeroed at Bregma directed toward 
both dorsal hippocampi (i.h.), AP -1.5 mm, lateral 1 mm, depth 2 mm (Franklin 
and Paxinos 1997). Each double guide cannula with inserted dummy cannula and 
dust cap was fixed to the skull with dental cement (3M ESPE AG, Seefeld, 
Germany). Administration of 1 mg/ml finadyne (2.5 mg/kg s.c.) before the surgery 





8.2.4.3 Intrahippocampal injections 
Bilateral i.h. injections were performed under short isoflurane anesthesia using a 
Hamilton microsyringe fitted to a syringe pump unit (TSE systems, Bad Homburg, 
Germany) at a constant rate of 0.3 µl/min (final volume: 0.3 µl per side). 
Oligomerized Aβ42 was injected in a final concentration of 30 pmol and PN22 or 
scrP in a final concentration of 150 pmol into the dorsal hippocampus. PBS (pH 
7.5) served as vehicle. ScrP was used as a sequence control peptide. One hour after 
the injection the animals were subjected to a training session in a fear conditioning 
paradigm (SCHEME 8.2). The number of animals per group varied from 7 to 10. 
 
Scheme 8.2: Schematic outline of the experimental in vivo setup. C57BL/6J mice were cannulated 7 
days prior i.h. injection with oligomerized Aβ42 and/or aggregation inhibiting peptides. One hour after 
the injection the animals were trained in a contextual fear conditioning paradigm. 24 h after the 
training session memory performance was assessed. 
 
8.2.4.4 Fear Conditioning 
Fear conditioning was performed in a plexiglas cage (44x22x44 cm) with constant 
illumination (12 V, 10W halogen lamp, 100–500 lux). The training (conditioning) 
consisted of a single trial. Before each individual mouse entered the box, the box 
was cleaned with 70% ethanol. The mouse was exposed to the conditioning context 
for 180 s followed by a scrambled footshock (0.7 mA, 2 s, constant current) 
delivered through a stainless steel grid floor. The mouse was removed from the fear 
conditioning box 30 s after shock termination to avoid an aversive association with 
the handling procedure. Memory tests were performed 24 h after fear conditioning. 
Contextual memory was tested in the fear conditioning box for 180 s without 
footshock presentation. Freezing, defined as the lack of movement except for 
respiration and heart beat, was assessed as the behavioral parameter of the defensive 
reaction of mice by a time-sampling procedure every 10 s throughout memory tests. 
In addition, mean activity of the animal during the training and retention test was 
measured with the Ethovision system (Noldus, Wageningen, The Netherlands). 
Immediately after the behavioral test mice were injected i.h. with methylene blue 
solution during sodium-pentobarbital anesthesia (0.1 ml/ 10g, i.p.). Brains were 
removed and serially sectioned at 50 µm. Sections were stained on glass for 5 min in 
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0.1% nuclear fast red solution. To identify the location of the injection, sections 
were analyzed using light microscopy. Only data from animals in which the proper 
intrahippocampal site of injection was confirmed, were evaluated. 
8.2.5 Statistical analysis 
Behavioral data were analyzed by analysis of variance (ANOVA) followed by the 
Bonferroni post-hoc test to determine statistical significance. For statistical analysis 
of the MTT assays, an unpaired Student’s t test with unequal variance was used. A 
p-value *< 0.05 was considered to be statistically significant. A p-value **< 0.005 was 
considered to be highly significant. Data are presented as mean value ± standard 
error of the mean (SEM). 
 
8.3 RESULTS 
8.3.1 MOLECULAR MODELING 
8.3.1.1 Stochastic conformational search in solution (EDMC calculations) 
In order to have a better view at the molecular level, it is crucial to assess the 
conformational behavior of PN20 and PN22 in solution. Therefore, all peptides 
were selected for energy calculations to determine the relevant conformations. The 
results of the theoretical calculations are summarized in TABLE 8.1S in 
APPENDIX A. Calculations yielded a large set of conformational families for each 
peptide studied. The total number of conformations generated was 70236 and 
79077, for PN20 and PN22 respectively, whereof 5000 conformations for each 
pentapeptide were accepted. In the clustering procedure, an R.M.S.D (Root Mean 
Square Deviation) of 0.75 Å and a ∆E of 30 kcal mol-1 were used. The number of 
families after clustering was 703 and 409, for PN20 and PN22, respectively. The 
total number of families accepted with a relative population higher than 0.50% was 
30 and 11, for PN20 and PN22, resp. that sum up to ca 85% of all conformations. 
All low-energy conformers of pentapeptides studied here were then compared to 
each other. The comparison involved the spatial arrangements, relative energy and 
populations. The PN20 evaluation showed that the most populated family (24.20%) 
is also the energetically preferred one, while its second most populated family 
(5.52%) has a relative energy of 2.55 kcal mol-1 above the global minimum. The 
third most populated family (3.76%) shows a relative energy of 1.66 kcal mol-1 
above the global minimum. On the other hand, the most populated family of PN22 
(62.38%) is also the global minimum, while its second most populated family 
showed a relative energy of 0.57 kcal mol-1 above the global minimum and a relative 




of 0.61 kcal mol-1 above the global minimum. It was observed that PN20 possesses a 
marked tendency to form folded conformations while PN22 shows high preference 
to form semi-extended or fully-extended conformations. TABLE 8.1 shows the 
values of φ and ψ torsional angles for the three most populated families of PN20 
and PN22. Spatial overlapped stereo views of selected conformations, for PN20 and 
PN22 are shown in FIGURE 8.2. 
 
TABLE 8.1: Backbone tortional angles of the three most populated families for PN20 and PN22 
found at the EDMC/SRFOPT/ECCEP/3 level of theory. All angles values are given in degrees. The 


















Figure 8.2: Stereoview of the three most populated families for PN20 and PN22 optimized at 
EDMC/SRFOPT/ECCEP/3 level of theory. (A) Overlapped geometries of family 1 (∆E = 0.00 
cal.mol-1, white), family 2 (∆E = 2.55 kcal.mol-1, magenta) and family 3 (∆E= 1.66 kcal mol-1, cyan) 
for PN20. (B) Overlapped geometries of family 1 (∆E = 0.00 kcal.mol-1, white), family 2 (∆E= 0.57 
kcal mol-1, magenta) and family 3 (∆E= 0.61 kcal mol-1, cyan) for PN22. All hydrogen atoms and side-
chains have been deleted for more clarity. N-Methyl groups are depicted in ball-and-stick model. 
8.3.1.2 Molecular dynamics 
PN20 and PN22 were examined by MD due to the need of exploring their 
conformational behavior in a more realistic system by means of an explicit solvent. 





Leu) as a function of the simulation time for PN20 and PN22. This 
parameter is a clear and easy way of depicting the conformational preferences of 
these peptides. In this figure, it is observed that PN20 prefers folded conformation 
with a d CαLys/ C
α
Leu= 4.22(0.49) Å while PN22 showed a marked preference to 
extended conformations (d CαLys/ C
α
Leu= 12.25(1.08) Å). 


































Figure 8.3: Distance between Cα atoms of residues Lys1 and Leu5 as a function of simulation time. 
The maximum ideal (for a fully extended conformation, where all φ and ψ ≡ 180º) distance between 
the above mentioned atoms is also shown. 
8.3.1.3 Docking studies 
The docking studies performed here have been analyzed on the basis of their 
conformational population distribution as a function of the binding energy. The 
clusterization procedure was run with a cut-off of 2.00 Å RMSD. FIGURE 8.4 
shows the density population distribution for PN20 and PN22 on the two target 
system-models used here. Monomeric Model. Two potential binding sites were found 
by using a single blind docking run (results not shown) on the monomeric Aβ42 
molecule (PDB code 1IYT). FIGURE 8.5A depicts the location of these potential 
binding sites. Site I encompasses the residues 21-26 containing Glu22 and Asp23, 
which were previously identified as residues for aggregation of the oligomers 
(Buchete and Hummer 2007; Masman et al. 2009a). Site II includes residues 6-12 
located in the portion of the molecule that loses all structural organization after 
oligomerization, thus forming part of the so-called disordered region. The docked-




can be observed that PN20 does not show a preference to bind either Site I or Site 
II. PN20 obviously binds both sites unselectively and with more or less the same 
intensity. On the other hand, the most populated conformations of PN22 show a 
binding preference for Site I. Thus, the binding of PN22 on Site II is energetically 
weaker than the one observed on Site I. In TABLE 8.2 the two most populated 
families of the complexes of PN20 and PN22 with the monomeric Aβ42 are 
summarized. PN22 showed lower binding energies, while site I was in general 
energetically preferred over site II. FIGURE 8.5B shows the interacting complex of 
PN22 on Site I. Amongst all the interaction observed here, it is important to 
highlight that the NH3
+ group of residue Lys forms a strong salt-bridge interaction 
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Figure 8.4: Density population distribution as a 
function of the binding energy: (A) PN20 and 
PN22 on the monomeric target model. (B) PN20 
and (C) PN22 on the pentameric aggregate target 
model. The histogram of the density population 




Table 8.2: The two most populated families of PN20 and PN22 found by docking simulations on the 
monomeric and pentameric Aβ42 peptide and the corresponding binding energy (EB, kcal mol-1) of the 
complexes. The binding constant (KB, M) and the relative populations (%P) are also shown. 
 
 
Pentameric Model. The target model used here was previously reported by Masman 
and coworkers (Masman et al. 2009a). This Aβ42 aggregates model contains two β-
sheet moieties (β1, residues 18-26 and β2, residues 31-42), which are proposed as 
putative binding sites. Moreover, a third possible site for interactions with ligand 
molecules is postulated, which involves both above mentioned sites (β1 and β2) at 
the edge of the aggregate. This site, here called the TOP site, is orientated into the 
oligomeric axis, in the same direction where the oligomers grows by aggregation. 
TABLE 8.2 shows the two most populated families of the complexes of PN20 and 
PN22 with the pentameric Aβ42. It is observed in FIGURE 8.4B that PN20, in 
contrast with our expectation, has no preference to bind any of the sites targeted 
here. PN20 unselectively binds to β1, β2 and TOP sites. On the other hand, PN22 

















Figure 8.5: (A) Location of site I and site II on the monomeric Aβ42 model. (B) Stereoview of the 
populated complex PN22/Aβ42 monomeric on site I. All ligand-target contact are depicted as wireframe 
spheres. Salt-bridge Lys-NH3
+/Asp23 is marked with a block-arrow. 
 
 
FIGURE 8.4C shows that the most populated conformations are energetically 
preferred when PN22 binds to site β2, while this peptide binds nonspecifically to 
β1 and TOP sites. FIGURE 8.6A illustrates an ideal H-bonding arrangement for 
TOP interaction of PN22 with an Aβ aggregate. It is depicted that PN22 may 
expose a “rich H-bonding face” to interact with the target molecule while exposing a 
“poor H-bonding face” that may stop the aggregation process. FIGURE 8.6B shows 
the atomic details of the interactions of the most populated complex (family 1 TOP, 
in TABLE 8.2). This interacting complex is the most similar arrangement to the 
ideal case. Even though the quantity of H-bonds was less abundant than in the ideal 
case, the orientation of the “poor and rich” H-bonding faces appear similar. 
FIGURE 8.7 reveals the atomic details of the interactions of the second most 
populated complex (family 2 β2, in TABLE 8.2) found between PN22 and the 
pentameric A42. All the ligand-target contacts are depicted as wireframe spheres. 
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PN22 is located in a transversal direction to the Aβ chains, and inside an important 
channel-like hydrophobic pocket formed between the residues Ile31 and Met35 of the 
aggregate. The side-chains of PN22 are localized parallel to the Aβ backbone. Thus, 
the side-chains act as hydrophobic anchors. Obviously, due to the highly 
hydrophobic nature of both, target and drug molecules, the predominant 
interaction type is the hydrophobic contact. Also, it is interesting to mention that 
the N-methyl groups face the Aβ aggregate, this way increasing the hydrophobic 
contact between drug and receptor. Accordingly, the “rich H-bonding face” is 
















































































































Figure 8.6: (A) An ideal TOP interaction of PN22 with an Aβ42 aggregate. The N-methyl amino acid 
residues are shaded in grey. Hydrogen bonds are represented as slashed lines (---). (B) A steroview of most 
populated complex PN22/Aβ42 pentameric model on site TOP. All ligand-target contact are depicted 









































Figure 8.7: A stereoview of the second most populated complex PN22/Aβ42 pentameric on site β2. 
Different views are shown: lateral (A), frontal (B), zoomed in (C and D). Panel C shows the ligand-
target contact which are depicted as wireframe spheres. Panel D shows a steroview of PN22 in the 
channel-like hydrophobic pocket formed, mainly by residues Ile31 and Met35. 
 
 
8.3.2 EXPERIMENTAL TESTING 
8.3.2.1 PN22 is neuroprotective against oligomeric Aβ42 in vitro 
Part of this study was to provide proof of principle that the newly designed 
aggregation modulator peptides have the potential to protect nerve cells against Aβ-
induced toxicity. Thus, we tested firstly whether these novel peptides exhibited any 
toxicity to neuronal cultures by themselves, and secondly whether PN20 and PN22 
were capable to neutralize the toxic effect of oligomeric Aβ42. To this purpose 
primary cortical neurons in culture were exposed to different concentrations of 
PN20 or PN22 alone, to Aβ42 alone (25 µM) or to pentapeptides and Aβ42 together 
for 24 h. Neither PN20 nor PN22 alone was toxic to neurons at any tested 
concentration (FIGURE 8.8). When exposed to 25 µM oligomeric Aβ42 only 30-40 
% of the cultured neurons survived a 24 h incubation. Furthermore, both PN20 
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and PN22 were able to protect the neurons from Aβ42-induced toxicity in a dose 
dependent manner (FIGURE 8.8). The methylated PN22 (FIGURE 8.8B) in that 
respect proved to be more effective reaching significance at 8 µM; P=0.02 when 
compared to the non-methylated PN20 (FIGURE 8.8A) (reaching significance at 32 
µM; P=0.01). With the highest concentration (250 µM) of PN20 up to 62.3± 12.9% 
of the neurons survived the Aβ treatment. 250 µM of PN22 was even more 
protective against the Aβ42 challenge with up to 86.3± 3.7% cell survival. 
 
Figure 8.8: Cell viability of primary cortical neurons determined by an MTT-assay. Neuronal survival 
was determined after incubating increasing concentrations of the pentapeptides (A) PN20 and (B) 
PN22 with or without 25 µM Aβ42 for 24 h. Bars indicate the mean cell viability in % relative to 
untreated controls ± SEM. (* = significant at p < 0.05; ** = highly significant at p<0.005). 
 
8.3.2.2 Cognitive deficits induced by oligomeric Aβ42 can be neutralized 
by PN22 
Based on the in vitro data we selected the most effective peptide PN22 and tested 
whether PN22 is able to reverse the Aβ-induced memory deficits. We further 
included a scrambled peptide (scrP) as a control for sequence specificity of the 
peptides. To that purpose we used an animal model in which we injected mice with 
oligomeric Aβ42 into the hippocampus to induce memory deficits (Granic et al., 
2010). 
One hour prior to the training session in a contextual fear conditioning paradigm 
C57BL/6J mice received a single injection of oligomeric Aβ42 (30 pmol) or vehicle 
with PN22 (150 pmol) or scrP (150 pmol). In general the injections did not affect 
locomotion or the shock reaction during training (data not shown). The vehicle 




memory score of 57.1± 2.2%, which did not differ from untreated control animals 
(58.1± 3.6 %). The injection of 30 pmol oligomerized Aβ42 led to a significant 
decrease in freezing behavior compared to the vehicle group (33.7± 6.5% vs 57.1± 
2.2; p=0.002) (FIGURE 8.9) indicative of impaired memory storage. 
 
Figure 8.9: Effect of Aβ42 and PN22 on contextual fear conditioning. Co-injection of Aβ42 with PN22 
prevented the Aβ-induced memory impairment significantly, whereas the non-specific control peptide scrP 
failed to revert memory deficits. Bars indicate the mean relative freezing score in % ± SEM. Differences 
were determined by ANOVA (* = significant at p < 0.05). 
The PN22 and the scrP injected mice showed an average freezing of 54.9± 5.0% 
and 63.0± 5.5% respectively, which did not significantly differ from the untreated 
control (61.1± 2.4%) or vehicle injected group (58.9± 2.9%). 
However, PN22 co-injected with Aβ42 was able to abolish the Aβ42 oligomer-induced 
memory impairment (53.7± 2.8% vs 33.7± 6.5%; p=0.01). Co-injection of Aβ with 
scrP resulted in an average freezing score of 48.0± 4.9%, which did not significantly 
reverse the Aβ-induced memory deficits. These results provide evidence that PN22 
is capable to neutralize the negative effects induced by Aβ42 oligomers on memory 





Crucial for the aggregation process of the Aβ molecule are the hydrophobic 
residues that encompass the β2 region (amino acids 30-42). Thus, it was also 
observed for Aβ42 monomers in solution that the sequence I31IGLMVGGVVIA42 
(namely, the β2 portion) may be responsible for the higher propensity of this 
peptide to form amyloid aggregates (Sgourakis et al. 2007). Therefore, small 
peptides like PN20 and PN22, which are partially homologous to this hydrophobic 
region, bind with a relatively high affinity to Aβ by similar intermolecular 
interactions, leading to a competitive replacement of Aβ molecules. Interestingly 
our docking results showed that PN22 binds preferably to the β2 portion of the 
aggregate (TABLE 8.2 and FIGURE 8.4C), which has a good correlation with the 
design of this pentapeptide. However, in contrast with our expectations, PN20 did 
not show such a binding profile. This may be explained by the fact that PN20 
displayed a complete different conformational behavior in solution than PN22 as 
shown by EDMC and MD simulations. PN22 had a strong preference for extended 
conformations, while PN20 showed a strong affinity to folded conformations. This 
was not only observed in solution but also in our docking results. Thus, an 
extended or semi-extended conformation was observed for the majority of the most 
populated complexes that PN22 formed, whereas the opposite was the case for 
PN20. It appears to be that an extended or semi-extended conformation is the 
possible “biologically relevant conformation” or “pharmacophoric patron” for these 
peptides. 
On the other hand, all the docked preferred conformations showed a tendency to 
extended or semi-extended ligand’s orientation. Moreover, the docking studies 
could predict that a modification of PN20 by alternated N-methylation, thereby 
moderately increasing its hydrophobicity, improves the interaction to the β2 
portion of the Aβ42.aggregates. Thus, PN22 shows a selective binging to the portion 
β2. Neither PN20 nor PN22 showed a preference to bind the monomeric or the 
pentameric Aβ42 model, which suggests us that the peptides may bind to both forms 
of Aβ42. 
We hypothesize that Site I-bound-PN22, especially on Asp23, causes impediment or 
slowing down of the conformational change that precedes the aggregation. 
Consequently, PN22 binding increases the possibilities of degradation or clearance 
of Aβ monomers (see FIGURE 8.1), since, Asp23 plays a crucial role in the 
stabilization of the Aβ aggregates. In general it can be observed that PN22 binds 
stronger and selectively to Site I, to the monomeric Aβ42 than PN20. 
The present results indicated that pentapeptides PN20 and PN22 can significantly 
preserve cultured neurons from Aβ-induced cell death in a dose dependent manner. 




than the non-methylated PN20. Similar results on PC12 cells by using different 
single N-methyl amino acid containing peptides were previously reported (Cruz et 
al. 2004; Hughes et al. 2000). Peptides endowed with N-methyl amino acids have 
some clear advantages with respect to their potential as a therapeutic agent. These 
peptides remain remarkably stable to changes in solvent conditions and resist 
denaturation by heating, changes in pH (from 2.5 to 10.5), and addition of 
denaturants. Furthermore, this kind of peptides despite their hydrophobic 
composition is highly water soluble. A water soluble but hydrophobic nature suggest 
that these peptides might be able to pass spontaneously through biological cell 
membranes (Gordon et al. 2002). 
An important aim of our study was to establish if a compound like PN22 is able to 
prevent Aβ–induced learning and memory deficits in a mammalian animal model. 
We showed that a 5-fold molar excess of PN22 to Aβ could overcome the 
detrimental effects of Aβ oligomers on memory when injected into the 
hippocampal region. Thus, we provide evidence that N-methyl containing peptides 
such as PN22 bear therapeutic potential against Aβ-induced memory impairment. 
The mechanism how these pentapeptides exert their protective effects on cell death 
and behavior is not yet fully understood. However, these peptides directly bind to 
Aβ and thereby may prevent possible interactions between Aβ and neuronal 
membrane proteins and in this way neutralize the toxic effect of Aβ oligomers. We 
hypothesize two options of interaction notably of PN22 with Aβ that are depicted 
in figure 1. Pathway 1 proposes that PN22 binds to the monomeric Aβ thus 
preventing and/or retarding the formation of toxic oligomers, by interfering with 
the conformational change that precedes the oligomer formation. Pathway 2 
suggests that PN22 binds to the already formed Aβ oligomers thereby preventing 
and/or modulating, somehow, its neurotoxic properties. By either of these actions, 
or both, the neurotoxicity of Aβ is decreased or reverted and the Aβ 
clearance/degradation processes be reactivated. 
We may conclude that this novel in silico designed N-methyl amino acid containing 
peptide interacts with Aβ42 and that different regions of Aβ may be selectively 
targeted by this peptide. Our findings provide evidence on how and where PN22 
interacts with Aβ42 mono- and oligomers, that PN22 can neutralize the neurotoxic 
effects of soluble Aβ42 oligomers in vitro and in vivo. In the latter condition we 
obtained proof of principle that this pentapeptide can effectively prevent the Aβ 
oligomer-induced deficits in memory performance. More structural evidence is 
required to consolidate the proposed mechanism and to further improve our 
peptide designs. Nevertheless, it is clear that these peptides can serve as promising 

















AD is a heterogeneous multifactorial disease, in which many different molecular 
mechanisms contribute to its pathogenesis. Even 100 years since the first 
description of the disease by Alois Alzheimer, the cause for the disease is still not 
exactly known.  
So far, ageing, oxidative stress, disrupted ion homeostasis, inflammation, and 
genetics have been identified as major contributors to the pathogenesis, which 
might be up- or downstream of the well-known hallmarks of the disease: the Aβ 
plaques and neurofibrillary tangles. As such all of those factors provide possible 
targets for intervention in the process of the disease initiation and progression. 
Here I will shortly elaborate on different therapeutic strategies, which are based on 
our current understanding of the pathogenesis of AD. The approaches used here, 
engage several molecular mechanisms underlying the disease process, such as 
neuroinflammation, neuronal death, Aβ aggregation and associated toxicity and 









9.1.1 Neuroinflammatory TNF signalling as therapeutic target in 
Alzheimer’s disease 
  
Next to plaques and tangles, neuroinflammation is another pathological feature of 
AD and is characterized by activated glia cells and notably microglia. These cells can 
be regarded as the “immune cells“ of the brain which secrete a large variety of 
factors, that can be trophic or toxic, depending on the target cell and on the 
activated receptor systems involved. One of the most potent factors released by 
microglia is the pro-inflammatory cytokine TNF, which is increased in many 
neurodegenerative disorders including AD. It is still under debate whether 
inflammation and associated elevated cytokine levels have beneficial or detrimental 
effects for the diseased brain. 
Several studies showed that TNF overexpression in mice leads to detrimental effects 
on synaptic plasticity resulting in impaired learning and memory (Aloe et al., 1999; 
Fiore et al., 2000). Moreover, TNF receptor signalling is involved in APP processing 
and Aβ production. Several groups have identified an NF-B binding –site in the β-
secretase (BACE1) promoter region (Christensen et al., 2004; Li et al., 2006b). This 
could implicate that sustained NF-B activation might lead to elevated β-secretase 
levels and increased Aβ production. Indeed, He and colleagues demonstrated that 
TNF treatment increases BACE1 activity in vivo which is mediated via TNFR1 (He 
et al., 2007). 
 
9.1.2 TNF as drug target in AD  
 
On the other hand TNF can protect adult neurons after traumatic brain injury or 
ischemic insults (Fontaine et al., 2002; Marchetti et al., 2004; Sullivan et al., 1999). 
Transgenic mice deficient for TNFR2 showed much larger damage in a model for 
retinal ischemia. In contrast transgenic animals lacking TNFR1 are well protected 
against ischemic damage (Fontaine et al., 2002). 
These and other studies suggest that modulation of the distinct TNFR signalling 
pathways holds therapeutic potential for the treatment of AD. So far anti-TNF 
agents have been used in clinical trials to treat heart failure and rheumatoid 
arthritis with mixed outcome. Results from smaller pilot studies using anti-TNF 
approaches, were encouraging, however larger scaled studies failed to prove clinical 
benefits (Dhillon et al., 2007; Mann et al., 2004). One of these anti-TNF agents is 
known under the name etanercept, which is a recombinant, soluble human TNF 
receptor that binds and neutralizes soluble TNF. Etanercept has received much 
attention in the scientific community, when in 2006 Tobinick and coworkers 
reported on beneficial effects of etanercept if administered perispinally in moderate 
to severe AD patients (Tobinick, 2007; Tobinick et al., 2006). To evaluate whether 




Another potential strategy for many neurodegenerative disorders involves the 
selective activation of the neuroprotective TNFR2 signalling. In an in vitro model of 
glutamate-induced cell death of primary cortical neurons, TNF was shown to be 
protective via TNFR2, PKB/Akt and NF-B signalling (Dolga et al., 2008; Fontaine 
et al., 2002; Marchetti et al., 2004). Although the involvement of TNFR2, PKB/Akt 
and NF-B was already suggested, only limited data are available on putative 
neuroprotective downstream targets of NF-B. 
 
A potential mechanism underlying the TNFR2 mediated protection against 
glutamate toxicity was dissected in chapter 3 of this thesis. Here I show that the 
protective effect of TNF against a glutamate challenge was accompanied by a 
selective, NF-B dependent increase in KCa2.2 channels. The expression of the 
KCa2.2 channels could be blocked by the specific inhibitor of NF-B (BAY11-
7082). It is very likely that NF-B interacts with one of two NF-B binding sites, 
which were recently identified as regulatory parts of the murine KCa2.2 promoter 
(Kye et al., 2007).  
Furthermore, the increased expression of KCa2.2 channels after TNF treatment was 
mediated by TNFR2, which corresponds well with previous findings that TNFR2 
mediates TNF-induced neuroprotection (Dolga et al., 2008; Fontaine et al., 2002; 
Marchetti et al., 2004). 
In the context of neuroprotection KCa2.2 channels can mediate a decrease in 
neuronal excitability which is likely part of the protective mechanism. Indeed, the 
neuroprotective potential of KCa2.2 was observed in an earlier study showing that 
over-expression of KCa2.2 channels in cultured hippocampal neurons increases 
resistance against a kainic acid induced excitotoxicity (Lee et al., 2003).  
 
In general, the overstimulation of neurons by excitatory neurotransmitters can 
trigger long lasting activation of ionotropic receptors (e.g. NMDA, AMPA), which 
can lead to excessive Ca2+ influx into the cell. Prolonged increase of intracellular 
Ca2+ can eventually result in neuronal cell death and functional impairment of 
affected brain areas.  
As a physiological response to changes of intracellular Ca2+ concentrations KCa2.2 
channels can be activated to induce a re-polarizing effect on the membrane. This re-
polarizing action of KCa2.2 can oppose the depolarizing effect of AMPA receptor 
activity, favouring Mg2+ re-blocking of NMDA receptors and thus reducing the Ca2+ 
transient (Faber et al., 2005; Lin et al., 2008; Ngo-Anh et al., 2005). In this way 
KCa2.2 channels may decrease glutamate-induced excitotoxicity which may lead to 
reduced susceptibility to glutamate-induced over-stimulation via their coupling to 




As described in the previous sections it becomes clear that neuroinflammation, 
neurodegeneration and neuroprotective signalling intersect at the molecular level of 
the nuclear transcription factor NF-B. NF-B is involved in a large variety of 
cellular processes and plays a central role in the initiation and amplification of 
inflammation by responding to proinflammatory stimuli such as TNF or 
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interleukin-1 (IL-1) (Hayden et al., 2006; Karin and Greten, 2005; Tak and 
Firestein, 2001). The aberrant regulation of NF-B leads to the development of 
many pathological states especially those involving acute inflammation such as AD 
and diabetes mellitus (DM) (Kaltschmidt et al., 1997; Katarina et al., 2007). 
 
 
9.2 Inflammation and NF-B as link between AD and Diabetes 
 
Inflammatory processes are a hallmark of many chronic diseases including AD and 
DM. Statistical evidence published in the Rotterdam study and but also several 
other studies linked DM with an increased risk to develop AD (Biessels et al., 
2006a; Biessels et al., 2006b). Such evidence encouraged researchers worldwide to 
search for the causal mechanisms underlying this relationship. 
 In Chapter 6 I provide an overview on the current literature linking AD and DM 
via inflammatory processes and NF-B. Because the NF-B pathway plays a major 
role in the etiology in both diseases, it seems reasonable to assume that mechanisms 
causing disturbances in this pathway are at the core of the relationship. From the 
present literature it seems obvious that inflammatory processes are playing essential 
roles in the etiology of T2DM and AD. Aberrant regulation of the inflammatory 
pathway involving NF-B, which includes TNF dependent and TNF independent 
mechanisms, directly underlies insulin resistance in peripheral tissue as well as in 
astrocytes in the brain. Since insulin resistance in the periphery can lead to glucose 
intolerance, neuronal inflammatory processes triggering (or triggered by) the NF-B 
pathway may be propagated even further via stimulation of the AGE/RAGE 
signalling pathway. Therefore, it might be expected that alleviating symptoms of 
T2DM may be an effective way to treat AD. Indeed, recent clinical trials with the 
insulin sensitizer rosiglitazone -i.e., an agonist for the peroxisome proliferator-
activated receptor gamma (PPAR), (whose biological actions are to regulate glucose 
and lipid metabolism and suppress inflammatory gene expression) have shown a 
significant improvement in memory and cognition in AD patients (Landreth et al., 
2008). 
  
9.3 Statins and Alzheimer's Disease 
 
Despite contradictory results reported in the recent literature, increasing evidence 
points to elevated cholesterol levels to enhance the risk to develop AD (Martins et 
al., 2009; Kivipelto et al., 2002; Panza et al., 2006; Pappolla et al., 2003). In fact 
cholesterol metabolism and catabolism are affected in many neurodegenerative 
disorders including AD. Since APP processing and subsequent Aβ production are 
dependent on membrane cholesterol content and on levels of isoprenoid 
intermediates in the cholesterol biosynthesis pathway, changes in cholesterol might 
have profound consequences on Aβ generation and the course of the disease. These 
pieces of evidence support the idea that inhibitors of cholesterol synthesis, like 
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statins could have a therapeutic role in AD. The following section discusses the 
potential role of statins as potential therapeutic for neurodegenerative disorders. 
 
9.3.1 Statins modulate neuroinflammatory processes 
 
Statins are widely prescribed as cholesterol lowering drugs and the use of statins is 
associated with a decreased risk for AD, although the mechanisms are poorly 
understood. However, recent studies have shown that statins have pleiotropic 
actions, which are not solely dependent on cholesterol reduction (Cole and Vassar, 
2006; Liao and Laufs, 2005). Dolga and co-workers could show in an in vitro study 
that lovastatin induces neuroprotection against glutamate induced excitotoxicity 
through TNFR2 mediated signalling (Dolga et al., 2008). However, from that study 
it remained unclear whether beneficial effects of lovastatin in vitro could be 
translated into an in vivo situation.  
Chapter 2 of this thesis provides evidence that mice pre-treated with lovastatin, are 
protected from NMDA-induced excitotoxic lesions of the nucleus basalis 
magnocellularis. Interestingly, lovastatin treatment fully prevented behavioral 
deficits associated with the cholinergic fiber loss. In contrast to acetylcholinesterase 
inhibitors, lovastatin is able to preserve cholinergic neurons from excitotoxic 
damage instead of “just boosting” the amount of available neurotransmitter and 
thereby improving cognitive performance.  
These results also show that the neuroprotective effect of lovastatin is dependent on 
the activation PKB/Akt signalling, since neuroprotection could be abolished by a 
selective inhibitor of phosphoinositide 3-kinases (PI3K). 
It is unlikely that behavioral alteration of lovastatin-treated animals can be 
attributed to direct drug effect since statins are rapidly cleared from the brain 
within 6 hours after drug administration (Johnson-Anuna et al., 2005). All 
behavioral tests were performed within 7 days after the last lovastatin 
administration. Statins such as lovastatin are able to cross the blood brain barrier 
and reach the cerebral cortex within one hour after drug administration but are 
significantly reduced 6 hours later after a single drug application. It is not clear 
whether the effects of statins as found in the present study can be directly associated 
with cholesterol dependent processes in brain tissue.  
Several studies report on brain cholesterol levels after statin treatment with 
conflicting results. One study, for example shows that long-term treatment of 
simvastatin for 3 months did not change the total cholesterol levels in the brain, 
although the plasma total cholesterol levels were strongly reduced (Li et al., 2006a). 
Other studies report on reduced brain cholesterol levels in young C57Bl/6J mice 
treated for 3 weeks with simvastatin or pravastatin, but not with lovastatin 




Beside the cholesterol lowering effects, statins might exert their neuroprotective 
actions via alternative mechanisms. Recently, Ma and co-workers reported that 
statins can activate the non-amyloidogenic cleavage of the APP by increasing -
secretase activity (Kojro et al., 2001; Ma et al., 2009). This leads to increased 
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secretion of sAPP which also mediates protection against excitotoxicity (Kojro et 
al., 2001). Interestingly, LY 294002 not only abolishes the statin mediated 
protective effect against NMDA, but also attenuates its effect on sAPP secretion 
(Ma et al., 2009).  
The pleiotropic actions of statins (and lovastatin in particular) might be attributed 
to the inhibition of the isoprenoid pathway, thereby inhibiting the activities of the 
Rho family of small GTPases-Rho A (Buxbaum et al., 2001; Ostrowski et al., 2007; 
Pedrini et al., 2005; Puglielli et al., 2001). Isoprenylated Rho proteins exert many of 
their effects via Rho-associated protein kinases (ROCKs). ROCK can phosphorylate 
substrates like PTEN and stimulates its phosphatase activity, which in turn 
antagonizes PI3K activity, resulting in reduced Akt phosphorylation (Li et al., 2005) 
and NF-B activation.   
 
In the CNS, active NF-B has a pro-survival effect on neurons and can counteract 
apoptotic signals. Inflammatory molecules such as TNF are capable to trigger the 
NF-B signalling pathway and thereby deploy its beneficial effects. In this way the 
modulation of neuroinflammatory processes via TNF has interesting therapeutic 
potential for treatment of  neurodegenerative disorders. 
 
Whereas the previous sections dealt with drug targets related to inflammatory 
processes and the impact of statins, the  next part of the discussion will focus on a 
neuroprotective approach at the very end of downstream pathological events; 
namely the neuroprotection via the inhibition of calpains. 
 
 
9.4 Calpain inhibition mediates neuroprotection against Aβ and 
excitotoxicity induced death 
 
A number of authors have suggested that the pathological effect of Aβ oligomers is 
mediated via the over-activation of the NMDA receptor (DeFelice and Goswami, 
2007; Kelly and Ferreira, 2006; Shankar et al., 2007), and that this excitotoxicity 
should be considered as a common principle for some major neurological diseases, 
including AD (Harkany et al., 2000; Lipton and Rosenberg, 1994; Mattson, 2004).  
Excitotoxic stimulation via the NMDA receptor leads to excessive entry of Ca2+ into 
the cell and eventually leads to the activation of the calcium-activated cystein 
protease calpain, which has been implicated in pathways ending in programmed 
neuronal cell death. Caba and colleagues could demonstrate that the inhibition of 
calpain provides protection against NMDA-exposure in hippocampal slice cultures 
(Caba et al., 2002). Another study revealed that calpain inhibition reduces 
neurodegeneration in the rat retina after NMDA-injection (Chiu et al., 2005). 
Calpain has therefore been discussed as a promising target for treatment of 
neurodegenerative disorders (Huang and Wang, 2001; Saez et al., 2006; Zatz and 
Starling, 2005). In chapters 4 and 5 I tested this hypothesis and provide evidence 
that calpain inhibition is, indeed, neuroprotective against different toxic stimuli in 
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vivo. Injection of NMDA or oligomeric Aβ to the nucleus basalis of rats and mice 
respectively caused a strong deterioration of cortical cholinergic projections leading 
to deficits in learning behavior. The cholinergic denervation in the parietal cortex 
and the associated behavioral decline were prevented by the application of the 
calpain inhibitor A-705253. Moreover, the extent of microglia activation around the 
injection site in the NBM was significantly reduced in animals pretreated with A-
705253.  
Interestingly, the in vitro studies in chapter 5 using Aβ indicate that calpain 
inhibition is not only effective when the compound is applied prior to the insult. 
Efficacy of A-705253 against Aβ-induced cell damage was demonstrated up to 1 
hour after administration of Aβ. This indicates that the Aβ-induced cell death 
cascade – once initiated – may not instantly kill the neuron, but requires some time 
until degeneration is irreversible. If this holds true also for other acute forms of 
neurodegeneration, this could offer a promising avenue for the treatment of acute 
neurodegenerative disorders.  
The calpain inhibitor A-705253 was introduced by Lubish and co-workers (Lubisch 
et al., 2003) and does not affect caspases or the proteasome (Ki calpain=27 nM; Ki 
proteasome>10000 nM; Ki caspases>10000 nM). Therefore, it is likely that the 
protective effects against NMDA and Aβ-oligomer toxicity are mediated by 
inhibition of calpain, and not by reducing proteasome or caspase activity. The 
proteasome complex (Pan et al., 2008; Rubinsztein, 2006) as well as caspases 
(Cribbs et al., 2004) potentially contribute to neurodegeneration, and a 
discrimination from these targets mandatory. Battaglia and colleagues by using 
another, less specific calpain inhibitor, E64 (Battaglia et al., 2003), showed that 
long-term (5 months) intraperitoneal application of E64 in APP(K670N/ 
M671L)/PS1(M146L) mice prevented synaptic impairment as measured by LTP. 
Chronic calpain inhibition also attenuated the development of deficits in spatial 
behavior of these mice. Recently Kelly and colleagues revealed the involvement of 
calpain in Aβ-mediated dysfunction of the synaptic vesicle machinery (Kelly and 
Ferreira, 2006; Kelly et al., 2005). Thus, it is likely that calpain inhibition serves to 
protect from acute and chronic neuronal decline, and from a variety of pathological 
features observed in AD. 
In summary calpain inhibition significantly decreases acute NMDA and/or Aβ 
oligomer-induced degeneration of NBM and its associated cholinergic fiber 
projections, and attenuates behavioral deficits associated with such lesions. 
Furthermore, the in vitro data suggest that inhibition of calpain is still effective when 
performed shortly after the insult. These findings indicate that inhibiting calpain 
could be a promising strategy for the therapeutic intervention of excitotoxic and Aβ 





Although statins and calpain inhibitors have different modes of action their 
neuroprotective mechanisms intersect on several molecular levels. Statins, in 
particular lovastatin, seem to intervene quite early/upstream in the sequence of 
pathogenic events, due to their pleiotropic actions (Cole and Vassar, 2006; Liao and 
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Laufs, 2005). Dolga et al showed that lovastatin stimulates selectively the expression 
of TNFR2 in primary cortical neurons which provides protection against excitotoxic 
insults (Dolga et al., 2008). This study implicates that the use of lovastatin might be 
beneficial under neurodegenerative conditions such as in AD by stimulating 
neuroprotective TNFR2 signalling. During neuronal insult and subsequent 
disruption of Ca2+ homeostasis, conversion of inactive p35 to active p25 is mediated 
via proteolytic cleavage by the calcium-regulated calpains. Recently, CDK5 has 
received considerable attention as a regulator of neuronal death (Cruz and Tsai, 
2004). In particular, studies using apoptotic and excitotoxic cell death models 
demonstrate that p25/CDK5 complexes accumulate within the nucleus and that 
this activity is required in excitotoxic death (O'Hare et al., 2005). Calpain inhibition 
might preserve the conversion of p35 to p25 and thereby prevent excitotoxic cell 
death. 
Interestingly, a study by Ma et al (2009) reported that statins can selectively 
modulate calpain cleavage of several target molecules, which are crucial for neuronal 
survival pathways (Ma et al., 2009) although the mechanism is unknown. Moreover, 
the PI3K/Akt pathway was identified as one of the crucial upstream signalling 
sequences activated by the insulin receptor, which is preserved by statins upon 
NMDA challenge (Ma et al., 2009). Furthermore, it was shown that the PI3K/Akt 
pathway is also activated by TNF via TNFR2 and that lovastatin mediates 
neuroprotection via increased the expression of TNFR2 (Dolga et al., 2008; 
Marchetti et al., 2004).   
Furthermore, we could speculate that the modulation of calpain cleavage might be 
mediated by the NF-B dependent expression of KCa2 channels, which counteracts 
Ca2+ influx via NMDA receptor. This reduction in intracellular Ca2+ levels could be 
sufficient to suppress calpain activation. In support of this view several studies have 
shown that the after-hyperpolarization of membranes via K+ channel openers 
reduced Ca2+ influx and resulted in neuroprotection against Aβ mediated toxicity 
(Goodman and Mattson, 1996; Mark et al., 1995; Pike et al., 1996). Overall 
neuroprotective mechanisms and the cellular survival pathways activated by statins 
are promising drug targets which will can become essential for future therapeutic 
design.  
The strategies discussed so far targeted molecular mechanisms which are involved in 
a broader range of neurodegenerative disorders and not exclusively AD. A more 




9.5 Modulating Aβ toxicity 
 
According to the "amyloid hypothesis" the Aβ peptide, which accumulates in the 
brain of patients suffering from AD, is a major pathogenic driving force in this 
disorder (Selkoe, 2002, 2003). Several strategies have been developed to minimize 
or reverse the negative effects of Aβ for example reducing Aβ generation, inhibiting 
of Aβ misfolding and aggregation, or enhancing Aβ clearance (Schenk et al., 1999; 
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Sigurdsson et al., 2000; Soto, 1999a, b). Approaches aiming at diminishing Aβ 
levels by inhibition of proteases involved in Aβ generation by APP processing, 
namely the β- and -secretase, have experienced a drawback since these proteases not 
only generate Aβ but are as well involved in important cellular processes like axonal 
myelination, synapse maintenance and Notch signalling (Bittner et al., 2009; Lleo et 
al., 2003; Willem et al., 2006). The challenge here is to develop selective inhibitors 
which target only the amyloidogenic cleavage without affecting other cellular 
processes.  
 
Another strategy involves immunization against Aβ-peptides. Aβ vaccination led to 
amyloid plaque clearance in a mouse model of AD (Schenk et al., 1999). 
Furthermore, it could be demonstrated that immunization can reverse memory 
deficits in APP transgenic mice (Dodart et al., 2002). Vaccination against Aβ was 
the most promising strategy until immunized patients showed strong brain 
inflammatory responses and a few eventually died (Imbimbo, 2002; Munch and 
Robinson, 2002).       
Potential safety concerns of anti-Aβ vaccines, lead to the development of alternative 
strategies to reduce the plaque burden in AD. This could be achieved by the 
inhibition of Aβ aggregation by use of small peptides (also referred as anti-amyloid 
peptides (AAPs)), which are designed to specifically interact with the protein 
fragment of Aβ that is undergoing the conformational changes followed by 
aggregation. AAPs destabilize an undesired conformation of Aβ by adding specific 
amino acid residues that favor or disfavor the adoption of a particular structural 
motif (Soto, 1999a, b; Soto et al., 1998). The initially synthesized compounds were 
peptides of 11 to 5 amino acids targeting the central region of the Aβ peptide and 
evolved to compounds like LPFFD (iAβ5) and/or LPYFDa.  
In chapter 7 and 8 I evaluate the potential therapeutic properties of short synthetic 
AAPs, which are designed to neutralize the devastating effect of Aβ peptides. In 
Chapter 7 I could demonstrate for the first time that the AAP LPYFDa is a potent 
inhibitor of Aβ oligomer induced toxicity and is capable to prevent Aβ-induced 
memory deficits.  
Several studies showed that elevated levels of soluble oligomeric Aβ correlate 
strongly with cognitive decline in AD patients (McLean et al., 1999; Wang et al., 
1999).  Furthermore, low-n oligomeric assembly of naturally secreted human Aβ 
alters hippocampal synaptic plasticity by inhibiting long-term potentiation which is 
associated with impaired memory formation (Walsh et al., 2002). Also the number 
of dendritic spines was dramatically decreased when neurons were incubated with 
Aβ oligomers, but not with monomers (Walsh et al., 2002). 
Chapter 
 9 Therefore, an important aim of this study was to investigate, whether a compound 
like LPYFDa is able to prevent Aβ oligomer–induced learning and memory deficits. 
Indeed a 5-fold molar excess of LPYFDa to Aβ could overcome the detrimental 
effects of Aβ oligomers on memory. Thus, we provide evidence that so-called β-sheet 
breaker peptides such as LPYFDa bear therapeutic potential against Aβ-induced 
memory impairment.  
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Recently it was demonstrated that intraperitoneally administered LPYFDa is able to 
cross the blood brain barrier and protects synapses against excitatory action of 
fibrillar Aβ (Juhasz et al., 2009). A general issue with peptide based drugs for 
neurological disorders is their rapid degradation in vivo by proteolytic enzymes and 
their poor blood-brain permeability (Adessi and Soto, 2002). These issues were 
overcome by chemical modifications, like C-terminal amidation and N-terminal 
carboxylation, which resulted in increased half life in vivo and rapid brain up-take 
(Permanne et al., 2002).  Although, our knowledge of the biochemistry in respect to 
catabolism and brain uptake of certain AAPs has developed greatly in recent years, 
the detailed mechanisms of action are still poorly understood. Therefore, it is 
essential to elucidate and study the 3D structure of the Aβ/AAP complex to gain 
more insight into the molecular dynamics of the Aβ aggregation process.  
In chapter 8 novel AAPs were rationally designed, employing the 3D structure and 
dynamic behaviour and docking studies of the full length Aβ molecule and the new 
peptides. The resulting novel peptides were based on the conformational behavior 
of the Aβ42 aggregates previously reported by Masman and co-workers (Masman et 
al. 2009). The highly hydrophobic sequence Ala30-Ile31-Ile32-Gly33-Leu34, of the 
Aβ42 aggregates was the starting point of the design for the new anti-amyloid peptide 
PN22. To overcome the high hydrophobicity and improve efficiency some chemical 
modifications were applied to increase the solubility of the final peptides, such as 
the introduction of positively charged residues and methyl groups. Furthermore, the 
N- and C-terminus were blocked by acetylation and amidation respectively which 
improved cell permeability and an increased stability towards digestion by 
aminopeptidases. Several studies could show that C-terminal amidation is essential 
for the biological activity of many neuropeptides and hormones (Fricker, 2005; Kim 
and Seong, 2001).  
Small peptides like LPYFDa and PN22, which are partially homologous to this 
hydrophobic region, bind with a relatively high affinity to Aβ by similar 
intermolecular interactions, leading to a competitive replacement of Aβ molecules. 
The new peptide PN22 and its non methylated version PN20 were synthesized and 
tested in vitro and in vivo for the ability of neutralizing Aβ induced toxicity and 
memory impairment. Similar to LPYFD, PN22 is able to preserve cultured neurons 
from oligomeric Aβ-induced cell death in a dose dependent manner. Comparable 
results have been previously reported on PC12 cells using different single N-methyl 
amino acid containing peptides (Cruz et al., 2004; Hughes et al., 2000). 
Furthermore, a compound like PN22 is able to prevent Aβ–induced learning and 
memory deficits. We showed that a 5-fold molar excess of PN22 to Aβ could 
overcome the detrimental effects of Aβ oligomers on memory. Thus, this study 
provides evidence that N-methyl containing peptides such as PN22 hold a 
therapeutic promise against Aβ-induced memory impairment.  
 
The mechanism how AAPs exert their protective effects on cell death and behavior 
is not yet fully understood. However, there are several options of how AAPs might 
interact with Aβ. Peptides such as PN22 or LPYFD can directly bind to Aβ, and 
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thereby prevent possible interactions between Aβ and neuronal membrane proteins 
and receptors, and in this way neutralize Aβ mediated effects. We could speculate 
that the AAPs might bind to the monomeric Aβ, thus preventing and/or retarding 
the formation of toxic oligomers, by disturbing the conformational change that 
precedes the oligomer formation. 
Another possibility would be that the peptides bind to already formed Aβ oligomers 
and thereby preventing and/or modulating, somehow, their neurotoxic properties. 
By either of these actions, or both, the neurotoxicity of Aβ is decreased or reverted 
and the Aβ clearance/degradation processes might be reactivated. 
In summary this findings provide evidence on how and where AAPs interact with 
Aβ42 mono- and oligomers that these peptides can neutralizes the neurotoxic effects 
of soluble Aβ oligomers, and in the present conditions, and as proof of principle, 
can effectively prevent the oligomer-induced deficits in memory performance. More 
structural evidence is required to consolidate the proposed mechanism and to 
further improve the designs. Nevertheless, it is clear that the method of in silico 
design is a valuable tool to develop and predict the efficacy of new drugs like AAPs 




9.6 Concluding remarks 
 
Therapies directed against specific aspects of AD pathogenesis like 
neuroinflammation, excitotoxicity and Aβ induced damage are all considered to 
alleviate problems associated with the disease. In this thesis several compounds were 
evaluated (Statins, Calpain Inhibitors, Anti-Amyloid Peptides) targeting different 
molecular mechanisms underlying AD. In conclusion it could be demonstrated that 
all tested compounds bear potential to intervene in certain aspects of AD pathology. 
However, at this stage it remains elusive, which type of treatment might be the best 
approach to halt or slow the progression of the disease, since our results have been 
obtained from cell culture and animal models for AD (van Dam et al., 2006) and 
have not been tested in human patients. Moreover, it is questionable whether a 
single drug in particular, will be able to stop or prevent such a complex 
multifactorial disorder like Alzheimer's disease.  
Chapter 
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From that point of view one might speculate that for an effective treatment it might 
be necessary to target multiple molecular processes underlying the AD pathology. 
Depending on the stage of the disease combined therapeutic approaches using 
AAPs with statins or calpain inhibitors could be worthwhile investigating. The 
AAPs would intervene early in the cascade of pathogenic events by neutralizing 
harmful actions of Aβ, whereas the calpain inhibitors interact downstream from Aβ. 
Since both drugs target different molecular mechanisms, their actions might be 
complementary. Lovastatin itself has already pleiotropic actions affecting several 
molecular pathways, which are involved in the progression of AD. A useful 
supplement for a neuroprotective lovastatin treatment would be a selective activator 
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of TNFR2 and/or a selective inhibitor of TNFR1. Finally, one should not disregard 
the importance of early diagnostic tools (e.g. CSF biomarkers (Le Bastard et al., 
2009)) for the detection of AD long time before the first symptoms occur in order 




Figure 9.1. Schematic overview of the neuroprotective strategies for Alzheimer’ s disease.  
Lovastatin treatment leads to an increased expression of TNFR2. Activation of TNFR2, can directly, 
lead to sustained activation of NF-κB to initiate transcription of NF-κB dependent anti apoptotic genes 
such as KCa2.2. Furthermore, Lovastatin triggers the non amyloidogenic APP cleavage via  increased α-
secretase activity. The resulting sAPPα has excitoprotective properties. Calpain inhibitor A705253 
prevents cleavage of substrates which are essential for normal cellular functioning. Anti Amyloid 
Peptides bind to soluble monomeric or oligomeric Aβ and neutralize its harmful properties.  
 
 
9.7 Future Perspectives 
A key challenge in current AD research has become to understand precisely what 
happens at the earliest stages of disease. In particular it is of great importance to 
identify and investigate factors, which are responsible for the onset of sporadic AD 
as this form accounts for majority of AD cases (Bouwman et al., 2009; Galimberti et 
al., 2003; Galimberti et al., 2006; Henneman et al., 2009). 
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Since many neurodegenerative disorders including AD mainly affect elderly people 
it seems plausible that changes, which occur during the ageing process, make the 
brain more susceptible to diseases. Cytokine profile, inflammation response and the 
expression of several proteins are altered during the ageing process and many of 
these proteins are crucial for maintaining normal physiological functioning (Toescu 
et al., 2009; von Bernhardi er al., 2010; Liu et al., 2010, Xu et al., 2010).  
Significant reduction of particular proteins during ageing can have devastating 
consequences. For instance the protein levels of the Aβ degrading enzyme neprilysin 
are drastically decreased during ageing, which reduces Aβ clearance and promotes 
its accumulation. In turn elevated Aβ levels can lead to more activated microglia, 
which release proinflammatory cytokines such as TNF. In a vicious cycle, cytokines 
can trigger the amyloidogenic APP processing by promoting BACE1 expression, 
which leads to more Aβ. As a consequence of elevated Aβ levels, oxidative stress, 
and inflammation result in disturbed calcium homeostasis. In combination with age 
related decrease of calcium binding “buffer” proteins, such as calbindin, calretinin 
and parvalbum, neuronal cells are more susceptible for cytotoxic insults (Pike et al., 
1995; Harkany et al., 1995; Yatin et al., 1999). 
 
 
Population based studies on ageing such as the Rotterdam study suggest that 
lifestyle can also influence the risk for developing AD. Moderate alcohol 
consumption has been reported to rather decrease the risk (Ruitenberg et al., 2002) 
contrary to smoking which seems to increase the risk for developing AD (Reitz et 
al., 2007). Another important factor for attenuating the risk of AD may be physical 
exercise. Exercise increases brain derived neurotrophic factor, promotes sprouting 
of dendrites and generation of new synapses (Vaynman et al., 2003; Ploughman et 
al., 2007; Fischer et al., 2007). 
Further characterization of the ageing process and specific cellular signalling 
pathways may provide us with novel drug targets and potential pharmacological 






















De ziekte van Alzheimer is de meest voorkomende vorm van dementie. In 
Nederland lijden ongeveer 130.000 mensen aan deze progressieve hersenziekte. 
Sinds de beschrijving van de ziekte 100 jaar geleden door Alois Alzheimer, is de 
oorzaak van de ziekte nog altijd niet precies bekend.  
Tot nu toe zijn o.a. veroudering, oxidatieve stress, verstoorde ionenhuishouding, 
verminderde hersendoorbloeding, neuronale ontstekingen en genetische 
afwijkingen geïdentificeerd als belangrijkste factoren die bijdragen aan de 
pathogenese van de ziekte.  
De karakteristieke pathologie van Alzheimer bestaat uit neuronale ontsteking, 
afsterven van zenuwcellen en ophoping en verklontering van het amyloide- eiwit. 
Dit leidt uiteindelijk tot het fysieke verval van de hersenen welke gepaard gaat met 
klinische symptomen zoals algemene cognitieve achteruitgang, geheugenverlies en 
veranderingen in de persoonlijkheid.  
 
Het doel van dit proefschrift is enkele nieuwe therapeutische strategieën te 
ontwikkelen en te evalueren gebaseerd op de huidige kennis van de ziekte van 
Alzheimer. Hierbij probeer ik de verschillende ziekteverwekkende moleculaire 
processen af te remmen of te vertragen.   
 
Epidemiologische studies naar cholesterolverlagende middelen suggereren dat deze 
medicijnen ook bruikbaar zijn bij de preventie of vertraging van Alzheimer. 
Lovastatine is éen van deze middelen welke, naast de cholesterolverlagende 
eigenschappen, een stimulering van de receptor 2 van de ontstekingsfactor Tumor 
Necrose Factor (TNFR2) oproept. Uit onderzoek in cel culturen (in vitro) is 
gebleken dat deze receptor een beschermende werking heeft op celdood veroorzaakt 
door overstimulatie van zenuwcellen met glutamaat, een proces dat aangeduid 
wordt met “excitotoxiciteit”.  Op moleculair nivo is verder  aangetoond dat de 
signaaloverdracht van TNFR2 leidt tot activatie van de transcriptie factor NF-B 
(Nuclear Factor kappa B) via Protein Kinase B (PKB/Akt) waardoor een aantal 
neuroprotectieve genen tot expressie komen. Hierdoor zijn verschillende schakels 
binnen deze route van signaaloverdracht een doelwit voor potentiële medicijnen 
tegen neurodegeneratieve aandoeningen. De neuroprotectieve werking van 
lovastatine via TNFR2 is tot nu toe alleen aangetoond op zenuwcellen in culture (in 
vitro) maar nog niet in levende organismen (in vivo).   
In hoofdstuk 2 is de beschermende werking van lovastatine bestudeerd in een in 
vivo model voor neurodegeneratie waarin de cholinerge neuronen in de nucleus 
basalis magnocellularis (NBM) in muizen uitgeschakeld is door toxische NMDA 
injecties. De dysfunctie en het verlies van de cholinerge neuronen en hun corticale 
projecties behoren tot een van de eerste pathologische manifestaties bij het ontstaan 
van Alzheimer wat resulteert in geheugenstoornissen. In dit onderzoek heb ik 
aangetoond dat voorbehandeling met lovastatine de degeneratie van cholinerge 







Daarnaast heb ik in vivo bevestigd dat lovastatine-gemedieerde neuroprotectie 
afhankelijk is van het PKB/Akt signaalpad doordat de inhibitie van de PKB/Akt 
met  LY294002 de neuroprotectieve werking blokkeert. Uit deze studie concludeer 
ik dat behandeling met lovastatine bescherming biedt tegen neuronale schade onder 
excitotoxische omstandigheden zoals in veel neurodegeneratieve ziekten voorkomt. 
 
De transcriptiefactor NF-κB reguleert de expressie van (small conductance) calcium-
geactiveerde kalium (KCa2) kanalen. Deze KCa2 kanalen verminderen de 
prikkelbaarheid van de zenuwcel wat leidt tot neuroprotectie tegen neuronale 
overstimulatie (excitotoxiciteit). In het algemeen wordt excitotoxiciteit beschouwd 
als een belangrijk mechanisme betrokken bij neurodegeneratie van het centrale 
zenuwstelsel zoals het geval is bij een hersenbloeding, trauma, Alzheimer en andere 
neurologische aandoeningen.  
In hoofdstuk 3 heb ik onderzocht of TNF-α-gemedieerde neuroprotectieve 
signalering, veranderingen induceert in de expressie van KCa2 kanalen. Ik vond een 
verhoogde expressie van KCa2 kanalen type 2 (KCa2.2) na behandeling met TNF in 
een tijdsafhankelijke manier. Deze toename blijkt afhankelijk van TNFR2 en NF-κB 
activering. De expressie van KCa2.1 en KCa2.3 kanalen blijft onveranderd na 
behandeling met TNF.  
 
Op fuctioneel niveau leidt de specifieke activering van KCa2.2 door NS309 of 
CyPPA tot neuroprotectie tegen glutamaat geïnduceerde overstimulatie. In 
tegenstelling tot de activering leidt de blokkade van KCa2.2, met apamin of de 
uitschakeling van het KCa2.2 kanaal met siRNA, tot vermindering van het 
neuroprotectieve effect. Uit deze studie concludeer ik dat behandeling van primaire 
corticale neuronen met TNF-α leidt tot een verhoogde KCa2.2 kanaal expressie in 
neuronen wat ze beter bestand maakt tegen excitotoxische celdood. 
 
Calpaine, een calcium-afhankelijke cysteïne protease, is onderdeel van het NMDA 
receptor-geïnduceerde excitotoxisch signaalpad. Ook het A eiwit is schadelijk voor 
neuronen en deze toxiciteit is -althans gedeeltelijk - gemedieerd via de NMDA 
receptor. De hoofdstukken 4 en 5 van dit proefschrift zijn gericht op de vraag of 
remming van Calpaine neuronale celdood kan voorkomen. Hiervoor heb ik in een 
ziekte-relevant diermodel, gebaseerd op excitotoxische laesies van de cholinerge 
nucleus basalis magnocellularis middels NMDA of A, onderzocht of de 
bijbehorende geheugenstoornissen te voorkomen zijn door behandeling met een 
Calpaine remmer. Excitotoxische laesies van de nucleus basalis leiden tot 
verminderde prestaties in leer- en geheugentaken. Behandeling met de Calpaine 
remmer A-705253, voorkomt deze geheugenafwijking in een dosisafhankelijke 
manier. Analyse van de cholinerge vesels in de corticale schors van de dieren met 
leasie bevestigen deze resultaten. Daarnaast blijkt uit immunohistochemische 
analyse van geactiveerde microglia cellen dat de remming van Calpaine ook tot een 
verminderde ontstekings reaktie leidt die meestal samen gaat met 
neurodegeneratieve ziektes.  
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Uit dit onderzoek kan geconcludeerd worden dat de remming van Calpaine een 
waardevolle strategie is in de preventie van oligomeer A en/of excitotoxiciteit-
geïnduceerde neuronale celdood. Op deze manier wordt ook de hiermee 
samenhangende cognitieve achteruitgang voorkomen zonder fysiologische 
neuronale functies te verstoren. De remming van Calpaine activiteit is een nieuwe 
en veelbelovende benadering in de behandeling van diverse neurodegeneratieve 
aandoeningen. 
 
Ontstekingsreacties zijn een kenmerk van veel, zo niet alle chronische ziekten, 
waaronder de ziekte van Alzheimer en diabetes mellitus. 
Een aantal recente studies laten zien dat type twee diabetes het risico op het 
ontwikkelen de ziekte van Alzheimer verhoogt. Deze kennis  heeft geleid tot 
onderzoek naar de gemeenschappelijke processen die een relatie tussen deze twee 
ziektes kan verklaren. In hoofdstuk 6 geef ik een  overzicht van de literatuur die 
betrekking heeft op de rol van ontsteksreacties in zowel Diabetes mellitus als de 
ziekte van Alzheimer en de mogelijke functie van de transcriptie factor NF-κB.  
 
Een verkeerde vouwing, oligomerisatie en ophoping van het amyloïd-beta (A) 
peptide wordt algemeen beschouwd als een centrale gebeurtenis in de pathogenese 
van de ziekte van Alzheimer. Recente studies hebben  oplosbare Aβ oligomeren 
geïdentificeerd als de belangrijkste ziekteverwekkers. Deze bevindingen zijn 
bevestigd door studies die laten zien dat deze neurotoxische Aβ aggregaten de 
synaptische plasticiteit verstoren en de lange termijn potentiatie (LTP) remmen. Een 
veelbelovende therapeutische strategie in de strijd tegen AD is het toedienen van 
kleine synthetische peptiden die zodanig zijn ontworpen dat ze aan specifieke regio’s 
van Aβ oligomeer binden en de verwoestende eigenschappen van oligomere Aβ 
neutraliseren. In hoofdstuk 7 onderzoek ik de eigenschappen van het pentapeptide 
LPYFDa op Aβ-geïnduceerde geheugenstoornis en celdood. In vitro heb ik 
aangetoond dat neuronen die behandeld zijn met LPYFDa beschermd zijn tegen 
Aβ-geïnduceerde celdood. Bovendien, kan LPYFDa een Aβ geinduceerde 
geheugenstoornis in vivo voorkomen. Dit is de eerste studie die aantoont dat een 
anti-amyloid peptide als LPYFDa geheugenfuncties kan beschermen tegen  door Aβ 
oligomeer veroorzaakte geheugenuitval. 
 
Als vervolg op de studie in hoofdstuk 7 is in hoofdstuk 8 met behulp van een 
driedimensionaal computermodel het Aβ aggregatie proces bestudeerd om meer 
inzicht te krijgen in de moleculaire interacties tussen de aggregatie remmende 
peptide en het Aβ oligomeer complex. Als resultaat van deze computersimulaties is 
een nieuw peptide ontworpen (PN22), gesynthetiseerd en in vitro en in vivo 
geëvalueerd op Aβ neutraliserende eigenschappen. In vitro heb ik aangetoond dat 
neuronen behandeld met PN22, beschermd zijn tegen Aβ-veroorzaakte celdood. 








Therapieën die gericht zijn op specifieke aspecten van de pathogenese van 
Alzheimer, zoals neuronale overstimulatie en schade veroorzaakt door Aβ, zouden 
de problemen die geassocieerd worden met de ziekte kunnen verlichten en 
bestrijden. In dit proefschrift worden verschillende middelen geëvalueerd, 
(waaronder statines, calpaine remmers en anti-amyloïde peptiden), welke gericht zijn 
op de verschillende onderliggende moleculaire mechanismen van de ziekte van 
Alzheimer.  
Echter, in dit stadium is het nog onduidelijk welk type behandeling de beste aanpak 
is om de progressie van de ziekte te vertragen of te stoppen. De resultaten uit dit 
onderzoek zijn verkregen uit celkweek en diermodellen voor Alzheimer en nog niet 
getest in patiënten. Bovendien blijft het de vraag of dergelijke geneesmiddelen in 
staat zullen zijn om alle aspecten van deze complexe ziekte te voorkomen of te 
stoppen. 
Vanuit dit oogpunt kan men speculeren dat voor een effectieve behandeling het 
noodzakelijk is om op meerdere moleculaire processen in te grijpen. Ten slotte 
moet men niet voorbijgaan aan het belang van goede diagnostische instumenten die 
de ziekte vroegtijdig  opsporen voordat de eerste symptomen zich voordoen om een 
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